

Bibliographie

Vous pourrez trouver toutes les références bibliographiques à l'adresse internet suivante : www.pourquoi-vacciner.fr/sources.php

Les graphes en couleur pourront se trouver sur le blog de l'auteur : loindutroupeau.blogspot.fr

1. Sanofi pasteur et merck vaccins nomment le dr jean-paul kress, président de sanofi pasteur MSD. <<http://www.sanofipasteur.com/fr/articles/anofi-pasteur-et-merck-vaccins-nomment-le-dr-jean-paul-kress-president-de-sanofi-pasteur-msd.aspx>> – 2. Les données - institut national du cancer. <<http://lesdonnees.e-cancer.fr/les-indicateurs/1-types-cancer/13-cancer-col-uterus/13-epidemiologie-cancer-col-uterus-france-metropolitaine-mortalite/27-evolution-mortalite-estimee-taux-standardise-monde-cancer-col-uterus-france-me.html>> – 3. Les données - institut national du cancer. <<http://lesdonnees.e-cancer.fr/les-indicateurs/1-types-cancer/13-cancer-col-uterus/13-epidemiologie-cancer-col-uterus-france-metropolitaine-mortalite/21-incidence-mortalite-estimees-taux-specifiques-cancer-col-uterus-france-femme-2.html>> – 4. Dupont, Nicolas. Données épidémiologiques sur le cancer du col de l'utérus. (2008). <http://www.invs.sante.fr/publications/2008/cancer_col_uterus_2008/cancer_col_uterus_2008.pdf> – 5. Chan, P. K. S. et al. Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS ONE 9, e107573 (2014). – 6. Cancer invasif du col utérin. (2007). <<http://www.e-cancer.fr/content/download/95896/1021012/file/GUIALDCOLMD12.pdf>> – 7. Merck. Monographie du produit gardasil. (2015). <http://www.merck.ca/assets/fr/pdf/products/GARDASIL-PM_F.pdf> – 8. Société Canadienne du Cancer. Tumeurs malignes du col de l'utérus - société canadienne du cancer. www.cancer.ca. <<https://www.cancer.ca/443/fr-ca/cancer-information/cancer-type/cervical/cervical-cancer/malignant-tumours/?region=qc>> – 9. Rambout, L., Hopkins, L., Hutton, B. & Fergusson, D. Prophylactic vaccination against human papillomavirus infection and disease in women: A systematic review of randomized controlled trials. CMAJ 177, 469–479 (2007). – 10. CDC. HPV (human papillomavirus) gardasil VIS. (2013). <<http://www.cdc.gov/vaccines/hcp/vis/statements/hpv-gardasil.html>> – 11. Cancer du col de l'utérus : Les réponses à vos questions - dépistage - institut national du cancer. <<http://www.e-cancer.fr/dépistage/cancer-du-col-de-luterus/espace-grand-public/les-reponses-a-vos-questions>> – 12. Borate de sodium, acheter borax poudre, achat tétraborate de sodium décahydraté - mon droguiste. <<http://www.mon-droguiste.com/borax-borate-de-sodium,fr,4,BORSOD02015DSN.cfm>> – 13. Coors, E. A., Seybold, H., Merk, H. F. & Mahler, V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann. Allergy Asthma Immunol. 95, 593–599 (2005). – 14. Gajdová, M., Jakubovský, J. & Válek, J. Delayed effects of neonatal exposure to tween 80 on female reproductive organs in rats. Food Chem. Toxicol. 31, 183–190 (1993). – 15. Toft, L. et al. Comparison of the immunogenicity and reactivity of cervarix and gardasil human papillomavirus vaccines in HIV-infected adults: A randomized, double-blind clinical trial. J. Infect. Dis. 209, 1165–1173 (2014). – 16. Einstein, M. H. et al. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum. Vaccin. 5, 705–719 (2009). – 17. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915–1927 (2007). – 18. Lehtinen, M. et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 89–99 (2012). – 19. Gonçalves, A. K., Cobucci, R. N., Rodrigues, H. M., Melo, A. G. de & Giraldo, P. C. Safety, tolerability and side effects of human papillomavirus vaccines: A systematic quantitative review. The Brazilian Journal of Infectious Diseases 18, 651–659 (2014). – 20. Centre régional de pharmacovigilance de Bordeaux. Suivi national des effets indésirables du vaccin papillomavirus humain gardasil. (2011). <http://ansm.sante.fr/content/download/37340/490672/version/3/file/RapportvaccinGardasil_version-finale.pdf> – 21. Slade, B. A. et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302, 750–757 (2009). – 22. Geier, D. A. & Geier, M. R. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin. Rheumatol. (2014). doi:10.1007/s10067-014-2846-1 – 23. VAERS data. <<http://vaers.hhs.gov/data/index>> – 24. Lee, S. H. Detection of human papillomavirus (HPV) I1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine gardasil. J. Inorg. Biochem. 117, 85–92 (2012). – 25. Lee, S. H. Melting profiles may affect detection of residual HPV I1 gene DNA fragments in gardasil. Curr. Med. Chem. 21, 932–940 (2014). – 26. Menores perdem sensibilidade das pernas e são internadas após vacina contra HPV - correio do estado. <<http://www.correiodoestado.com.br/brasilmundo/adolescentes-perdem-sensibilidade-das-pernas-e-sao-internadas-apos-vac/226651/>> – 27. Choques entre comunidad y policía carmen de bolívar - 3 de septiembre de 2014 - YouTube. <<https://www.youtube.com/watch?v=hY2B1jxvs2A>> – 28. New website launched for gardasil victims | the truth about gardasil. <<http://truthaboutgardasil.org/breaking-news-truth-about-gardasil-makes-head>>

- lines/new-website-launched-for-gardasil-victims/> – **29**. Gardasil victims action alliance. Facebook. <<https://www.facebook.com/momonamission4shelby>> – **30**. VICTIMES DU VACCIN GARDASIL. Facebook. <<https://www.facebook.com/pages/VICTIMES-DU-VACCIN-GARDASIL/142779429124878>> – **31**. Cervix vaccine issues trigger health notice. The Japan Times Online (2013). <<http://www.japantimes.co.jp/news/2013/06/15/national/cervix-vaccine-issues-trigger-health-notice/>> – **32**. Health risks push israeli health ministry to reconsider HPV vaccine for teen girls. Haaretz.com. <<http://www.haaretz.com/news/israel/premium-1.545014>> – **33**. <http://economictimes.indiatimes.com/articleshow/17932298.cms>. The economic times. <<http://economictimes.indiatimes.com/articleshow/17932298.cms>> – **34**. Dhar, A. HPV vaccine programme: Brinda seeks impartial enquiry. The Hindu (2010). <<http://www.thehindu.com/news/national/article3911111.ece>> – **35**. Shetty, P. Vaccine trial's ethics criticized. Nat. News 474, 427–428 (2011). – **36**. Syrjänen, K. J. Prophylactic HPV vaccines: The Finnish perspective. Expert Rev Vaccines 9, 45–57 (2010). – **37**. Bonanni, P. et al. An overview on the implementation of HPV vaccination in europe. Hum. Vaccin. 7, 128–135 (2011). – **38**. Arbyn, M. et al. Worldwide burden of cervical cancer in 2008. <<http://annonc.oxfordjournals.org>> – **39**. Sander, B. B., Rebolj, M., Valentiner-Branth, P. & Lyngé, E. Introduction of human papillomavirus vaccination in nordic countries. vaccine 30, 1425–1433 (2012). – **40**. Human papillomavirus (HPV) vaccines. National cancer institute. <<http://www.cancer.gov/cancertopics/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet>> – **41**. Cancer de l'utérus : Le champignon shiitake détruirait le virus HPV. <<http://france.euroclinix.net/blog/sante-sexuelle/le-champignon-shiitake-cancer-de-luterus.html>> – **42**. Introduction of HPV vaccines in european union countries: An update. (ECDC [u.a.], 2012). <http://ecdc.europa.eu/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf> – **43**. Infections à HPV : Nouveau schéma vaccinal du vaccin gardasil. <<http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=416>> – **44**. Vaccination contre les infections à papillomavirus humains. données actualisées. <<http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=454>> – **45**. Relevé épidémiologique hebdomadaire. (2014). <<http://www.who.int/wer/2014/wer8943.pdf?ua=1>> – **46**. GARDASIL : La fiche technique ! - TaSante.com. <<http://www.tasante.com/article/lire/4268/GARDASIL-La-fiche-technique.html>> – **47**. Nouvelle, L. François Hollande réhabilite le vaccin contre le cancer du col de l'utérus. usinouvelle.com. (2014). <<http://www.usinouvelle.com/article/francois-hollande-rehabilite-le-vaccin-contre-le-cancer-du-col-de-l-uterus.N238037>> – **48**. L'affaire gardasil: Premières plaintes déposées. Atticus avocats. <<http://www.atticusavocats.com/vaccin-gardasil-plainte/>> – **49**. Merck & its HPV vaccine: Sales & skepticism are both up. Forbes. <<http://www.forbes.com/sites/edsilverman/2013/03/27/merck-its-hpv-vaccine-sales-skepticism-are-both-up/>> – **50**. Gardasil la publicité diffusée à la télévision. Dailymotion. <http://www.dailymotion.com/video/x54jx0_gardasil-la-publicite-diffusee-a-la-news> – **51**. The nobel prize in physiology or medicine 2008. <http://www.nobelprize.org/nobel_prizes/medicine/laureates/2008/> – **52**. Tout le monde doit connaître cette histoire. Stock. <<http://www.editions-stock.fr/tout-le-monde-doit-connaître-cette-histoire-9782234063754>> – **53**. Bo angelin. <<http://ki.se/en/people/boang>> – **54**. admin. The nobel assembly. The nobel prize in physiology or medicine. <<http://www.nobelprizemedicine.org/selecting-laureates/the-nobel-assembly/>> – **55**. AstraZeneca appoints bo angelin to its board of directors. <<http://www.firstwordpharma.com/node/93520>> – **56**. AstraZeneca nobel medicine initiative. <http://www.nobelprize.org/nobel_organizations/nobelmedia/s_partners/astrazeneca/> – **57**. AstraZeneca - AstraZeneca nobel medicine initiative. <<http://www.astrazeneca.com/Research/nobel-medicine-initiative>> – **58**. About MedImmune. AstraZeneca careers. <<http://www.astrazenecacareers.com/about-us/medimmune/>> – **59**. Padmanabhan, S., Amin, T., Sampat, B., Cook-Deegan, R. & Chandrasekharan, S. Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in india. Nat. Biotechnol. 28, 671–678 (2010). – **60**. Gardasil: Critiques et controverses à l'étranger : Pharmacritique. <<http://pharmacritique.20minutes-blogs.fr/gardasil-tres-critique-a-l-etranger/>> – **61**. Inserm. Pourquoi le virus de la rougeole est-il si contagieux ? (2011). <<http://www.inserm.fr/espace-journalistes/pourquoi-le-virus-de-la-rougeole-est-il-si-contagieux>> – **62**. OMS. Les sept raisons essentielles pour que la vaccination reste une priorité dans la région européenne de l'OMS. <http://www.euro.who.int/__data/assets/pdf_file/0016/84310/Seven_Key_ReasonsF.pdf?ua=1> – **63**. Parent du Châtelier, I. & Levy-Bruhl, Daniel. Surveillance de la rougeole en france. <http://www.invs.sante.fr/publications/2004/rougeole_071204/rapport_rougeole.pdf> – **64**. Richard, J.L., Boubaker, K., Doutaz, M. & Schubiger, G. Déclaration obligatoire de la rougeole en suisse: Forte augmentation du nombre de cas au printemps 2003. (2003). <<http://www.saez.ch/docs/saez/archiv/fr/2003/2003-27/2003-27-640.pdf>> – **65**. InVS. Rougeole / maladies à prévention vaccinale / maladies infectieuses / dossiers thématiques / accueil. <<http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Rougeole>> – **66**. Bankamp, B., Takeda, M., Zhang, Y., Xu, W. & Rota, P. A. Genetic characterization of measles vaccine strains. J Infect Dis. 204, S533–S548 (2011). – **67**. Hilleman, M. R. et al. Development and evaluation of the moraten measles virus vaccine. jama 206, 587–590 (1968). – **68**. Euro-Surveillance. BULLETIN EUROPÉEN SUR LES MALADIES TRANSMISSIBLES. 3, 115–126 (1998). – **69**. Ministère de la Santé Publique. Calendrier des vaccinations et recommandations vaccinales 2014. (2014). <http://www.social-sante.gouv.fr/IMG/pdf/Calendrier_vaccinal_ministere_sante_2014.pdf> – **70**. Groupe d'études sur la vaccination. SYNTHÈSE DES RECOMMANDATIONS DU GROUPE D'ÉTUDES SUR LA VACCINATION. (2012). <<http://www.annpoursinoff.fr/wp-content/uploads/2012/03/GE-Vaccination-13-mars-2012-AN.pdf>> – **71**. Direction générale de la santé & Comité technique des vaccinations. Guide des vaccinations 2012, rougeole. (2012). <http://www.inpes.sante.fr/10000/themes/vaccination/guide-vaccination-2012/pdf/GuideVaccinations2012_Vaccination_contre_la_rougeole.pdf> – **72**. Rey, M., Celers, J., Mouton, Y. & Netter, R. Impact of measles in france. Rev. Infect. Dis. 5, 433–438 (1983). – **73**. Hendriks, J. & Blume, S. Measles vaccination before the measles-mumps-rubella vaccine. Am J Public Health 103, 1393–1401 (2013). – **74**. Merler, S. & Ajelli, M. Deciphering the relative weights of

- demographic transition and vaccination in the decrease of measles incidence in Italy. *Proc. Biol. Sci.* 281, 20132676 (2014). – **75.** WHO. WHO vaccine-preventable diseases: Monitoring system. 2014 global summary. (2014). <http://apps.who.int/immunization_monitoring/globalsummary/incidences?c=FRA> – **76.** Garg, R. Subacute sclerosing panencephalitis. *Postgrad Med J* 78, 63–70 (2002). – **77.** Antona, D. et al. La rougeole en France. *médecine/sciences* 28, 1003–1007 (2012). – **78.** Campbell, H., Andrews, N., Brown, K. E. & Miller, E. Review of the effect of measles vaccination on the epidemiology of SSPE. *Int. J. Epidemiol.* 36, 1334–1348 (2007). – **79.** Mgone, C. S. et al. Clinical presentation of subacute sclerosing panencephalitis in Papua New Guinea. *Tropical Medicine & International Health* 8, 219–227 (2003). – **80.** Akram, M., Naz, F., Malik, A. & Hamid, H. Clinical profile of subacute sclerosing panencephalitis. *J Coll Physicians Surg Pak* 18, 485–488 (2008). – **81.** Marin, M. et al. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: Implications for vaccination policy. *Clin. Infect. Dis.* 42, 315–319 (2006). – **82.** Poland, G. A. & Jacobson, R. M. The re-emergence of measles in developed countries: Time to develop the next-generation measles vaccines? *vaccine* 30, 103–104 (2012). – **83.** Gregory a. Poland, M.D. - Mayo Clinic faculty profiles - Mayo Clinic Research. <<http://www.mayo.edu/research/faculty/poland-gregory-a-m-d/bio-00078220>> – **84.** A physician's guide for anti-vaccine parents - ScienceDaily. <<http://www.sciencedaily.com/releases/2012/04/120423131344.htm>> – **85.** Gregory a. Poland - Patent inventor. <<http://www.freshpatents.com/Gregory-A-Poland-Rochester-invdxp.php>> – **86.** Poland, G. A. MMR vaccine and autism: Vaccine nihilism and postmodern science. *Mayo Clin Proc* 86, 869–871 (2011). – **87.** Boulianne, N. et al. [Major measles epidemic in the region of Quebec despite a 99% vaccine coverage]. *Can J Public Health* 82, 189–190 (1991). – **88.** Yeung, L. F. et al. A limited measles outbreak in a highly vaccinated US boarding school. *pediatrics* 116, 1287–1291 (2005). – **89.** Journal/MMWR articles of MMR vaccine failure. <<http://www.whale.to/vaccines/mmrjournal.html>> – **90.** OMS. OMS | l'Assemblée mondiale de la santé s'achève sur de nombreuses résolutions adoptées. (2010). <http://www.who.int/mediacentre/news/releases/2010/wha_closes_20100521/fr/> – **91.** OMS. OMS | rougeole. (2015). <<http://www.who.int/mediacentre/factsheets/fs286/fr/>> – **92.** Ministère de la Santé et des Solidarités. PLAN d'ÉLIMINATION DE LA ROUGEOLE ET DE LA RUBEOLE CONGÉNITALE EN FRANCE 2005-2010. (2005). <http://www.sante.gouv.fr/IMG/pdf/plan_elimination_rougeole.pdf> – **93.** Sencer, D. J., Dull, H. B. & Langmuir, A. D. Epidemiologic basis for eradication of measles in 1967. *Public Health Rep* 82, 253–256 (1967). – **94.** NHS England. NHS public health functions agreement 2015-16. (2014). <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/383184/1516_No10_Measles_Mumps_and_Rubella_MMR_Immunisation_Programme_FINAL.pdf> – **95.** Malaiyan, J. & Menon, T. Low vaccine efficacy of mumps component among MMR vaccine recipients in Chennai, India. *Indian J Med Res* 139, 773–775 (2014). – **96.** Ong, G., Goh, K. T., Ma, S. & Chew, S. K. Comparative efficacy of rubini, jeryl-lynn and urabe mumps vaccine in an Asian population. *J. Infect.* 51, 294–298 (2005). – **97.** EuroSurveillance. Deux épidémies d'oreillons chez des enfants vaccinés avec la souche rubini en Espagne indiquent une faible efficacité vaccinale. 5, (2000). – **98.** Office fédérale de la santé publique Suisse. Bulletin 16/02. 300–311 (2002). <<http://www.bag.admin.ch/dokumentation/publikationen/01435/01800/index.html?lang=fr&download=NHZLpZig7t,lnp6lONTU042l2Z6ln1ae2lZn4Z2qZpnO2Yuvq2Z6gpjCEdoR4g2ym162pdYbUzd,Gpd6emK2Oz9aGodetmqan19Xl2lDvoaCUZs,->>> – **99.** Oreillons : La souche vaccinale rubini abandonnée en Suisse - rougeole - destination santé. L'information santé au quotidien. (2002). <<https://destinationsante.com/oreillons-la-souche-vaccinale-rubini-abandonnee-en-suisse.html>> – **100.** OMS. Relevé épidémiologique hebdomadaire. 82, 49–60 (2007). – **101.** United States District Court for the Eastern District of Pennsylvania. Civil action no. 10-4374. (2012). <<http://www.rescuepost.com/files/june-mumps-suit-1.pdf>> – **102.** Gans, H. A. & Maldonado, Y. A. Loss of passively acquired maternal antibodies in highly vaccinated populations: An emerging need to define the ontogeny of infant immune responses. *J Infect Dis.* jit144 (2013). doi:10.1093/infdis/jit144 – **103.** Waaijenborg, S. et al. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. *J Infect Dis.* jit143 (2013). doi:10.1093/infdis/jit143 – **104.** D'Souza, R. M. & D'Souza, R. Vitamin A for treating measles in children. *Cochrane Database Syst Rev* CD001479 (2002). doi:10.1002/14651858.CD001479 – **105.** OMS. Vaccination contre les maladies contagieuses courantes de l'enfance. (1950). <http://whqlibdoc.who.int/trs/WHO_TRS_6_fre.pdf> – **106.** Très forte augmentation du nombre de cas de rougeole en 2011. (2011). <http://www.ars.centre.sante.fr/fileadmin/CENTRE/Internet_ARS/Notre_sante/Prevenir_les_risques/Vaccination/Idees_recues_rougeole_DEF.pdf> – **107.** Demicheli, V., Rivetti, A., Debalini, M. G. & Di Pietrantonj, C. Vaccines for measles, mumps and rubella in children. *Cochrane Database Syst Rev* 2, CD004407 (2012). – **108.** Black, C., Kaye, J. A. & Jick, H. MMR vaccine and idiopathic thrombocytopenic purpura. *Br J Clin Pharmacol* 55, 107–111 (2003). – **109.** Retornaz, F. & Soubeyrand, J. Le purpura thrombotique thrombocytopenique : Physiopathologie et traitement. *Réanimation* 2002 (2002). <http://www.srlf.org/rc/org/srlf/html/Article/2011/20110808-095613-020/src/html_full-Text/fr/0207-Reanimation-Vol11-N5-p333_340.pdf> – **110.** Brown, E. G., Furesz, J., Dimock, K., Yarosh, W. & Contreras, G. Nucleotide sequence analysis of urabe mumps vaccine strain that caused meningitis in vaccine recipients. *vaccine* 9, 840–842 (1991). – **111.** Dourado, I. et al. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: Implications for immunization programs. *Am. J. Epidemiol.* 151, 524–530 (2000). – **112.** Sharma, H. J. et al. No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. *Clin. Microbiol. Infect.* 16, 347–352 (2010). – **113.** Résumé des caractéristiques du produit m-m-RVAXPRO. <http://www.euro.ema.europa.eu/docs/fr_FR/document_library/EPAR_-_Product_Information/human/000604/WC500030170.pdf> – **114.** Erlewyn-Lajeunesse, M., Hunt, L. P., Heath, P. T. & Finn, A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. *Arch. Dis. Child.* 97, 487–490 (2012). – **115.** Sanofi Pasteur. Sanofi pasteur va cesser la production et la commercialisation de ses

vaccins contenant l'antigène rougeole. (2014).

- <http://sanofi-pasteur.com/fr/Documents/PDF/Information_sur_les_vaccins_contenant_la_rougeole.pdf> – **116**. Sørup, S., Benn, C. S., Stensballe, L. G., Aaby, P. & Ravn, H. Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contact. *vaccine* 33, 237–245 (2015). – **117**. McKeever, T. M., Lewis, S. A., Smith, C. & Hubbard, R. Vaccination and allergic disease: A birth cohort study. *Am J Public Health* 94, 985–989 (2004). – **118**. Ligue Nationale Pour la Liberté des Vaccinations. Composants des vaccins. (2015). <<http://www.infovaccin.fr/composants.html>> – **119**. ANSM. THIOMERSAL - ANSM : Agence nationale de sécurité du médicament et des produits de santé. (2009). <<http://www.ansm.sante.fr/s-informer/Presse-Communiques-Points-presse/THIOMERSAL>> – **120**. Wakefield, A. J. et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet* 351, 637–641 (1998). – **121**. Royal Courts of Justice. Wakefield v channel four television corporation & anor [2005] EWHC 2410 (QB) (04 novembre 2005). (2005). <<http://www.bailii.org/ew/cases/EWHC/QB/2005/2410.html>> – **122**. BBC news - profile: Dr andrew wakefield. <<http://news.bbc.co.uk/2/hi/health/3513365.stm>> – **123**. MMR row doctor andrew wakefield struck off register | sociology | the guardian. <<http://www.theguardian.com/science/2010/may/24/mmr-doctor-andrew-wakefield-struck-off>> – **124**. Justia. Immunostimulating method patent (patent # 4,755,382 issued July 5, 1988) - justia patents database. <<http://patents.justia.com/patent/4755382>> – **125**. Flaherty, D. K. The vaccine-autism connection: A public health crisis caused by unethical medical practices and fraudulent science. *Ann Pharmacother* 45, 1302–1304 (2011). – **126**. Pharmaceutiques. Pharmaceutiques - archives : Revue de presse. (2003). <<http://www.pharmaceutiques.com/phq/rdp/art/12005>> – **127**. The Telegraph. Reed elsevier begins hunt for a successor to sir crispin davis - telegraph. (2008). <<http://www.telegraph.co.uk/finance/newsbysector/mediatechnologyandtelecoms/2793149/Reed-Elsevier-begins-hunt-for-a-successor-to-Sir-Crispin-Davis.html>> – **128**. Wakefield, A. et al. RE-TRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *The Lancet* 351, 637–641 (1998). – **129**. The Sunday Times. MMR doctor andrew wakefield fixed data on autism | the sunday times. (2009). <<http://www.thesundaytimes.co.uk/sto/public/news/article148992.ece>> – **130**. Dyer, C. US parents take government to court over MMR vaccine. *BMJ* 334, 1241 (2007). – **131**. The Telegraph. Six city chiefs made knights in honours list - telegraph. (2004). <<http://www.telegraph.co.uk/finance/2887791/Six-City-chiefs-made-knights-in-honours-list.html>> – **132**. Forbes. Rupert murdoch & family. Forbes. (2015). <<http://www.forbes.com/profile/rupert-murdoch/>> – **133**. Le Monde. James Murdoch démissionne de la direction du. *Le Monde.fr: International* (2011). <http://www.lemonde.fr/europe/article/2011/11/23/james-murdoch-démissionne-de-la-direction-du-sun-et-du-times_1608220_3214.html> – **134**. Reuters. James murdoch to quit GSK board. reuters (2012). <<http://www.reuters.com/article/2012/01/27/us-glaxosmithkline-idUSTRE80QOJ20120127>> – **135**. Wikipédia. Scandale du piratage téléphonique par News International. Wikipédia (2013). <https://fr.wikipedia.org/w/index.php?title=Scandale_du_piratage_t%C3%A9l%C3%A9phonique_par_News_International&oldid=97957770> – **136**. Adventures in Autism. Adventures in autism: Revisiting james murdoch, brian deer, the sunday times, GlaxoSmithKline and the attack on andrew wakefield. (2011). <<http://adventuresinautism.blogspot.fr/2011/07/revisiting-james-murdoch-brian-deer.html>> – **137**. Wakefield, A. J. Callous disregard: Autism and vaccines—the truth behind a tragedy. (Skyhorse Publishing, 2011). – **138**. Mercola, Joseph. A special interview with dr. andrew wakefield. (2010). <<http://mercola.fileburst.com/PDF/ExpertInterviewTranscripts/InterviewAndrewWakefield.pdf>> – **139**. InVS. Épidémie de rougeole en france. (2014). <<http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Rougeole/Points-d-actualites/Archives/Epidemie-de-rougeole-en-France-Actualisation-des-donnees-de-surveillance-au-23-janvier-2014>> – **140**. Poursinoff, Anny. Le vaccin contre la rougeole, une nécessité à relativiser. *Rue89*. (2011). <<http://www.rue89.com/2011/05/31/le-vaccin-contre-la-rougeole-une-neeessite-a-relativiser-206375>> – **141**. Gregory, Andrew. First measles death in five years and doctors warn epidemic could claim more lives. *Mirror*. (2013). <<http://www.mirror.co.uk/news/uk-news/first-measles-death-five-years-1840895>> – **142**. The Editorial Board. The aftermath of measles vaccine scare in britain. *The New York Times* (2013). <<http://www.nytimes.com/2013/05/23/opinion/the-aftermath-of-measles-vaccine-scare-in-britain.html>> – **143**. Le Parisien. Californie : flambée de rougeole à Disneyland. leparisien.fr. (2015). <<http://www.leparisien.fr/laparisienne/sante/californie-flambée-de-rougeole-a-disneyland-22-01-2015-4470289.php>> – **144**. California Department of Public Health. California department of public health confirms 59 cases of measles. (2015). <<http://www.cdph.ca.gov/Pages/NR15-008.aspx>> – **145**. CDC. CDC - coverage 2013 national immunization survey infographic - vaccines. (2014). <<http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/infographic-2013.html>> – **146**. 20 Minutes. États-unis: La rougeole envahit la californie depuis disneyland. 20minutes.fr. (2015). <<http://www.20minutes.fr/sante/1524203-20150123-etats-unis-rougeole-envahit-californie-depuis-disneyland>> – **147**. Le Figaro. Des dizaines de cas de rougeole en californie. *Le figaro*. (2015). <<http://www.lefigaro.fr/flash-actu/2015/01/22/97001-20150122FILWWW00519-des-dizaines-de-cas-de-rougeole-en-californie.php>> – **148**. La Dépêche. USA : Une épidémie qui part de disneyland. *Ladepeche.fr*. (2015). <<http://www.ladepeche.fr/article/2015/01/26/2036650-usa-une-epidemie-qui-part-de-disneyland.html>> – **149**. Paris Match. La rougeole s'est déclarée à disneyland - avant le super bowl, la peur d'une épidémie. *ParisMatch.com*. (2015). <<http://www.parismatch.com/Actu/Sport/Avant-le-Super-Bowl-la-peur-d-une-epidemie-700280>> – **150**. France Info. Aux États-unis, certains parents refusent de faire vacciner leurs enfants contre la rougeole. *France info*. (2015). <<http://www.franceinfo.fr/emission/en-direct-du-monde/2014-2015/aux-etats-unis-certains-parents-refusent-de-faire-vacciner-leurs-enfants-contre-la>> – **151**. TFI. TFI. Les vidéos inf - une épidémie de rougeole partie de disneyland inquiète les services sanitaires américain. (2014). <<http://videos.tfi.fr/infos/2015-une-epidemie-de-rougeole-partie-de-disneyland-inquiete-les-services-855184.html>> – **152**. Le Quotidien du Médecin. Flambée de cas de rougeole aux États-unis : Les anti-vaccins mis en accusation. *Le quotidien du médecin*. (2014).

- <http://www.lequotidiendumedecin.fr/actualites/article/2014/06/27/flambee-de-cas-de-rougeole-aux-etats-unis-les-anti-vaccins-mis-en-accusation_703586> – **153**. Los Angeles Times. Blame disneyland measles outbreak on anti-science stubbornness. Los Angeles Times (2015). <<http://www.latimes.com/opinion/editorials/la-ed-measles-disneyland-20150116-story.html>> – **154**. Inserm. Grippe. <<http://www.inserm.fr/thematiques/immunologie-inflammation-infectiologie-et-microbiologie/dossiers-d-information/grippe>> – **155**. Le Figaro. Un vaccin peu efficace contre la grippe cet hiver. (2015). <<http://sante.lefigaro.fr/actualite/2015/01/29/23317-vaccin-peu-efficace-contre-grippe-cet-hiver>> – **156**. Inpes. Les grippest. (2011). <<http://www.inpes.sante.fr/10000/themes/grippest/index.asp>> – **157**. InVS, ANSM & HCSP. Campagne de vaccination contre la grippe saisonnière une priorité de santé publique. (2013). <http://www.grog.org/documents/dp_grippe_2013_081013.pdf> – **158**. Direction générale de la santé. Avis du conseil supérieur d'hygiène publique de france. (2004). <http://www.hcsp.fr/explorer.cgi/a_mt_160104_grippe_collectivite.pdf> – **159**. Groupe d'Expertise et d'Information sur la Grippe. Couverture vaccinale. <<http://www.grippe-geig-com/webapp/website/website.html?id=2535762&pageId=198625>> – **160**. Savulescu, C. et al. Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza a(H1N1) than in a(H3N2) seasons: Test-negative case-control studies using surveillance data, spain, 2003-2011. *vaccine* 32, 4404-4411 (2014). – **161**. Vidal. Grippe : Le seuil épidémique a été franchi en france, prédominance de la souche virale a(H3N2) mutée. (2015). <http://www.vidal.fr/actualites/14905/grippe_le_seuil_epidémique_a_ete_franchi_en_france_predominance_de_la_souche_virale_a_h3n2_mutée/> – **162**. CDC. Early estimates of seasonal influenza vaccine effectiveness united states, january 2015. (2015). <<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6401a4.htm>> – **163**. Sanofi-Pasteur, S. P. premier producteur mondial de vaccin contre la grippe. Dossier de presse, la grippe saisonnière. (2013). <http://www.sanofipasteur.com/fr/Documents/PDF/Press_Kit_Seasonal_Influenza_FR_2013-09.pdf> – **164**. Pebody, Richard & Warburton, F. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the united kingdom: 2014/15 midseason result. (2015). <<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21025>> – **165**. Osterholm, M. T., Kelley, N. S., Sommer, A. & Belongia, E. A. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. *Lancet Infect. Dis.* 12, 36-44 (2012). – **166**. Osterholm, Michael et al. The compelling need for game- changing influenza vaccines. CIDRAP (2012). <http://www.cidrap.umn.edu/sites/default/files/public/downloads/ccivi_report.pdf> – **167**. Bach, J.-F. Immunosénescence. *Comptes Rendus Biologies* 325, 751-753 (2002). – **168**. Haut Conseil de la Santé Publique. Avis relatif à l'utilisation du vaccin contre la grippe saisonnière FluarixTetra. (2014). <https://www.mesvaccins.net/textes/hcspa20140523_placefluarixetragrippe.pdf> – **169**. Kieninger, D. et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III, randomized trial in adults aged 18 years. *BMC Infect Dis* 13, 343 (2013). – **170**. Domachowski, J. B. et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. *J Infect Dis* 207, 1878-1887 (2013). – **171**. Jain, V. K. et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. *N. Engl. J. Med.* 369, 2481-2491 (2013). – **172**. Jain, V. K. et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. *N. Engl. J. Med.* 369, 2481-2491 (2013). – **173**. Kieninger, D. et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III, randomized trial in adults aged 18 years. *BMC Infect Dis* 13, 343 (2013). – **174**. Food and Drug Administration. FLUARIX QUADRIVALENT (influenza vaccine). (2014). <<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220624.pdf>> – **175**. Cour des Comptes. La campagne de lutte contre la grippe a(H1N1) : Bilan et enseignements. (2011). <https://www.c-comptes.fr/content/download/1512/14991/version/1/file/5_lutte_contre_la_grippe_a_H1N1.pdf> – **176**. Inserm. Grippe a/H1N1 : Bilan et perspectives de la recherche à un an. (2010). <<http://www.inserm.fr/espace-journalistes/grippe-a-h1n1-bilan-et-perspectives-de-la-recherche-a-un-an>> – **177**. InVS. Épidémie de grippe a(H1N1)2009 : Premiers éléments de bilan en france. *Bulletin Épidémiologique Hebdomadaire* (2010). <http://www.invs.sante.fr/beh/2010/24_25_26/beh_24_25_26_2010.pdf> – **178**. Morgan, O. W. et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza a(H1N1) disease. *PLoS ONE* 5, e9694 (2010). – **179**. Fezeu, L. et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza a (h1N1) patients: A systematic review and meta-analysis. *Obes Rev* 12, 653-659 (2011). – **180**. Zarychanski, R. et al. Correlates of severe disease in patients with 2009 pandemic influenza (h1N1) virus infection. *CMAJ* 182, 257-264 (2010). – **181**. Tricco, A. C., Lillie, E., Soobiah, C., Perrier, L. & Straus, S. E. Impact of h1N1 on socially disadvantaged populations: Systematic review. *PLoS ONE* 7, e39437 (2012). – **182**. Viasus, D. et al. Factors associated with severe disease in hospitalized adults with pandemic (h1N1) 2009 in spain. *Clin. Microbiol. Infect.* 17, 738-746 (2011). – **183**. Ribeiro, A. F. et al. Risk factors for death from influenza a(H1N1)pdm09, state of são paulo, brazil, 2009. *PLoS ONE* 10, e0118772 (2015). – **184**. Murhekar, M. et al. Risk factors associated with death among influenza a (h1N1) patients, tamil nadu, india, 2010. *J. Postgrad. Med.* 59, 9 (2013). – **185**. Van Kerkhove, M. D. et al. Risk factors for severe outcomes following 2009 influenza a (h1N1) infection: A global pooled analysis. *PLoS Med.* 8, e1001053 (2011). – **186**. Résumé des caractéristiques du produit pandemrix. <http://www.ema.europa.eu/docs/fr_FR/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf> – **187**. Pelat, C. et al. Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 a(H1N1) influenza: Estimations from surveillance data in france. *PLoS ONE* 6, e19621 (2011). – **188**. Hardehid, P. et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza a(H1N1)2009 infection in england and scotland 2009-2010. *Euro Surveill.* 16, (2011). – **189**. Valenciano, M. et al. Estimates of pandemic influenza vaccine effectiveness in europe, 2009-2010: Results of influenza monitoring vaccine effectiveness in europe (i-MOVE) multicentre case-control study. *PLoS Med.* 8, e1000388 (2011).

- **190.** Centers for Disease Control and Prevention. H1N1 flu | non-safety-related voluntary recall of sanofi pasteur pediatric vaccine (december 2009). (2009). <http://www.cdc.gov/h1n1flu/vaccination/syringes_qa.htm> – **191.** Dauvilliers, Y. et al. Increased risk of narcolepsy in children and adults after pandemic h1N1 vaccination in france. *brain* 136, 2486–2496 (2013). – **192.** Le Parisien. La facture de la grippe A s'alourdit. *leparisien.fr*. (2013). <<http://www.leparisien.fr/societe/la-facture-de-la-grippe-a-s-alourdit-20-12-2013-3427137.php>> – **193.** Medical Products Agency de Suède. Report from an epidemiological study in sweden on vaccination with pandemic and narcolepsy - medical products agency, sweden. (2011). <<https://lakemedelsverket.se/english/All-news/NYHETER-2011/Report-from-an-epidemiological-study-in-Sweden-on-vaccination-with-Pandemrix-and-narcolepsy-/>> – **194.** Jefferson, T. et al. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev* CD001269 (2010). doi:10.1002/14651858.CD001269.pub4 – **195.** Goldman, G. S. Comparison of VAERS fetal-loss reports during three consecutive influenza seasons was there a synergistic fetal toxicity associated with the two-vaccine 2009/2010 season? *Hum Exp Toxicol* 32, 464–475 (2013). – **196.** Stowe, J., Andrews, N., Wise, L. & Miller, E. Investigation of the temporal association of guillain-barré syndrome with influenza vaccine and influenzalike illness using the united kingdom general practice research database. *Am. J. Epidemiol.* 169, 382–388 (2009). – **197.** Fell, D. B. et al. Fetal death and preterm birth associated with maternal influenza vaccination: Systematic review. *BJOG* 122, 17–26 (2015). – **198.** Häberg, S. E. et al. Risk of fetal death after pandemic influenza virus infection or vaccination. *N. Engl. J. Med.* 368, 333–340 (2013). – **199.** Bednarczyk, R. A., Adjaye-Gbewonyo, D. & Omer, S. B. Safety of influenza immunization during pregnancy for the fetus and the neonate. *Am. J. Obstet. Gynecol.* 207, S38–46 (2012). – **200.** Groupes Régionaux d'Observation de la Grippe. Estimation GROG du coût direct de l'épidémie de grippe 2005/2006. <http://open-rome.org/documents/eco/2007_JNL_poster_ecogrippe.pdf> – **201.** INRS. Influenza aviaire, grippe aviaire et menace de pandémie : Un nouvel enjeu en santé au travail. (2006). <<http://www.inrs.fr/dms/inrs/CataloguePapier/DMT/TT-TC-107/tc107.pdf>> – **202.** Institut Pasteur. Grippe. Institut pasteur. (2014). <<http://www.pasteur.fr/fr/institut-pasteur/presse/fiches-info/grippe>> – **203.** Boursier. Retraites : La pension moyenne atteint 1.288 euros en france. *Boursier.com*. (2014). <<http://www.boursier.com/actualites/economie/retraites-la-pension-moyenne-atteint-1-288-euros-en-france-23806.html>> – **204.** Groupe d'Expertise et d'Information sur la Grippe. Impact économique. <<http://www.grippe-geig.com/webapp/website/website.html?id=2535762&pageld=198621>> – **205.** Europe 1. Roselyne bachelot : 'Faites-vous vacciner !'. *Dailymotion*. (2009). <http://www.dailymotion.com/video/xb4f0y_roselyne-bachelot-faites-vous-vacci_news> – **206.** Sénat. Grippe a - sénat. (2010). <<http://www.senat.fr/commission/enquete/Grippe/index.html>> – **207.** Sénat. La grippe a (h1N1)v : Retours sur la première pandémie du XXIe siècle (rapport). (2010). <<http://www.senat.fr/rap/r09-685-1/r09-685-127.html>> – **208.** Sénat. Communiqué du 5 aout. (2010). <<http://www.senat.fr/presse/cp20100805.html>> – **209.** Cour des Comptes. Le patrimoine immobilier des hôpitaux non affecté aux soins. (2012). <https://www.ccomptes.fr/content/download/1838/18436/version/1/file/Patrimoine_immobilier_hopitaux_non_affecte_aux_soins.pdf> – **210.** TFI. Journal télévisé. (2009). <<http://www.wat.tv/embedframe/200162ncl0K1112384593#MYTF1NEWS/videos/catchup/jt-20h/2009/&autoStart=0&permalink=http://videos.tf1.fr/infos/2015/grumpy-cat-la-chatte-aux-oeufs-d-or-8609338.html>> – **211.** Trépo, C., Chan, H. L. Y. & Lok, A. Hepatitis b virus infection. *lancet* 384, 2053–2063 (2014). – **212.** Inpes. L'hépatite b. (2012). <<http://www.inpes.sante.fr/10000/themes/hepatites/hepatite-B.asp>> – **213.** AFSSAPS. Etat des lieux des dispositifs médicaux de diagnostic in vitro de dépistage de l'antigène HBs du virus de l'hépatite b : Problématique des mutants de l'AgHBs. (2009). <http://www.ansm.sante.fr/var/ansm_site/storage/original/application/bdc3db923d4f6b75ad4ec895932a237b.pdf> – **214.** Antona, D. & Larsen, C. Épidémiologie de l'hépatite b en france. *virologie* 14, 23–34 (2010). – **215.** Soulié, J. C. et al. [The perinatal transmission of the hepatitis b virus in the paris area]. *Ann Pediatr (Paris)* 38, 595–601 (1991). – **216.** Denis, F., Tabaste, J. L. & Ranger-Hopet, S. [Prevalence of HBs ag in about 21,500 pregnant women. survey at twelve french university hospitals. the multicentric study group]. *Pathol. Biol.* 42, 533–538 (1994). – **217.** INRS. VIRUS DE L'HEPATITE b (VHB) - agent de l'hépatite b. (2011). <<http://www.inrs.fr/eficatt/eficatt.nsf/%28allDocParRef%29/FCVHB?OpenDocument>> – **218.** Institut Pasteur. Hépatites virales. Institut pasteur. (2013). <<https://www.pasteur.fr/fr/institut-pasteur/presse/fiches-info/hepatites-virales>> – **219.** InVS. Estimation nationale de la mortalité associée et imputable à l'hépatite c et à l'hépatite b en france métropolitaine en 2001. (2008). <<http://www.invs.sante.fr/beh/2008/27/>> – **220.** Inserm. Hépatites b et c : 4 000 morts par an en france. (2008). <http://www.inserm.fr/content/download/8723/65401/version/1/file/hepatites_b_c_IA_210.pdf> – **221.** Gouvernement du Canada, S. C. Figure 1 prévalence de l'immunité contre l'hépatite b acquise par vaccination, selon le groupe d'âge, population à domicile de 14 à 79 ans, canada, 2007 à 2011. (2013). <<http://www.statcan.gc.ca/pub/82-003-x/2013011/article/11876/c-g/fig1-fra.htm>> – **222.** Chiew Tong, N. K. et al. Immunogenicity and safety of an adjuvanted hepatitis b vaccine in pre-hemodialysis and hemodialysis patients. *Kidney Int* 68, 2298–2303 (2005). – **223.** Somi, M. H. & Hajipour, B. Improving hepatitis b vaccine efficacy in end-stage renal diseases patients and role of adjuvants. *Int. Sch. Res. Not.* 2012, e960413 (2012). – **224.** Assad, S. & Francis, A. Over a decade of experience with a yeast recombinant hepatitis b vaccine. *vaccine* 18, 57–67 (1999). – **225.** OMS. Hépatite b, aide-mémoire n204. (2014). <<http://www.who.int/mediacentre/factsheets/fs204/fr/>> – **226.** GlaxoSmithKline Inc. Monographie de produit, EngerixB. (2013). <<http://www.gsk.ca/french/docs-pdf/product-monographs/Engerix-B.pdf>> – **227.** Direction générale de la santé & Comité technique des vaccinations. Guide des vaccinations 2012, hépatite b. (2012). <http://www.inpes.sante.fr/10000/themes/vaccination/guide-vaccination-2012/pdf/GuideVaccinations2012_Vaccination_contre_hepatite_B.pdf> – **228.** InVS. Bilans réguliers de surveillance - maladies infectieuses. Bulletin Épidémiologique Hebdomadaire (2007). <http://www.invs.sante.fr/beh/2007/51_52/beh_51_52_2007.pdf> – **229.** Haut Conseil de la Santé Publique. Avis re-

- latif à la vaccination contre l'hépatite b. (2008). <http://sante-etudiant.univ-pau.fr/live/digitalAssets/61/61691_hcsp_avis_vaccination_hepatite_b_021008.pdf> – **230**. Inserm. Incidence et prévalence des hépatites b et d. <<http://www.ipubli.inserm.fr/bitstream/handle/10608/205?sequence=12>> – **231**. Assemblée Nationale & Sénat. N 237 - rapport de m. paul blanc, établi au nom de cet office, sur la politique vaccinale de la france. (2007). <<http://www.assemblee-nationale.fr/13/rap-off/i0237.asp>> – **232**. Antona, Denise. L'hépatite b en france : Aspects épidémiologiques et stratégie vaccinale. <http://opac.invs.sante.fr/doc_num.php?explnum_id=3713> – **233**. team, E. C. for D. P. & Communication Unit- Eurosurveillance editorial, C. (ECDC)-Health. Surveillance and epidemiology of hepatitis b and c in europe a review. (2008). <<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18880>> – **234**. Roque-Afonso, A. M. et al. Viral and clinical factors associated with surface gene variants among hepatitis b virus carriers. *Antivir. Ther. (Lond.)* 12, 1255–1263 (2007). – **235**. Ogura, Y. et al. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis b virus. *J. Infect. Dis.* 180, 1444–1451 (1999). – **236**. Avellón, A. & Echevarria, J. M. Frequency of hepatitis b virus 'a' determinant variants in unselected spanish chronic carriers. *J. Med. Virol.* 78, 24–36 (2006). – **237**. Song, B.-C. et al. Prevalence of naturally occurring surface antigen variants of hepatitis b virus in korean patients infected chronically. *J. Med. Virol.* 76, 194–202 (2005). – **238**. Société Nationale Française de Gastro-Entérologie. Controverse sur la vaccination anti-hépatite b : L'approche scientifique. (2001). <<http://www.snfge.org/content/controverse-sur-la-vaccination-anti-hepatite-b-l-approche-scientifique>> – **239**. Hamza, H. et al. Hepatitis b vaccine induces apoptotic death in hepa1-6 cells. *Apoptosis* 17, 516–527 (2012). – **240**. Initiative Citoyenne. Scientifiquement prouvé: Le vaccin anti-hépatite b DETRUIT les cellules du foie. un comble! (2012). <<http://www.initiativecitoyenne.be/article-c-est-prouve-le-vaccin-anti-hepatite-b-detruit-les-cellules-du-foie-un-comble-109224685.html>> – **241**. Hewitson, L. et al. Delayed acquisition of neonatal reflexes in newborn primates receiving a thimerosal-containing hepatitis b vaccine: Influence of gestational age and birth weight. *J. Toxicol. Environ. Health Part A* 73, 1298–1313 (2010). – **242**. GlaxoSmithKline Inc. Monographie de produit, twinrix. (2014). <<http://www.gsk.ca/french/docs-pdf/product-monographs/Twinrix.pdf>> – **243**. GlaxoSmithKline Inc. Twinrix | questions et réponses. (2015). <<http://www.twinrix.ca/fr/q-and-a.html>> – **244**. L'Express. Vaccin contre l'hépatite b: 2,4 millions d'euros d'indemnités pour une patiente. (2014). <http://www.lexpress.fr/actualite/societe/sante/vaccin-contre-l-hepatite-b-2-4-millions-d-euros-d-indemnités-pour-une-patiente_1566309.html> – **245**. Sénat. Vaccins : Convaincre et innover pour mieux protéger. (2007). <<http://www.senat.fr/rap/r06-476/r06-47617.html>> – **246**. Assemblée Nationale. 3043 - rapport de m. philippe nauche: Commission d'enquête - campagne de vaccination de masse contre l'hépatite b, à la responsabilité de l'Etat en la matière, à la prise en charge et à l'indemnisation des victimes (AFFAIRES CULTURELLES). (2001). <http://www.assemblee-nationale.fr/rap-reso/r3043.asp#P231_30844> – **247**. Fromont, A. et al. Geographic variations of multiple sclerosis in france. *Brain* 133, 1889–1899 (2010). – **248**. Grunitzky, Eric. La sclérose en plaques en afrique noire. *African Journal of Neurological Sciences* (2001). <http://ajns.paans.org/article.php?id_article=127> – **249**. Martínez-Sernández, V. & Figueiras, A. Central nervous system demyelinating diseases and recombinant hepatitis b vaccination: A critical systematic review of scientific production. *J. Neurol.* 260, 1951–1959 (2013). – **250**. Beytout, Jean. Les polémiques autour de la vaccination. <<http://www.infectiologie.com/site/medias/diaporamas/CEMI/2011/CEMI2011-BEYTOU.pdf>> – **251**. Touzé, E., Gout, O., Verdier-Taillefer, M. H., Lyon-Caen, O. & Alperovitch, A. [The first episode of central nervous system demyelination and hepatitis b virus vaccination]. *Rev. Neurol. (Paris)* 156, 242–246 (2000). – **252**. Touzé, E. et al. Hepatitis b vaccination and first central nervous system demyelinating event: A case-control study. *neuroepidemiology* 21, 180–186 (2002). – **253**. Zipp, F., Weil, J. G. & Einhäupl, K. M. No increase in demyelinating diseases after hepatitis b vaccination. *Nat Med* 5, 964–965 (1999). – **254**. ANSM. Vaccination anti hépatite b mise à jour des données et des études de pharmacovigilance. (2000). <http://ansm.sante.fr/var/ansm_site/storage/original/application/b460a-bed4a9a61d8dad78d4364033354.pdf> – **255**. Sadovnick, A. D. & Scheifele, D. W. School-based hepatitis b vaccination programme and adolescent multiple sclerosis. *lancet* 355, 549–550 (2000). – **256**. Le Houézec, D. Evolution of multiple sclerosis in france since the beginning of hepatitis b vaccination. *Immunol. Res.* 60, 219–225 (2014). – **257**. Ascherio, A. et al. Hepatitis b vaccination and the risk of multiple sclerosis. *N. Engl. J. Med.* 344, 327–332 (2001). – **258**. Confavreux, C., Suissa, S., Saddinger, P., Bourdès, V. & Vukusic, S. Vaccinations and the risk of relapse in multiple sclerosis. *N. Engl. J. Med.* 344, 319–326 (2001). – **259**. The New England Journal of Medicine. Table of contents. (2001). <<http://www.nejm.org/toc/nejm/344/5/>> – **260**. DeStefano, F. et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. *Arch. Neurol.* 60, 504–509 (2003). – **261**. National Vaccine Information Center. Hepatitis b vaccine facts. National vaccine information center (NVIC). <<http://www.nvic.org/vaccines-and-diseases/Hepatitis-B.aspx>> – **262**. Fourier, A. et al. Hepatitis b vaccine and first episodes of central nervous system demyelinating disorders: A comparison between reported and expected number of cases. *Br J Clin Pharmacol* 51, 489–490 (2001). – **263**. Mikaeloff, Y. et al. Hepatitis b vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. *brain* 130, 1105–1110 (2007). – **264**. Mikaeloff, Y., Caridade, G., Suissa, S. & Tardieu, M. Hepatitis b vaccine and the risk of CNS inflammatory demyelination in childhood. *neurology* 72, 873–880 (2009). – **265**. ANSM. Vaccination contre le virus de l'hépatite b : Résumé des débats de la commission nationale de pharmacovigilance du 30 septembre 2008. (2008). <<http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Vaccination-contre-le-virus-de-l-hepatite-B-resume-des-debats-de-la-Commission-nationale-de-pharmacovigilance-du-30-septembre-2008/>> – **266**. Payne, D. C. et al. Anthrax vaccination and risk of optic neuritis in the united states military, 1998-2003. *Arch. Neurol.* 63, 871–875 (2006). – **267**. Hernán, M. A., Jick, S. S., Olek, M. J. & Jick, H. Recombinant hepatitis b vaccine and the risk of multiple sclerosis: A prospective study. *neurology* 63, 838–842 (2004). – **268**. Geier, D. A. & Geier, M. R. A case-control study of serious autoimmune adverse events following hepatitis b immunization. *autoimmunity* 38, 295–301 (2005). – **269**. Farez, M. F. & Correale, J. Immunizations

- cadrage. (2009). <http://www.has-sante.fr/portail/jcms/c_895662/fr/mise-en-evidence-de-limmuno-protection-antitetanique-en-contexte-durgence-note-de-cadrage> – **310**. InVS. Le tétanos en France entre 2008 et 2011. Bulletin Épidémiologique Hebdomadaire (2012). <http://www.invs.sante.fr/content/download/39487/184311/version/4/file/beh_26_2012.pdf> – **311**. INED. Causes de décès en France 1925 - 1999. Ined - institut national d'études démographiques. <<http://www.ined.fr/fr/tout-savoir-population/chiffres/bases-donnees/causes-deces-depuis-1925/>> – **312**. Christophe Jy. Français : Taux de mortalité par tétanos pour 100000 français de 1925 à 1999. (2013). <<https://commons.wikimedia.org/wiki/File:Tetanos-mortalite-pour-100000-France-1925-1999.png>> – **313**. Fraser, D. W. Tetanus in the united states, 1900-1969: Analysis by cohorts. *Am. J. Epidemiol.* 96, 306–312 (1972). – **314**. Maselle, S. Y., Matre, R., Mbise, R. & Hofstad, T. Neonatal tetanus despite protective serum antitoxin concentration. *FEMS Microbiol Immunol* 3, 171–175 (1991). – **315**. OMS. Les bases immunologiques de la vaccination - le tétanos. (1993). <http://www.apima.org/freevax/documentation/Tetanos/vaccin_tetanos.pdf> – **316**. Roper, M. H., Vandelaer, J. H. & Gasse, F. L. Maternal and neonatal tetanus. *Lancet* 370, 1947–1959 (2007). – **317**. Talukdar, B., Rath, B., Puri, R. K. & Sachdev, H. P. Neonatal tetanus despite antenatal immunization. *Indian Pediatr* 31, 724–725 (1994). – **318**. Moraes-Pinto, M. I. de et al. Neonatal tetanus despite immunization and protective antitoxin antibody. *J. Infect. Dis.* 171, 1076–1077 (1995). – **319**. Livorsi, D. J., Eaton, M. & Glass, J. Generalized tetanus despite prior vaccination and a protective level of anti-tetanus antibodies. *Am. J. Med. Sci.* 339, 200–201 (2010). – **320**. Pryor, T., Onarecker, C. & Coniglione, T. Elevated antitoxin titers in a man with generalized tetanus. *J Fam Pract* 44, 299–303 (1997). – **321**. Crone, N. E. & Reder, A. T. Severe tetanus in immunized patients with high anti-tetanus titers. *Neurology* 42, 761–764 (1992). – **322**. Demicheli, V., Barale, A. & Rivetti, A. in *Cochrane database of systematic reviews* (John Wiley & Sons, Ltd, 2013). <<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002959.pub3/abstract>> – **323**. Newell, K. W., Lehmann, A. D., Leblanc, D. R. & Osorio, N. G. The use of toxoid for the prevention of tetanus neonatorum. *Bull World Health Organ* 35, 863–871 (1966). – **324**. Centers for Disease Control and Prevention. Tetanus surveillance — united states, 2001–2008. (2011). <<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6012a1.htm>> – **325**. European Centre for Disease Prevention and Control. Annual epidemiological report vaccine-preventable diseases 2014. (2014). <http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f5ad51-4aed-4d32-b960-af70113dbb90&ID=1227> – **326**. Eubelen, C. et al. Effect of an audiovisual message for tetanus booster vaccination broadcast in the waiting room. *BMC Fam Pract* 12, 104 (2011). – **327**. Service Public. Calendrier des vaccinations. (2014). <<http://vosdroits.service-public.fr/particuliers/F724.xhtml>> – **328**. Haut Conseil de la Santé Publique. AVIS relatif aux rappels de vaccination antitétanique dans le cadre de la prise en charge des plaies. (2013). <http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20130524_rappelvacinationantitetanique.pdf> – **329**. InVS. Enquête nationale de couverture vaccinale, France. (2011). <<http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2011/Enquete-nationale-de-couverture-vaccinale-France-janvier-2011>> – **330**. Insee. Statistiques d'état civil sur les naissances en 2011. (2012). <http://www.insee.fr/fr/themes/document.asp?ref_id=sd20111> – **331**. Cissoko, Y. Coût direct de la prise en charge hospitalière et facteurs prédictifs de mauvais pronostic du tétanos a dakar (sénégal). *Médecine D39Afrique Noire* 61, 411–6 (2014). – **332**. OMS. Relevé épidémiologique hebdomadaire. 89, 177–188 (2014). – **333**. OMS, Unicef & UNFPA. Éliminer durablement le tétanos maternel et néonatal plan stratégique 2012-2015. (2012). <http://www.who.int/immunization/diseases/MNTEStrategicPlan_F.pdf> – **334**. Lam, P. K. et al. Prognosis of neonatal tetanus in the modern management era: An observational study in 107 vietnamese infants. *Int. J. Infect. Dis.* 33, 7–11 (2015). – **335**. Unicef. Tétanos maternel et néonatal, vaccination. <http://www.unicef.org/french/immunization/23245_mnt.html> – **336**. Thwaites, C. L., Beeching, N. J. & Newton, C. R. Maternal and neonatal tetanus. *Lancet* 385, 362–370 (2015). – **337**. Unicef. Élimination du tétanos maternel et néo-natal. UNICEF. (2010). <http://www.unicef.org/french/health/index_43509.html> – **338**. OMS. Manuel d'application pratique pour l'élimination du tétanos néonatal. (1999). <http://whqlibdoc.who.int/hq/1999/WHO_V\&B_99.14_fre.pdf> – **339**. Unicef. Maternal and neonatal tetanus eliminated in China. (2012). <http://www.unicef.org/eapro/media_19860.html> – **340**. Unicef. Campagne de vaccination contre le tétanos maternel et néonatal. (2007). <http://www.unicef.org/wcaro/WCARO_Niger_Factsheet_Fr_CampagneTetanos.pdf> – **341**. Imdad, A. et al. The effect of umbilical cord cleansing with chlorhexidine on omphalitis and neonatal mortality in community settings in developing countries: A meta-analysis. *BMC Public Health* 13, S15 (2013). – **342**. OMS. Relevé épidémiologique hebdomadaire. 81, 197–208 (2006). – **343**. Alfén, N. van, Engelen, B. G. van & Hughes, R. A. in *Cochrane database of systematic reviews* (ed. The Cochrane Collaboration) (John Wiley & Sons, Ltd, 2009). <<http://doi.wiley.com/10.1002/14651858.CD006976.pub2>> – **344**. Dominicus, R., Galtier, F., Richard, P. & Baudin, M. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (repevax) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (revaxis) in adults aged 6–40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years. *Vaccine* 32, 3942–3949 (2014). – **345**. ANSM. BOOSTRIXETRA, suspension injectable en seringue préremplie. (2015). <<http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid=62404793&&typedoc=N\&ref=N0214502.htm>> – **346**. Ministère de la Santé Publique. Tableau de correspondances entre les valences vaccinales recommandées dans le calendrier vaccinal et les vaccins disponibles en France. <http://www.sante.gouv.fr/IMG/pdf/3-7_-_Tableau_de_correspondances_entre_les_valences_vaccinales_recommandees_dans_le_calendrier_vaccinal_et_les_vaccins_disponibles_en_France.pdf> – **347**. ANSM. Résumé des caractéristiques du produit DTVax. (2011). <<http://agence-prd.ansm.sante.fr/php/ecodex/rp/R0190629.htm>> – **348**. Questions comptoir. Le Moniteur des phar-

- macies (2012). <http://www.acppav.org/pmb/opac_css/doc_num.php?explnum_id=1743> – **349**. E3M. DT polio : Des autorités sanitaires sous influence. (2012). <<http://www.myofasciite.fr/Contenu/Divers/DTPolioAutoritesSanitairesInfluence.pdf>> – **350**. Sénat. Vaccination DT polio. (2009). <<http://www.senat.fr/questions/base/2009/qSE-Q091111086.html>> – **351**. Ministère de la Santé Publique. Notice patient - REVAXIS, suspension injectable en seringue préremplie. vaccin diphtérique, tétanique et poliomyélique (inactivé), (adsorbé) - base de données publique des médicaments. (2015). <<http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=60917345&typedoc=N>> – **352**. Ministère de la Santé Publique. Notice patient - INFANRIX TETRA, suspension injectable en seringue préremplie. vaccin diphtérique, tétanique, coquelucheux acellulaire, poliomyélique inactivé, adsorbé - base de données publique des médicaments. (2012). <<http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=69777706&typedoc=N>> – **353**. Résumé des caractéristiques du produit, infanrix hexa. <http://ec.europa.eu/health/documents/community-register/2014/20140930129832/anx_129832_fr.pdf> – **354**. EurekaSanté. TÉTAGRIP. EurekaSante.fr par vidal. (2012). <<http://www.eurekaSante.fr/medicaments/vidal-famille/medicament-dtetg501-TETAGRIP.html>> – **355**. Hemilä, H. & Koivula, T. in Cochrane database of systematic reviews (John Wiley & Sons, Ltd, 1996). <<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006665.pub3/abstract>> – **356**. Jahan, K., Ahmad, K. & Ali, M. A. Effect of ascorbic acid in the treatment of tetanus. *Bangladesh Med Res Counc Bull* 10, 24–28 (1984). – **357**. Dey, P. K. Efficacy of vitamin c in counteracting tetanus toxin toxicity. *Naturwissenschaften* 53, 310 (1966). – **358**. Sikendar, R. I., Samad, B. us, Ali, S. & Memon, M. I. Post traumatic tetanus and role of magnesium sulphate. *J Ayub Med Coll Abbottabad* 21, 132–135 (2009). – **359**. Karanikolas, M. et al. Prolonged high-dose intravenous magnesium therapy for severe tetanus in the intensive care unit: A case series. *J. Med. Case Reports* 4, 100 (2010). – **360**. Société d'Anesthésie Réanimation d'Afrique Noire Francophone. Tétanos grave et sulfate de magnésium à propos d'un cas en unité de soins intensifs du centre hospitalier universitaire de libreville. (2013). <<http://saranf.net/Tetanos-grave-et-sulfate-de.html>> – **361**. Attygalle, D. & Rodrigo, N. Magnesium sulphate for control of spasms in severe tetanus. can we avoid sedation and artificial ventilation? *anaesthesia* 52, 956–962 (1997). – **362**. Thwaites, C. L. et al. Magnesium sulphate for treatment of severe tetanus: A randomised controlled trial. *lancet* 368, 1436–1443 (2006). – **363**. Direction générale de la santé & Comité technique des vaccinations. Guide des vaccinations 2012, diphtérie. (2012). <http://www.inpes.sante.fr/10000/themes/vaccination/guide-vaccination-2012/pdf/GuideVaccinations2012_Vaccination_contre_la_diphtherie.pdf> – **364**. Haut Conseil de la Santé Publique. Conduite à tenir lors de l'apparition d'un cas de diphtérie. (2011). <http://www.sante.gouv.fr/IMG/pdf/rapport_du_HCSP_Conduite_a_tenir_lors_de_l_apparition_d_un_cas_de_diphtherie.pdf> – **365**. Scott, S. & Duncan, C. J. *Human demography and disease*. (Cambridge University Press, 2005). – **366**. GOV.UK. in *Immunisation against infectious disease* (2011). <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147952/Green-Book-Chapter-15.pdf> –
- 367**. Jungeblut, C. W. Studies on the inactivation of diphtheria toxin by vitamin c (l-ascorbic acid). *The Journal of Infectious Diseases* 69, 70–80 (1941). – **368**. Al Aswad, I. H. & Shubair, M. E. Efficacy of diphtheria and tetanus vaccination in Gaza, palestine. *East. Mediterr. Health J.* 15, 285–294 (2009). – **369**. Blatter, M., Friedland, L. R., Weston, W. M., Li, P. & Howe, B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. *vaccine* 27, 765–772 (2009). – **370**. Haute Autorité de Santé. Avis de la commission pour le repevax. (2004). <<http://www.has-sante.fr/portail/upload/docs/application/pdf/ct031585.pdf>> – **371**. Chiappini, E., Stival, A., Galli, L. & Martino, M. de. Pertussis re-emergence in the post-vaccination era. *BMC Infect Dis* 13, 151 (2013). – **372**. Haute Autorité de Santé. Avis de la commission pour l'INFANRIX hexa. (2013). <<http://www.has-sante.fr/portail/upload/docs/application/pdf/ct031585.pdf>> – **373**. Gajdos, V. et al. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT polio) given as a booster dose at 6 years of age. *Hum Vaccin* 7, 549–556 (2011). – **374**. team, E. C. for D. P. & Communication Unit- Eurosurveillance editorial, C. (ECDC)-Health. La diphtérie dans les années 1990 - possédons-nous toutes les réponses ? (1997). <<http://www.eurosurveillance.org/images/dynamic/EM/v02n08/v02n08.pdf>> – **375**. García-Corbeira, P., Dal-Ré, R., García-de-Lomas, J. & Aguilar, L. Low prevalence of diphtheria immunity in the spanish population: Results of a cross-sectional study. *vaccine* 17, 1978–1982 (1999). – **376**. Public Health, England. Public health control and management of diphtheria (in england and wales). (2015). <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/416108/Diphtheria_Guidelines_Final.pdf> – **377**. Lang, P.-O. Adverse effects of the herd immunity or when childhood vaccination becomes deleterious for the epidemiology of infectious diseases in adults. *Gériatrie Psychol. Neuropsychiatr. Vieil.* 9, 11–19 (2011). – **378**. Antona, D. La rougeole en france en 2009. (2009). <<http://www.geres.org/docpdf/J19l%2006da2.pdf>> – **379**. McDonald, K. L., Huq, S. I., Lix, L. M., Becker, A. B. & Kozyrskyj, A. L. Delay in diphtheria, pertussis, tetanus vaccination is associated with a reduced risk of childhood asthma. *J. Allergy Clin. Immunol.* 121, 626–631 (2008). – **380**. ANSM. Résumé des caractéristiques du produit BoostrixTetra. (2012). <<http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0214502.htm>> – **381**. Nakayama, T., Aizawa, C. & Kuno-Sakai, H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. *J. Allergy Clin. Immunol.* 103, 321–325 (1999). – **382**. Nakayama, T. & Aizawa, C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. *J. Allergy Clin. Immunol.* 106, 591–592 (2000). – **383**. Institute of Medicine (US) Vaccine Safety Committee. Adverse events associated with childhood vaccines: Evidence bearing on causality. (National Academies

- Press (US), 1994). <<http://www.ncbi.nlm.nih.gov/books/NBK236291/>> – **384**. Infectious Disease Surveillance Center, Japon. Incidence of diphtheria in japan, 1945-1997. <<http://idsc.nih.gov/jp/iasr/19/224/graph/f2241.gif>> – **385**. Infectious Disease Surveillance Center, Japon. Diphtheria in japan. <<http://idsc.nih.gov/jp/iasr/19/224/tpc224.html>> – **386**. Pfeiffer, J. K. Innate host barriers to viral trafficking and population diversity: Lessons learned from poliovirus. *Adv Virus Res* 77, 85–118 (2010). – **387**. Rutty, C. Brève histoire de la polio. <http://www.polio-vaccine.com/fr/histoire/histoire_rutty.pdf> – **388**. Nathanson, N. & Kew, O. M. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. *Am. J. Epidemiol.* 172, 1213–1229 (2010). – **389**. LaForce, F. M., Lichnevski, M. S., Keja, J. & Henderson, R. H. Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries. *Bull. World Health Organ.* 58, 609–620 (1980). – **390**. Ministère de la Santé Publique. Poliomyélite antérieure aiguë (PAA). (2010). <<http://www.sante.gouv.fr/poliomyelite-anterieure-aigue-paa.html>> – **391**. Direction générale de la santé & Comité technique des vaccinations. Guide des vaccinations 2012, poliomyélite. (2012). <http://www.inpes.sante.fr/10000/themes/vaccination/guide-vaccination-2012/pdf/GuideVaccinations2012_Vaccination_contre_la_poliomyelite.pdf> – **392**. Monto, A. S. Francis field trial of inactivated poliomyelitis vaccine: Background and lessons for today. *Epidemiol Rev* 21, 7–23 (1999). – **393**. Singh, J. et al. Epidemiological evaluation of oral polio vaccine efficacy in delhi. *Indian J Pediatr* 59, 321–323 (1992). – **394**. Deivanayagam, N., Nedunchelian, K., Ahamed, S. S. & Rathnam, S. R. Clinical efficacy of trivalent oral poliomyelitis vaccine: A case-control study. *Bull World Health Organ* 71, 307–309 (1993). – **395**. Kotb, M. M., Shouman, A. E. & Mortagy, A. Epidemiological evaluation of oral polio vaccine efficacy in cairo. *J Egypt Public Health Assoc* 68, 617–625 (1993). – **396**. Sutter, R. W. et al. Outbreak of paralytic poliomyelitis in oman: Evidence for widespread transmission among fully vaccinated children. *lancet* 338, 715–720 (1991). – **397**. Jenkins, H. E. et al. Effectiveness of immunization against paralytic poliomyelitis in nigeria. *N. Engl. J. Med.* 359, 1666–1674 (2008). – **398**. Mateen, F. J., Shinohara, R. T. & Sutter, R. W. Oral and inactivated poliovirus vaccines in the newborn: A review. *vaccine* 31, 2517–2524 (2013). – **399**. OMS. Questions fréquentes sur la poliomyélite. (2015). <<http://www.who.int/topics/poliomyelitis/faq/fr/>> – **400**. Liu, G.-F. et al. A case-control study on children with guillain-barre syndrome in north china. *Biomed. Environ. Sci.* 16, 105–111 (2003). – **401**. Kinnunen, E., Färkkilä, M., Hovi, T., Juntunen, J. & Weckström, P. Incidence of guillain-barré syndrome during a nationwide oral poliovirus vaccine campaign. *neurology* 39, 1034–1036 (1989). – **402**. Haber, P., Sejvar, J., Mikae-loff, Y. & DeStefano, F. Vaccines and guillain-barré syndrome. *Drug Saf* 32, 309–323 (2009). – **403**. GOV.UK. In Immunisation against infectious disease (2011). <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148141/Green-Book-Chapter-26-Polio-updated-18-January-2013.pdf> – **404**. Axelsson, P. 'Do not eat those apples; they've been on the ground!': Polio epidemics and preventive measures. *Asclepio Arch. Iberoam. Hist. Med. Antropol. Médica* 61, 23–38 (2009). – **405**. OMS. Poliomyelitis in 1953. (1955). <http://whqlibdoc.who.int/bulletin/1955/Vol12/Vol12-No4/bulletin_1955_12%284%29_595-649.pdf> – **406**. OMS. Immunization summary (the 2014 edition). (2014). <http://www.who.int/immunization/monitoring_surveillance/Immunization_Summary_2013.pdf> – **407**. Kew, O. M. et al. Possible eradication of wild poliovirus type 3—worldwide, 2012. *MMWR Morb. Mortal. Wkly. Rep.* 63, 1031–1033 (2014). – **408**. OMS. Initiative mondiale pour l'éradication de la poliomyélite, situation en 2000. (2001). <http://libdoc.who.int/hq/2001/WHO_POLIO_01.03_fr.pdf> – **409**. Tukei, P. M. Polio eradication by the year 2000. *Afr J Health Sci* 3, 65 (1996). – **410**. Fondation Gates. Polio, strategy overview. Bill & melinda gates foundation. <<http://www.gatesfoundation.org/What-We-Do/Global-Development/Polio>> – **411**. Rotary. Sommet mondial sur la vaccination : Promesses de financement pour l'éradication de la polio. (2013). <<https://www.rotary.org/myrotary/fr/global-vaccine-summit-yields-us4-billion-funding-commitments-polio-endgame-plan>> – **412**. IMEP. Info polio. (2013). <http://www.polioeradication.org/Portals/0/Document/Media/Newsletter/PN201304_FR.pdf> – **413**. Rasch, G., Schreier, E., Kiehl, W. & Kurth, R. [Worldwide eradication of poliomyelitis]. *Wien. Klin. Wochenschr.* 113, 839–845 (2001). – **414**. Modlin, J. & Wenger, J. Achieving and maintaining polio eradication new strategies. *N. Engl. J. Med.* 371, 1476–1479 (2014). – **415**. Polio Global Eradication Initiative. Annual report 2009. (2010). <http://www.polioeradication.org/content/publications/AnnualReport2009_ENG.pdf> – **416**. Diop, O. M., Burns, C. C., Wassilak, S. G., Kew, O. M. & Centers for Disease Control and Prevention (CDC). Update on vaccine-derived polioviruses - worldwide, july 2012-december 2013. *MMWR Morb. Mortal. Wkly. Rep.* 63, 242–248 (2014). – **417**. Pavlov, D. N., Van Zyl, W. B., Van Heerden, J., Grabow, W. O. K. & Ehlers, M. M. Prevalence of vaccine-derived polioviruses in sewage and river water in south africa. *Water Res.* 39, 3309–3319 (2005). – **418**. Jain, S. et al. Polio eradication/Lessons from the past and future perspective. *J Clin Diagn Res* 8, ZC56–ZC60 (2014). – **419**. OMS. Relevé épidémiologique hebdomadaire. 84, 281–288 (2009). – **420**. OMS. Le directeur général de l'OMS célèbre l'élimination de la poliomyélite en inde. (2014). <<http://www.who.int/dg/speeches/2014/india-polio-free/fr/>> – **421**. Vaincre la poliomyélite. La surveillance des cas de polio. <<http://www.polio-vaccine.com/fr/eradication/surveillance.html>> – **422**. Laxmivandana, R., Yergolkar, P., Gopalkrishna, V. & Chitambar, S. D. Characterization of the non-polio enterovirus infections associated with acute flaccid paralysis in south-western india. *PLoS ONE* 8, e61650 (2013). – **423**. Kaushik, R., Kharbanda, P. S., Bhalla, A., Rajan, R. & Prabhakar, S. Acute flaccid paralysis in adults: Our experience. *J Emerg Trauma Shock* 7, 149–154 (2014). – **424**. Saraswathy Subramaniam, T. S., Apandi, M. A., Jahis, R., Samsudin, M. S. & Saat, Z. Viral aetiology of acute flaccid paralysis surveillance cases, before and after vaccine policy change from oral polio vaccine to inactivated polio vaccine. *J Trop Med* 2014, (2014). – **425**. OMS. Case count of polio. (2015). <<https://extranet.who.int/polis/public/CaseCount.aspx>> – **426**. Mansoor, F., Hamid, S., Mir, T., Abdul Hafiz, R. & Mounts, A. Incidence of traumatic injection neuropathy among children in pakistan. *East. Mediterr. Health J.* 11, 798–804 (2005). – **427**. Vashisht, N. & Puliyl, J. Polio programme: Let us declare victory and move on. *Indian J Med Ethics* 9, 114–117 (2012). – **428**.

- Puliyel, J. National polio surveillance india data 2000 -2010. <<http://jacob.puliyel.com/paper.php?id=248>> – **429**.
- Lloyd-Smith, J. O. Vacated niches, competitive release and the community ecology of pathogen eradication. *Philos Trans R Soc Lond B Biol Sci* 368, (2013). – **430**.
- Jiang, P. et al. Evidence for emergence of diverse polioviruses from c-cluster coxsackie a viruses and implications for global poliovirus eradication. *Proc Natl Acad Sci U S A* 104, 9457–9462 (2007). – **431**.
- Combela, N., Holmblat, B., Joffret, M.-L., Colbère-Garapin, F. & Delpyroux, F. Recombination between poliovirus and coxsackie a viruses of species c: A model of viral genetic plasticity and emergence. *viruses* 3, 1460–1484 (2011). – **432**.
- Rieder, E. et al. Will the polio niche remain vacant? *Dev Biol (Basel)* 105, 111–122; discussion 149–150 (2001). – **433**.
- Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication – india, december 1995 and january 1996. (1996). <<http://www.cdc.gov/mmwr/preview/mmwrhtml/00041414.htm>> – **434**.
- OMS. Relevé épidémiologique hebdomadaire. 89, 165–176 (2014). – **435**.
- National Post. Virus that can cause polio-like paralysis on the rise in canada. *National post*. (2014). <<http://news.nationalpost.com/news/canada/virus-that-cause-polio-like-paralysis-on-the-rise-in-canada>> – **436**.
- Puliyel, J. M., Gupta, M. A. & Mathew, J. L. Polio eradication & the future for other programmes: Situation analysis for strategic planning in india. *Indian J. Med. Res.* 125, 1–4 (2007). – **437**.
- Sathyamala, C. Polio eradication programme in india. *Indian J. Med. Res.* 125, 695–696 (2007). – **438**.
- La Croix. En inde, la polio est éradiquée. (2014). <<http://www.la-croix.com/Actualite/Monde/En-Inde-la-polio-est-eradiquee-2014-01-13-1088618>> – **439**.
- L'Express. L'Inde se débarrasse enfin de la polio. (2014). <http://www.leexpress.fr/actualite/societe/sante/l-inde-se-debarrasse-enfin-de-la-polio_1313463.html> – **440**.
- Le Figaro. L'Inde se débarrasse de la polio. (2014). <<http://sante.lefigaro.fr/actualite/2014/01/13/21856-linde-se-debarrasse-polio>> – **441**.
- Sanofi Pasteur. la victoire de l'Inde sur la polio est pour nous tous un appel à l'action déclare le PDG de sanofi pasteur. (2014). <<http://sanofipasteur.com/fr/articles/la-victoire-de-l-Inde-sur-la-polio-est-pour-nous-tous-un-appel-a-l-action.aspx>> – **442**.
- IMEP. Contributions and pledges to the global polio eradication initiative, 1985-2018. <<http://www.polioeradication.org/Portals/0/Document/Financing/HistoricalContributions.pdf>> – **443**.
- IMEP. Financial resource requirements. (2014). <http://www.polioeradication.org/Portals/0/Document/Financing/FRR_EN_A4.pdf> – **444**.
- Klepac, P., Metcalf, C. J. E., McLean, A. R. & Hampson, K. Towards the endgame and beyond: Complexities and challenges for the elimination of infectious diseases. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 368, 20120137 (2013). – **445**.
- Politique Internationale. Fondations gates : En finir avec la poliomyélite. (2011). <http://www.politiqueinternationale.com/revue/read2.php?id_revue=130&cid=972&content=texte> – **446**.
- O'Reilly, K. M. et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in pakistan and afghanistan, 200111: A retrospective analysis. *lancet* 380, 491–498 (2012). – **447**.
- La Croix. Au pakistan, des extrémistes bloquent l'éradication de la polio. (2013). <http://www.la-croix.com/Actualite/Monde/Au-Pakistan-des-extremistes-bloquent-l-eradication-de-la-polio_NG_-2013-01-02-894361> – **448**.
- Peshawar, A. P. in. Pakistan jails 471 parents who refused to give polio vaccine to children. *The guardian*. (2015). <<http://www.theguardian.com/society/2015/mar/02/parents-jailed-pakistan-refusing-children-polio-vaccinations>> – **449**.
- HHS hides information on how vaccines cause autism. (2015). <<https://www.youtube.com/watch?v=17E1ORNfomg>> – **450**.
- Dailymotion. Partie 03 -une épidémie d'assassinats de vacinateurs polio. *Dailymotion*. <http://www.dailymotion.com/video/x1aixhs_partie-03-une-epidemie-d-assassinats-de-vacinateurs-polio_news> – **451**.
- Le Potentiel. La première phase des journées nationales de vaccination 2013 s'est clôturée samedi. (2013). <http://www.lepotentielonline.com/index.php?option=com_content&view=article&id=1314:la-premiere-phase-des-journees-nationales-de-vaccination-2013-s-est-cloturee-samedi&catid=88:sociale> – **452**.
- Eudier, J.-P. & Tarte, D. Chroniques d'un voyage au congo. (2007). <<http://www.sunsimiao.org/AFRIQUE-ET-VACCINATIONS>> – **453**.
- OMS. Comité consultatif mondial de la sécurité vaccinale, 11-12 décembre 2013. (2014). <http://www.who.int/vaccine_safety/committee/reports/Dec_2013/fr/> – **454**.
- Fitzpatrick, M. The cutter incident: How america's first polio vaccine led to a growing vaccine crisis. *J R Soc Med* 99, 156 (2006). – **455**.
- Petricciani, J., Sheets, R., Griffiths, E. & Knezevic, I. Adventitious agents in viral vaccines: Lessons learned from 4 case studies. *biologicals* 42, 223–236 (2014). – **456**.
- Pershouse, M. A., Heivly, S. & Girtsman, T. The role of SV40 in malignant mesothelioma and other human malignancies. *Inhal Toxicol* 18, 995–1000 (2006). – **457**.
- Poulin, D. L. & DeCaprio, J. A. Is there a role for SV40 in human cancer? *J. Clin. Oncol.* 24, 4356–4365 (2006). – **458**.
- Qi, F., Carbone, M., Yang, H. & Gaudino, G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. *Expert Rev Respir Med* 5, 683–697 (2011). – **459**.
- Cristaudo, A. et al. [SV40: A possible co-carcinogen of asbestos in the pathogenesis of mesothelioma?]. *Med Lav* 93, 499–506 (2002). – **460**.
- Butel, J. S., Vilchez, R. A., Jorgensen, J. L. & Kozinetz, C. A. Association between SV40 and non-hodgkin's lymphoma. *Leuk. Lymphoma* 44 Suppl 3, S33–39 (2003). – **461**.
- Immunization safety review: SV40 contamination of polio vaccine and cancer. (National Academies Press, 2003). – **462**.
- Elswood, B. F. & Stricker, R. B. Polio vaccines and the origin of AIDS. *Med. Hypotheses* 42, 347–354 (1994). – **463**.
- Worobey, M. et al. Origin of AIDS: Contaminated polio vaccine theory refuted. *nature* 428, 820 (2004). – **464**.
- Baguley, D. SUBACUTE SCLEROSING PANENCEPHALITIS AND SALK VACCINE. *The Lancet* 302, 763–765 (1973). – **465**.
- Pastoret, P.-P. Human and animal vaccine contaminations. *Biologicals* 38, 332–334 (2010). – **466**.
- Lwoff, A. & Lwoff, M. Remarques méthodologiques à propos de la thermosensibilité du développement viral. *Annales de l'Institut Pasteur* 101, 313–315 (1961). – **467**.
- Ogra, P. L. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. *N. Engl. J. Med.* 284, 59–64 (1971). – **468**.
- Haute Autorité de Santé. Évaluation des actes d'amygdalectomie à l'amygdalotome. (2006). <http://www.has-sante.fr/portail/upload/docs/application/pdf/rapport_amygdalectomie_amygdalotome.pdf> – **469**.
- Strelbel, P. M., Ion-Nedelcu, N., Baughman, A. L., Sutter, R. W. & Cochi, S. L. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine a risk factor for vaccine-associated paralytic poliomyelitis. *N. Engl. J. Med.* 332, 500–506 (1995). – **470**.
- Bosley, A. R. J., Speirs, G. & Markham, N. I. Pro-vocation poliomyelitis: Vaccine associated paralytic poliomyelitis related to a rectal abscess in an infant. *J. Infect.* 47,

- 82–84 (2003). – **471.** Health Protection Scotland. Poliomyelitis - immunisation and vaccines - HPS. (2013). <<http://www.hps.scot.nhs.uk/immvax/poliomyelitis.aspx>> – **472.** Sutter, R. W. et al. Attributable risk of DTP (diphtheria and tetanus toxoids and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman. *J. Infect. Dis.* 165, 444–449 (1992). – **473.** Gromeier, M. & Wimmer, E. Mechanism of injury-provoked poliomyelitis. *J. Virol.* 72, 5056–5060 (1998). – **474.** OMS. Global polio eradication progress 2000. (2001). <http://stacks.cdc.gov/view/cdc/13108/cdc_13108_DS2.pdf> – **475.** Jungeblut, C. W. A FURTHER CONTRIBUTION TO VITAMIN C THERAPY IN EXPERIMENTAL POLIOMYELITIS. *J. Exp Med* 70, 315–332 (1939). – **476.** Klenner, F. R. Virus pneumonia and its treatment with vitamin c. *South Med Surg* 110, 36–38 (1948). – **477.** Klenner, F. R. The treatment of poliomyelitis and other virus diseases with vitamin c. *South Med Surg* 111, 209–214 (1949). – **478.** Klenner, F. R. Massive doses of vitamin c and the virus diseases. *South Med Surg* 113, 101–107 (1951). – **479.** Klenner, F. R. The vitamin and massage treatment for acute poliomyelitis. *South Med Surg* 114, 194–197 (1952). – **480.** Jones, J. H. & Foster, C. Dietary deficiencies and poliomyelitis; effects of low protein and of low tryptophan diets on the response of mice to the Lansing strain of poliomyelitis virus. *Arch Biochem* 11, 481–487 (1946). – **481.** Kim-Farley, R. J. et al. Outbreak of paralytic poliomyelitis, Taiwan. *Lancet* 2, 1322–1324 (1984). – **482.** Roberts, J. Polio: The virus and the vaccine. (2004). <<http://www.vaclib.org/basic/polio/polio1.pdf>> – **483.** Devitalizing composition of matter. (1943). <<http://www.freepatentsonline.com/2329074.html>> – **484.** EHESP. Projet d'estimation des risques sanitaires. (2010). <http://documentation.ehesp.fr/memoires/2010/persan_igs/insecticides.pdf> – **485.** Lie, E. et al. Does high organochlorine (OC) exposure impair the resistance to infection in polar bears (*Ursus maritimus*)? Part II: Possible effect of OCs on mitogen- and antigen-induced lymphocyte proliferation. *J. Toxicol. Environ. Health Part A* 68, 457–484 (2005). – **486.** Rozee, K. R., Lee, S. H., Crocker, J. F. & Safe, S. H. Enhanced virus replication in mammalian cells exposed to commercial emulsifiers. *Appl Environ Microbiol* 35, 297–300 (1978). – **487.** Upham, J. et al. The pesticide adjuvant, toximul, alters hepatic metabolism through effects on downstream targets of PPARalpha. *Biochim. Biophys. Acta* 1772, 1057–1064 (2007). – **488.** Direction générale de la santé & Comité technique des vaccinations. Guide des vaccinations 2012, coqueluche. (2012). <http://www.inpes.sante.fr/10000/themes/vaccination/guide-vaccination-2012/pdf/GuideVaccinations2012_Vaccination_contre_la_coqueluche.pdf> – **489.** Haut Conseil de la Santé Publique. Conduite à tenir devant un ou plusieurs cas de coqueluche. (2008). <<http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=36>> – **490.** Grimprel, E. La coqueluche en pratique en 2006. *Revue Française d'Allergologie et d'Immunologie Clinique* (2006). <<http://www.sp2a.fr/pdf/CFP2A-2006/coqueluche-en-pratique.pdf>> – **491.** InVS. Diphtérie-tétanos, poliomyélite, coqueluche / données / couverture vaccinale. (2011). <<http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Couverture-vaccinale/Donnees/Diphterie-tetanos-poliomyelite-coqueluche>> – **492.** Institut Pasteur. Coqueluche. Institut Pasteur. (2013). <<http://www.pasteur.fr/fr/institut-pasteur/presse/fiches-info/coqueluche>> – **493.** Institut Pasteur. Vaccins disponibles au centre médical. Institut Pasteur. (2015). <<http://www.pasteur.fr/fr/sante/vaccinations-internationales/vaccins-disponibles-au-centre-medical>> – **494.** Zhang, L., Prietsch, S. O. M., Axelsson, I. & Halperin, S. A. Acellular vaccines for preventing whooping cough in children. *Cochrane Database Syst Rev* 3, CD001478 (2012). – **495.** team, E. C. for D. P. & Communication Unit- Eurosurveillance editorial, C. (ECDC)-Health. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. (1999). <<http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=84>> – **496.** Olin, P. et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. *vaccine* 21, 2015–2021 (2003). – **497.** Romanus, V., Jonsell, R. & Bergquist, S. O. Pertussis in Sweden after the cessation of general immunization in 1979. *Pediatr. Infect. Dis. J.* 6, 364–371 (1987). – **498.** Inpes. Vaccination. le point sur la coqueluche. (2012). <<http://www.inpes.sante.fr/CFESBases/catalogue/pdf/1168.pdf>> – **499.** Carollo, M. et al. Humoral and b-cell memory responses in children five years after pertussis acellular vaccine priming. *vaccine* 32, 2093–2099 (2014). – **500.** Labrest. Diagnostic de la coqueluche. (2013). <<http://www.labrestsonline.fr/tests/Pertussis.html?tab=3>> – **501.** Zouari, A. et al. [The re-emergence of pertussis in Tunisia]. *Med Mal Infect* 41, 97–101 (2011). – **502.** Mughal, A. A. Diagnosis of pertussis in vaccinated children of Khairpur, Sindh, Pakistan by cough plate method. *J. Microbiol. Infect. Dis.* 01, 68–72 (2011). – **503.** Mughal, A., Kazi, Y. F., Bukhari, H. A. & Ali, M. Pertussis resurgence among vaccinated children in Khairpur, Sindh, Pakistan. *Public Health* 126, 518–522 (2012). – **504.** Lin, Y.-C. et al. Epidemiological shift in the prevalence of pertussis in Taiwan: Implications for pertussis vaccination. *J. Med. Microbiol.* 56, 533–537 (2007). – **505.** Sotir, M. J. et al. A countywide outbreak of pertussis: Initial transmission in a high school weight room with subsequent substantial impact on adolescents and adults. *Arch Pediatr Adolesc Med* 162, 79–85 (2008). – **506.** Torres, J. et al. [Outbreak of whooping cough with a high attack rate in well-vaccinated children and adolescents]. *Enferm. Infecc. Microbiol. Clin.* 29, 564–567 (2011). – **507.** Fabiánová, K., Benes, C. & Kriz, B. A steady rise in incidence of pertussis since nineties in the Czech Republic. *Epidemiol Mikrobiol Immunol* 59, 25–33 (2010). – **508.** Hochwald, O., Bamberger, E. S., Rubin, L., Gershtein, R. & Srugo, I. A pertussis outbreak among daycare children in northern Israel: Who gets sick? *Isr. Med. Assoc. J.* 12, 283–286 (2010). – **509.** Eshofonie, A. O., Lin, H., Valcin, R. P., Martin, L. R. & Grunenwald, P. E. An outbreak of pertussis in rural Texas: An example of the resurgence of the disease in the United States. *J. Community Health* 40, 88–91 (2015). – **510.** Cordova, S. P., Gilles, M. T. & Beers, M. Y. The outbreak that had to happen: Bordetella pertussis in north-west western Australia in 1999. *Commun. Dis. Intell.* 24, 375–379 (2000). – **511.** Linstow, M.-L. von, Pontoppidan, P. L., König, C.-H. W. von, Cherry, J. D. & Hogh, B. Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children. *Eur J Pediatr* 169, 1119–1122 (2010). – **512.** UCLA Health. James cherry, MD, pediatric infectious diseases. <<https://www.uclahealth.org/provider/james-cherry-md>> – **513.** Cherry, J. D. Adult pertussis in the pre- and post-vaccine eras: Lifelong vaccine-induced immunity? *Expert Rev Vaccines* 13, 1073–1080 (2014). – **514.** Grimprel, E. et al. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. *Clin Diagn*

- Lab Immunol 3, 93–97 (1996). – **515.** Litt, D. J., Neal, S. E. & Fry, N. K. Changes in genetic diversity of the bordetella pertussis population in the united kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. *J. Clin. Microbiol.* 47, 680–688 (2009). – **516.** Mooi, F. R., Loo, I. H. van & King, A. J. Adaptation of bordetella pertussis to vaccination: A cause for its reemergence? *Emerging Infect. Dis.* 7, 526–528 (2001). – **517.** Mooi, F. R. et al. Polymorphism in the bordetella pertussis Virulence factors p.69/Pertactin and pertussis toxin in the netherlands: Temporal trends and evidence for vaccine-driven evolution. *Infect. Immun.* 66, 670–675 (1998). – **518.** Zieliński, A. & Rosińska, M. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components. *Przegl Epidemiol* 62, 589–596 (2008). – **519.** Ray, P. et al. Encephalopathy after whole-cell pertussis or measles vaccination: Lack of evidence for a causal association in a retrospective case-control study. *Pediatr. Infect. Dis. J.* 25, 768–773 (2006). – **520.** Kuno-Sakai, H. & Kimura, M. Safety and efficacy of acellular pertussis vaccine in japan, evaluated by 23 years of its use for routine immunization. *Pediatr Int* 46, 650–655 (2004). – **521.** Gale, J. L. et al. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. a population-based case-control study. *Jama* 271, 37–41 (1994). – **522.** Miller, D. L., Ross, E. M., Alderslade, R., Bellman, M. H. & Rawson, N. S. Pertussis immunisation and serious acute neurological illness in children. *Br Med J (Clin Res Ed)* 282, 1595–1599 (1981). – **523.** Steinman, L. et al. Pertussis toxin is required for pertussis vaccine encephalopathy. *Proc Natl Acad Sci U S A* 82, 8733–8736 (1985). – **524.** Cody, C. L., Baraff, L. J., Cherry, J. D., Marcy, S. M. & Manclark, C. R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. *pediatrics* 68, 650–660 (1981). – **525.** Hinman, A. R. & Koplan, J. P. Pertussis and pertussis vaccine. reanalysis of benefits, risks, and costs. *Jama* 251, 3109–3113 (1984). – **526.** EurekaSanté. REPEVAX. EurekaSanté.fr par vidal. <<http://www.eurekaSanté.fr/medicaments/vidal-famille/medicament-gp1594-REPEVAX.html>> – **527.** David A Geier, M. R. G. An evaluation of serious neurological disorders following immunization: A comparison of whole-cell pertussis and acellular pertussis vaccines. *Brain Amp Dev.* 26, 296–300 (2004). – **528.** OMS. Observed rate of vaccine reactions: Diphtheria, pertussis, tetanus vaccines. (2014). <http://www.who.int/vaccine_safety/initiative/tools/DTP_vaccine_rates_information_sheet.pdf> – **529.** Wilson, K., Potter, B., Manuel, D., Keelan, J. & Chakraborty, P. Revisiting the possibility of serious adverse events from the whole cell pertussis vaccine: Were metabolically vulnerable children at risk? *Med. Hypotheses* 74, 150–154 (2010). – **530.** Wharton, M. Vaccine safety: Current systems and recent findings. *Curr. Opin. Pediatr.* 22, 88–93 (2010). – **531.** Reyes, I. S., Hsieh, D. T., Laux, L. C. & Wilfong, A. A. Alleged cases of vaccine encephalopathy rediagnosed years later as dravet syndrome. *pediatrics* 128, e699–e702 (2011). – **532.** Zamponi, N. et al. Vaccination and occurrence of seizures in SCN1A mutation-positive patients: A multicenter italian study. *Pediatr. Neurol.* 50, 228–232 (2014). – **533.** Tro-Baumann, B. et al. A retrospective study of the relation between vaccination and occurrence of seizures in dravet syndrome. *epilepsia* 52, 175–178 (2011). – **534.** McIntosh, A. M. et al. Effects of vaccination on onset and outcome of dravet syndrome: A retrospective study. *Lancet Neurol* 9, 592–598 (2010). – **535.** Petrelli, C. et al. Early clinical features in dravet syndrome patients with and without SCN1A mutations. *Epilepsy Res.* 99, 21–27 (2012). – **536.** Verbeek, N. E. et al. Prevalence of SCN1A-related dravet syndrome among children reported with seizures following vaccination: A population-based ten-year cohort study. *PLoS One* 8, (2013). – **537.** Rosander, C. & Hallböök, T. Dravet syndrome in sweden: A population-based study. *Dev Med Child Neurol* (2015). doi:10.1111/dmcn.12709 – **538.** Bayat, A., Hjalgrim, H. & Møller, R. S. The incidence of SCN1A-related dravet syndrome in denmark is 1:22,000: A population-based study from 2004 to 2009. *epilepsia* 56, e36–39 (2015). – **539.** Patel, M. K., Patel, T. K. & Tripathi, C. B. Diphtheria, pertussis (whooping cough), and tetanus vaccine induced recurrent seizures and acute encephalopathy in a pediatric patient: Possibly due to pertussis fraction. *J Pharmacol Pharmacother* 3, 71–73 (2012). – **540.** Centers for Disease Control and Prevention. International notes pertussis – england and wales. (1982). <<http://www.cdc.gov/mmwr/preview/mmwrhtml/00001197.htm>> – **541.** Campbell, H. et al. Accelerating control of pertussis in england and wales. *Emerg Infect Dis* 18, 38–47 (2012). – **542.** Hansen SN, Schendel DE & Parner ET. Explaining the increase in the prevalence of autism spectrum disorders: The proportion attributable to changes in reporting practices. *JAMA Pediatr* 169, 56–62 (2015). – **543.** Zenopa. Otsuka et lundbeck pour la co-développeur de nouveaux vaccins d'Alzheimer. (2013). <<http://fr.zenopa.com/news/801672213/otsuka-et-lundbeck-pour-la-co-developper-de-nouveaux-vaccins-d39alzheimer>> – **544.** Hertz-Picciotto, I. & Delwiche, L. The rise in autism and the role of age at diagnosis. *Epidemiology* 20, 84–90 (2009). – **545.** CDC. NIP: Vacsafe/Concerns/Autism/FAQs-autism and MMR. (2007). <<http://web.archive.org/web/20070102082155/http://www.cdc.gov/nip/vacsafe/concerns/autism/autism-mmtr.htm>> – **546.** Chess, S. Autism in children with congenital rubella. *J Autism Child Schizophr* 1, 33–47 (1971). – **547.** Chess, S. Follow-up report on autism in congenital rubella. *J Autism Dev Disord* 7, 69–81 (1977). – **548.** Schaefer, G. B. & Mendelsohn, N. J. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. *Genet. Med.* 10, 4–12 (2008). – **549.** Frye, R. E. & Rossignol, D. A. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. *Pediatr Res* 69, 41R–47R (2011). – **550.** Chinnery, P. F. in *GeneReviews* (eds Pagon, R. A. et al.) (University of Washington, Seattle, 1993). <<http://www.ncbi.nlm.nih.gov/books/NBK1224/>> – **551.** Geier, D. A., Kern, J. K., King, P. G., Sykes, L. K. & Geier, M. R. An evaluation of the role and treatment of elevated male hormones in autism spectrum disorders. *Acta Neurobiol Exp (Wars)* 72, 1–17 (2012). – **552.** Auyeung, B. et al. Fetal testosterone and autistic traits. *Br J Psychol* 100, 1–22 (2009). – **553.** Auyeung, B., Taylor, K., Hackett, G. & Baron-Cohen, S. Foetal testosterone and autistic traits in 18 to 24-month-old children. *Mol. Autism* 1, 11 (2010). – **554.** Werling, D. M. & Geschwind, D. H. Sex differences in autism spectrum disorders. *Curr Opin Neurol* 26, 146–153 (2013). – **555.** Geier, D. A. & Geier, M. R. A prospective assessment of androgen levels in patients with autistic spectrum disorders: Biochemical underpinnings and suggested therapies. *Neuro Endocrinol. Lett.* 28, 565–573 (2007). – **556.** El-Baz, F., Hamza, R. T., Ayad, M. S. E. & Mahmoud, N. H. Hyperandrogene-

- mia in male autistic children and adolescents: Relation to disease severity. *Int J Adolesc Med Health* 26, 79–84 (2014). – **557**. Tordjman, S., Ferrari, P., Sulmont, V., Duyme, M. & Roubertoux, P. Androgenic activity in autism. *Am J Psychiatry* 154, 1626–1627 (1997). – **558**. Baron-Cohen, S. L'autisme : une forme extrême du cerveau masculin ? *Terrain Rev. D'ethnologie L'Europe* 17–32 (2004). doi:10.4000/terrain.1703 – **559**. Sarachana, T. & Hu, V. W. Genome-wide identification of transcriptional targets of RORA reveals direct regulation of multiple genes associated with autism spectrum disorder. *Mol. Autism* 4, 14 (2013). – **560**. Raz, R. et al. Autism spectrum disorder and particulate matter air pollution before, during, and after pregnancy: A nested case-control analysis within the nurses' health study II cohort. *Environ. Health Perspect.* 123, 264–270 (2015). – **561**. Lyall, K., Schmidt, R. J. & Hertz-Picciotto, I. Maternal lifestyle and environmental risk factors for autism spectrum disorders. *Int J Epidemiol* 43, 443–464 (2014). – **562**. Kałużna-Czaplińska, J., Michalska, M. & Rynkowski, J. Homocysteine level in urine of autistic and healthy children. *Acta Biochim. Pol.* 58, 31–34 (2011). – **563**. Kałużna-Czaplińska, J., Żurawicz, E., Michalska, M. & Rynkowski, J. A focus on homocysteine in autism. *Acta Biochim. Pol.* 60, 137–142 (2013). – **564**. Nevison, C. D. A comparison of temporal trends in united states autism prevalence to trends in suspected environmental factors. *Environ. Health* 13, 73 (2014). – **565**. *Courrier International*. Roundup : L'herbicide le plus vendu au monde. (2005). <<http://www.courrierinternational.com/article/1999/07/01/roundup-l-herbicide-le-plus-vendu-au-monde>> – **566**. Carneiro, R. T. A. et al. Removal of glyphosate herbicide from water using biopolymer membranes. *J. Environ. Manage.* 151, 353–360 (2015). – **567**. *notre-planete.info*. L'herbicide le plus vendu dans le monde, le glyphosate, contamine notre organisme. (2013). <<http://www.notre-planete.info/actualites/3764-glyphosate-danger-sante>> – **568**. Carlo, G. L., Marica, T. J. & others. Wireless radiation in the aetiology and treatment of autism: Clinical observations and mechanisms. (2007). <http://www.buergerwelle.de/assets/files/emr_autism_acnem_final_1.pdf?cultureKey=&q=pdf/emr_autism_acnem_final_1.pdf> – **569**. Mortazavi, S. M. J. et al. Mercury release from dental amalgam restorations after magnetic resonance imaging and following mobile phone use. *Pak. J. Biol. Sci.* 11, 1142–1146 (2008). – **570**. Byun, Y.-H. et al. Mobile phone use, blood lead levels, and attention deficit hyperactivity symptoms in children: A longitudinal study. *PLoS ONE* 8, e59742 (2013). – **571**. Angelidou, A. et al. Perinatal stress, brain inflammation and risk of autism-review and proposal. *BMC Pediatr* 12, 89 (2012). – **572**. Zhang, B. et al. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. *J. Neuroinflammation* 7, 80 (2010). – **573**. Theoharides, T. C. Is a subtype of autism an allergy of the brain? *Clin Ther* 35, 584–591 (2013). – **574**. *Anti-inflammatory compositions for treating brain inflammation*. (2012). <<http://www.google.com.ar/patents/US8268365>> – **575**. Rossignol, D. A. & Frye, R. E. Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. *Front Physiol* 5, (2014). – **576**. L'énigme de l'autisme, la piste bactérienne. (2015). <<https://www.youtube.com/watch?v=9RSZW065pcl>> – **577**. Schmidt, C. Mental health: Thinking from the gut. *nature* 518, S12–S15 (2015). – **578**. D'Eufemia, P. et al. Abnormal intestinal permeability in children with autism. *Acta Paediatr.* 85, 1076–1079 (1996). – **579**. Valenti-McDermott, M. et al. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. *J Dev Behav Pediatr* 27, S128–S136 (2006). – **580**. Peters, B. et al. Rigid-compulsive behaviors are associated with mixed bowel symptoms in autism spectrum disorder. *J Autism Dev Disord* 44, 1425–1432 (2014). – **581**. Coury, D. L. et al. Gastrointestinal conditions in children with autism spectrum disorder: Developing a research agenda. *pediatrics* 130, S160–S168 (2012). – **582**. The Editors of The Lancet. Retraction|Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *The Lancet* 375, 445 (2010). – **583**. Wakefield, A. J. et al. Enterocolitis in children with developmental disorders. *Am. J. Gastroenterol.* 95, 2285–2295 (2000). – **584**. Wakefield, A. et al. RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *The Lancet* 351, 637–641 (1998). – **585**. General Medical Council. Fitness to practise panel hearing. (2010). <<http://briandeer.com/solved/gmc-charge-sheet.pdf>> – **586**. Uhlmann, V. et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. *Mol Pathol* 55, 84–90 (2002). – **587**. Wakefield, A. J., Ashwood, P., Limb, K. & Anthony, A. The significance of ileocolonic lymphoid nodular hyperplasia in children with autistic spectrum disorder. *Eur J Gastroenterol Hepatol* 17, 827–836 (2005). – **588**. Galitsatos, P., Gologan, A. & Lamoureux, E. Autistic enterocolitis: Fact or fiction? *Can J Gastroenterol* 23, 95–98 (2009). – **589**. Larry king - jim carrey & jenny mcCarthy. (2015). <<https://www.youtube.com/watch?v=HX-SCdJDOra>> – **590**. Jenny McCarthy's Autism Organization. Treatments to explore generation rescue. <<http://www.generationrescue.org/recovery/biomedical-treatment/treatments-to-explore>> – **591**. Offit, P. A. Vaccines and autism revisited the hannah poling case. *N. Engl. J. Med.* 358, 2089–2091 (2008). – **592**. US Court of Federal Claims. Decision awarding damages. (2010). <<https://www.generationrescue.org/assets/Documents/Hannah-Poling-case.pdf>> – **593**. Lawyers And Settlements. Poling family receives \$1.5 million in first autism vaccine settlement. (2010). <<http://www.lawyersandsettlements.com/settlements/14938/poling-family-receives-1-5-million-in-autism-vaccine.html#VVw3gEa9EQs>> – **594**. Amanda Ernst. U.S. officials concede vaccines led to disorder. (2008). <<http://www.law360.com/articles/49378/u-s-officials-concede-vaccines-led-to-disorder>> – **595**. Kirby, D. The vaccine-autism court document every american should read. *The huffington post*. (2008). <http://www.huffingtonpost.com/david-kirby/the-vaccineautism-court-d_b_88558.html> – **596**. Artkisson, S., 2008 & Pm, 3. Learning from a previous vaccine-autism case? (2008). <<http://www.cbsnews.com/news/learning-from-a-previous-vaccine-autism-case/>> – **597**. Poling, J. S., Frye, R. E., Shoffner, J. & Zimmerman, A. W. Developmental regression and mitochondrial dysfunction in a child with autism. *J Child Neurol* 21, 170–172 (2006). – **598**. US Court of Federal Claims. Decision awarding damages. (2012). <<http://www.uscourts.gov/sites/default/files/opinions/CAMPBELL-SMITH.MOJABI-PROFFER.12.13.2012.pdf>> – **599**. Tribunale di Milano. Sentenza. (2012). <<http://www.rescuepost.com/files/vaccine-italia-decision.pdf>> – **600**. GlaxoSmithKline Inc. Infanrix hexa, summary bridging report. (2011). <<https://autism-moevaccini.files.wordpress.com/2012/12/vaccin-dc3a9cc3a8s.pdf>> – **601**. Ministero della Salute. Autismo provocato da

vaccini, il ministero ha proposto appello. (2014). <http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&cp=dalministero&cid=1845> – **602**. La Stampa. Autismo e vaccino trivalente. i pediatri: 'Non esiste alcuna correlazione'. LaStampa.it. (2012). <<http://www.lastampa.it/2012/04/26/scienza/benessere/gravidanza-parto-pediatria/autismo-e-vaccino-trivalente-i-pediatri-non-esiste-alcuna-correlazione-vx7BxazujZdcla0y1pWuMI/pagina.html>> – **603**. Cheatham, T. HHS question. (2008). <<https://childhealthsafety.files.wordpress.com/2011/01/atkinson-cbs-hrsa-email-exchanges-autistic-conditions-vaccines.pdf>> – **604**. Merck. Merck announces appointment of dr. julie gerberding as executive vice president for strategic communications, global public policy and population health. (2014). <<http://www.mercknewsroom.com/news-release/corporate-news/merck-announces-appointment-dr-julie-gerberding-executive-vice-president>> – **605**. CDC chief admits that vaccines trigger autism. (2015). <<https://www.youtube.com/watch?v=Dh-nkD5LSIg>> – **606**. DeStefano, F., Bhasin, T. K., Thompson, W. W., Yeargin-Allsopp, M. & Boyle, C. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: A population-based study in metropolitan atlanta. *pediatrics* 113, 259–266 (2004). – **607**. Hooker, B. S. Measles-mumps-rubella vaccination timing and autism among young african american boys: A reanalysis of CDC data. *Transl. Neurodegener.* 3, 16 (2014). – **608**. Hooker, B. S. Retraction: Measles-mumps-rubella vaccination timing and autism among young african american boys: A reanalysis of CDC data. *Transl. Neurodegener.* 3, 22 (2014). – **609**. Statement of william w. thompson, ph.D., regarding the 2004 article examining the possibility of a relationship between MMR vaccine and autism. (2014). <<http://www.morganverkamp.com/august-27-2014-press-release-statement-of-william-w-thompson-ph-d-regarding-the-2004-article-examining-the-possibility-of-a-relationship-between-mmr-vaccine-and-autism/>> – **610**. Centers for Disease Control and Prevention. CDC 2004 pediatrics statement - concerns about autism | vaccine safety. (2014). <<http://www.cdc.gov/vaccinesafety/Concerns/Autism/cdc2004pediatrics.html>> – **611**. eplettnr. Fraud at the CDC uncovered, 340% risk of autism hidden from public. CNN iReport. (2014). <<http://ireport.cnn.com/docs/DOC-1164794>> – **612**. DeStefano, F. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: A population-based study in metropolitan atlanta. (2004). <<http://iom.edu/-/media/Files/Activity%20Files/PublicHealth/ImmunizationSafety/DeStefanoslides.pdf>> – **613**. Van Meter, K. C. et al. Geographic distribution of autism in california: A retrospective birth cohort. *Autism Res* 3, 19–29 (2010). – **614**. Taylor, B., Jick, H. & MacLaughlin, D. Prevalence and incidence rates of autism in the UK: Time trend from 2004/2010 in children aged 8 years. *BMJ Open* 3, e003219 (2013). – **615**. Taylor, B. et al. Autism and measles, mumps, and rubella vaccine: No epidemiological evidence for a causal association. *The Lancet* 353, 2026–2029 (1999). – **616**. Wikipedia.en. Bandim health project. Wikipedia, the free encyclopedia (2015). <https://en.wikipedia.org/w/index.php?title=Bandim_Health_Project&oldid=662127502> – **617**. UK Parliament. Early day motion 1197 - MHRA. UK parliament. (2013). <<http://www.parliament.uk/business/publications/business-papers/commons/early-day-motions/edm-detail1/?session=2012-13&ednumber=1197>> – **618**. Kaye, J. A., Melero-Montes, M. del M. & Jick, H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: A time trend analysis. *bmj* 322, 460–463 (2001). – **619**. NHS England. NHS immunisation statistics, england 2012-13. (2013). <<http://www.hsc.gov.uk/catalogue/PUB11665/nhs-immu-stat-eng-2012-13-rep.pdf>> – **620**. Division, P. H. W. H. P. Public health wales health protection division - national immunisation uptake data. <<http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=54144>> – **621**. Dales L, Hammer S & Smith NJ. Time trends in autism and in mmr immunization coverage in california. *jama* 285, 1183–1185 (2001). – **622**. Google. Vaccine inassignee: 'Us health' - google search. (2015). <https://www.google.fr/search?tbo=p&tbm=pts&chl=en&q=vaccine-inassignee:%22Us+Health%22&gws_rd=cr&ei=ij9cVZyRG8OzUaXVgcAL#hl=en&tbnm=pts&q=vaccine-inassignee:%22Us+Health%22> – **623**. Madsen, K. M. et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N. Engl. J. Med.* 347, 1477–1482 (2002). – **624**. Madsen, K. M. et al. Thimerosal and the occurrence of autism: Negative ecological evidence from danish population-based data. *pediatrics* 112, 604–606 (2003). – **625**. Andrews, N. et al. Thimerosal exposure in infants and developmental disorders: A retrospective cohort study in the united kingdom does not support a causal association. *pediatrics* 114, 584–591 (2004). – **626**. OMS. Thiomersal and vaccines. WHO. (2014). <http://www.who.int/vaccine_safety/committee/topics/thiomersal/en/> – **627**. Pichichero, M. E., Cernichiaro, E., Lopreato, J. & Treanor, J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: A descriptive study. *lancet* 360, 1737–1741 (2002). – **628**. Hviid A, Stellfeld M, Wohlfahrt J & Melbye M. Association between thimerosal-containing vaccine and autism. *jama* 290, 1763–1766 (2003). – **629**. Price, C. S. et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. *pediatrics* 126, 656–664 (2010). – **630**. Bose-O'Reilly, S., McCarty, K. M., Steckling, N. & Lettmeier, B. Mercury exposure and children's health. *Curr Probl Pediatr Adolesc Health Care* 40, 186–215 (2010). – **631**. Garrecht, M. & Austin, D. W. The plausibility of a role for mercury in the etiology of autism: A cellular perspective. *Toxicol Environ Chem* 93, 1251–1273 (2011). – **632**. Eke, D. & Celik, A. Genotoxicity of thimerosal in cultured human lymphocytes with and without metabolic activation sister chromatid exchange analysis proliferation index and mitotic index. *Toxicol In Vitro* 22, 927–934 (2008). – **633**. Minami, T., Miyata, E., Sakamoto, Y., Yamazaki, H. & Ichida, S. Induction of metallothionein in mouse cerebellum and cerebrum with low-dose thimerosal injection. *Cell Biol. Toxicol.* 26, 143–152 (2010). – **634**. Minami, T., Miyata, E., Sakamoto, Y., Yamazaki, H. & Ichida, S. Induction of metallothionein in mouse cerebellum and cerebrum with low-dose thimerosal injection. *Cell Biol. Toxicol.* 26, 143–152 (2010). – **635**. MonBebe. Calculer le poids et la taille de bébé. <http://www.monbebe.com/guide_monbebe/_calculer_le_poids_et_la_taille_de_bebes> – **636**. Redwood, L., Bernard, S. & Brown, D. Predicted mercury concentrations in hair from infant immunizations: Cause for concern. *neurotoxicology* 22, 691–697 (2001). – **637**. NCIERS. Thiomersal. (2009). <<http://www.nciers.edu.au/immunisation/factsheets/thiomersal-fact-sheet.pdf>> – **638**. Gerber, J. S. & Offit, P. A. Vaccines and autism: A tale of shifting hypotheses.

- Clin Infect Dis 48, 456–461 (2009). – **639**. Geier, D. A., Young, H. A. & Geier, M. R. Thimerosal exposure & increasing trends of premature puberty in the vaccine safety datalink. *Indian J. Med. Res.* 131, 500–507 (2010). – **640**. Kern, J. K. et al. Thimerosal exposure and the role of sulfation chemistry and thiol availability in autism. *Int J Environ Res Public Health* 10, 3771–3800 (2013). – **641**. Bernard, S., Enayati, A., Redwood, L., Roger, H. & Binstock, T. Autism: A novel form of mercury poisoning. *Med. Hypotheses* 56, 462–471 (2001). – **642**. Geier, D., King, P. & Geier, M. Mitochondrial dysfunction, impaired oxidative-reduction activity, degeneration, and death in human neuronal and fetal cells induced by low-level exposure to thimerosal and other metal compounds. *Toxicol Environ Chem* 91, 735–749 (2009). – **643**. Parran, D. K., Barker, A. & Ehrlich, M. Effects of thimerosal on NGF signal transduction and cell death in neuroblastoma cells. *Toxicol. Sci.* 86, 132–140 (2005). – **644**. Gallagher, C. M. & Goodman, M. S. Hepatitis b vaccination of male neonates and autism diagnosis, NHIS 1997–2002. *J. Toxicol. Environ. Health Part A* 73, 1665–1677 (2010). – **645**. Delong, G. A positive association found between autism prevalence and childhood vaccination uptake across the U.S. population. *J. Toxicol. Environ. Health Part A* 74, 903–916 (2011). – **646**. Laidler, J. R. US department of education data on 'autism' are not reliable for tracking autism prevalence. *pediatrics* 116, e120–e124 (2005). – **647**. Goldberg, W. A. et al. Language and other regression: Assessment and timing. *J Autism Dev Disord* 33, 607–616 (2003). – **648**. Kern, J. K. et al. Evidence of parallels between mercury intoxication and the brain pathology in autism. *Acta Neurobiol Exp (Wars)* 72, 113–153 (2012). – **649**. Kern, J. K. & Jones, A. M. Evidence of toxicity, oxidative stress, and neuronal insult in autism. *J Toxicol Environ Health B Crit Rev* 9, 485–499 (2006). – **650**. Palmer, R. F., Blanchard, S. & Wood, R. Proximity to point sources of environmental mercury release as a predictor of autism prevalence. *Health Place* 15, 18–24 (2009). – **651**. Thomas Curtis, J., Chen, Y., Buck, D. J. & Davis, R. L. Chronic inorganic mercury exposure induces sex-specific changes in central TNF expression: α importance in autism? *Neurosci. Lett.* 504, 40–44 (2011). – **652**. Curtis, J. T., Hood, A. N., Chen, Y., Cobb, G. P. & Wallace, D. R. Chronic metals ingestion by prairie voles produces sex-specific deficits in social behavior: An animal model of autism. *Behav. Brain Res.* 213, 42–49 (2010). – **653**. Majewska, M. D., Urbanowicz, E., Rok-Bujko, P., Namysłowski, I. & Mierzejewski, P. Age-dependent lower or higher levels of hair mercury in autistic children than in healthy controls. *Acta Neurobiol Exp (Wars)* 70, 196–208 (2010). – **654**. Geier, D. A., Kern, J. K., King, P. G., Sykes, L. K. & Geier, M. R. Hair toxic metal concentrations and autism spectrum disorder severity in young children. *Int. J. Environ. Res. Public Health* 9, 4486–4497 (2012). – **655**. Centre Ressources Autismes, Nord Pas de Calais. CARS, echelle d'évaluation de l'Autisme infantile. <<http://www.cra-npdc.fr/wp-content/uploads/2012/03/cars.pdf>> – **656**. Elsheshtawy, E., Tobar, S., Sherra, K., Atallah, S. & Elkasaby, R. Study of some biomarkers in hair of children with autism: Middle East *Curr. Psychiatry* 18, 6–10 (2011). – **657**. Woods, J. S. et al. Urinary porphyrin excretion in neurotypical and autistic children. *Environ Health Perspect* 118, 1450–1457 (2010). – **658**. Woods, J. S. Altered porphyrin metabolism as a biomarker of mercury exposure and toxicity. *Can. J. Physiol. Pharmacol.* 74, 210–215 (1996). – **659**. Nataf, R. et al. Porphyrinuria in childhood autistic disorder: Implications for environmental toxicity. *Toxicol. Appl. Pharmacol.* 214, 99–108 (2006). – **660**. Nishiyama, S., Taguchi, T. & Onosaka, S. Induction of zinc-thionein by estradiol and protective effects on inorganic mercury-induced renal toxicity. *Biochem. Pharmacol.* 36, 3387–3391 (1987). – **661**. Tang, C. Y. et al. Influence of polluted SY river on child growth and sex hormones. *Biomed. Environ. Sci.* 25, 291–296 (2012). – **662**. Wikipédia. Thiomersal. Wikipédia (2015). <<https://fr.wikipedia.org/w/index.php?title=Thiomersal&oldid=112394071>> – **663**. Centers for Disease Control and Prevention. Notice to readers: Thimerosal in vaccines: A joint statement of the American Academy of Pediatrics and the Public Health Service. (1999). <<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4826a3.htm>> – **664**. Bigham, M. & Copes, R. Thiomersal in vaccines: Balancing the risk of adverse effects with the risk of vaccine-preventable disease. *Drug Saf* 28, 89–101 (2005). – **665**. AFSSAPS. Point presse, le thiomersal. (2009). <<http://www.sante.gouv.fr/IMG/pdf/Fiche-Thiomersal-2.pdf>> – **666**. notre-planete.info. Comment manger du poisson sans s'intoxiquer au mercure ? (2013). <http://www.notre-planete.info/actualites/actu_3653_poisson_mercure_sante.php> – **667**. Non-au-mercure-dentaire. MERCURE AMAL-GAME DENTAIRE PLOMBAGE NAMD MELET GROSMAN INTOXICATION METAUX LOURDS. <<http://www.non-au-mercure-dentaire.org/mercure.php>> – **668**. Evaluation of certain food additives and contaminants: Sixty-seventh report of the joint FAO/WHO expert committee on food additives ; [Rome, 20 - 29 June 2006]. (World Health Organization, 2007). – **669**. notre-planete.info. Augmentation des émissions de mercure dans les pays en développement. (2013). <http://www.notre-planete.info/actualites/actu_3613_emissions_mercure_monde.php> – **670**. AFSSAPS, InVS & AFSSA. Evaluation des risques sanitaires liés à l'exposition de la population française à l'aluminium. (2003). <http://opac.invs.sante.fr/doc_num.php?explnum_id=5228> – **671**. Crapper McLachlan, D. R. et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. *Lancet* 337, 1304–1308 (1991). – **672**. Kawahara, M. & Kato-Negishi, M. Link between aluminum and the pathogenesis of Alzheimer's disease: The integration of the aluminum and amyloid cascade hypotheses. *Int J Alzheimers Dis* 2011, (2011). – **673**. Zatta, P. et al. A fatal case of aluminum encephalopathy in a patient with severe chronic renal failure not on dialysis. *Nephrol. Dial. Transplant.* 19, 2929–2931 (2004). – **674**. Kumar, V., Bal, A. & Gill, K. D. Aluminium-induced oxidative DNA damage recognition and cell-cycle disruption in different regions of rat brain. *Toxicology* 264, 137–144 (2009). – **675**. Offit, P. A. & Jew, R. K. Addressing parents' concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? <<http://pediatrics.aappublications.org>> – **676**. Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: Current state and future trends. *Immunol Cell Biol* 82, 488–496 (2004). – **677**. He, P., Zou, Y. & Hu, Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. *Hum Vaccin Immunother* 11, 477–488 (2015). – **678**. Inserm. Vaccins et vaccination. (2010). <<http://www.inserm.fr/thematiques/immunologie-inflammation-infectiologie-et-microbiologie/dossiers-d-information/vaccins-et-vaccination>> – **679**. HogenEsch, H. Mechanism of immunopotentiality and safety of aluminum adjuvants. *Front. Immun.* 3, 406 (2013). – **680**. Terhune, T. D. & Deth, R. C. A role for

impaired regulatory t cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals. *vaccine* 32, 5149–5155 (2014). – **681.**Bergfors, E. & Trollfors, B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. *Eur. J. Pediatr.* 172, 171–177 (2013). – **682.**Bergfors, E. et al. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. *Eur. J. Pediatr.* 173, 1297–1307 (2014). – **683.**Bergfors, E., Björkelund, C. & Trollfors, B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. *Eur. J. Pediatr.* 164, 691–697 (2005). – **684.**Gente Lidholm, A. et al. Unexpected loss of contact allergy to aluminium induced by vaccine. *Contact Derm.* 68, 286–292 (2013). – **685.**Petrik, M. S., Wong, M. C., Tabata, R. C., Garry, R. F. & Shaw, C. A. Aluminium adjuvant linked to gulf war illness induces motor neuron death in mice. *Neuromolecular Med.* 9, 83–100 (2007). – **686.**Asa, P. B., Wilson, R. B. & Garry, R. F. Antibodies to squalene in recipients of anthrax vaccine. *Exp. Mol. Pathol.* 73, 19–27 (2002). – **687.**Khan, Z. et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. *BMC Med.* 11, 99 (2013). – **688.**Asa, P. B., Cao, Y. & Garry, R. F. Antibodies to squalene in gulf war syndrome. *Exp. Mol. Pathol.* 68, 55–64 (2000). – **689.**Golomb, B. A. Acetylcholinesterase inhibitors and gulf war illnesses. *PNAS* 105, 4295–4300 (2008). – **690.**Gherardi, R. K. et al. Macrophagic myofasciitis: An emerging entity. groupe d'Etudes et recherche sur les maladies musculaires acquises et dysimmunitaires (GERMMAD) de l'Association française contre les myopathies (AFM). *lancet* 352, 347–352 (1998). – **691.**Vaccins & aluminium - myofasciite à macrophages. (2015). <<https://www.youtube.com/watch?v=Bh6vBWMZYU>> – **692.**Shoenfeld, Y. & Agmon-Levin, N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. *J. Autoimmun.* 36, 4–8 (2011). – **693.**OMS. Comité consultatif mondial sur la sécurité des vaccins. WHO. (2002). <http://www.who.int/vaccine_safety/committee/reports/june_2002/fr/> – **694.**Gherardi, R. K. [Lessons from macrophagic myofasciitis: Towards definition of a vaccine adjuvant-related syndrome]. *Rev. Neurol. (Paris)* 159, 162–164 (2003). – **695.**Gherardi, R. K. et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. *brain* 124, 1821–1831 (2001). – **696.**Verdier, F. et al. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey. *vaccine* 23, 1359–1367 (2005). – **697.**Académie Nationale de Médecine. Les adjuvants vaccinaux: Quelle actualité en 2012 ? (2012). <<http://www.academie-medicine.fr/wp-content/uploads/2013/10/adjuvants-vaccinaux-rapport-ANM1.pdf>> – **698.**Haut Conseil de la Santé Publique. Aluminium et vaccins. (2013). <http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcsp20130711_aluminiumetvaccins.pdf> – **699.**Guis, S. et al. Identical twins with macrophagic myofasciitis: Genetic susceptibility and triggering by aluminic vaccine adjuvants? *Arthritis & Rheumatism* 47, 543–545 (2002). – **700.**Guis, S. et al. HLADRB1*01 and macrophagic myofasciitis. *Arthritis & Rheumatism* 46, 2535–2537 (2002). – **701.**Santiago, T., Rebelo, O., Negrão, L. & Matos, A. Macrophagic myofasciitis and vaccination: Consequence or coincidence? *Rheumatol. Int.* 35, 189–192 (2015). – **702.**Ragunathan-Thangarajah, N. et al. Distinctive clinical features in arthro-myalgic patients with and without aluminium hydroxyde-induced macrophagic myofasciitis: An exploratory study. *J. Inorg. Biochem.* 128, 262–266 (2013). – **703.**Couette, M. et al. Long-term persistence of vaccine-derived aluminium hydroxide is associated with chronic cognitive dysfunction. *J. Inorg. Biochem.* 103, 1571–1578 (2009). – **704.**Hommet, C. et al. Latéralisation cérébrale et interactions hémisphériques chez le sujet âgé : Place du test d'écoute dichotique. *Psychol. Neuropsychiatr. Vieil.* 7, 65–72 (2009). – **705.**Koeger, A.-C. Maladies auto-immunes et prothèses mammaires en silicone. <<http://www.ipubli.inserm.fr/bitstream/handle/10608/201/?sequence=35>> – **706.**Académie Nationale de Médecine. Le refus des vaccinations. aspects actuels en 2012 et solutions en santé publique. (2012). <<http://www.academie-medicine.fr/publication100036465/>> – **707.**Food and Drug Administration. Database of select committee on GRAS substances (SCOGS) reviews. (2015). <<http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?filter=aluminum\&sortColumn=\&rpt=scogsListing#>> – **708.**Nutrition, C. for F. S. & Applied. GRAS substances (SCOGS) database. (2015). <<http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm2006852.htm>> – **709.**Turk, J. L. Von pirquet, allergy and infectious diseases: A review. *J R Soc Med* 80, 31–33 (1987). – **710.**Igea, J. M. The history of the idea of allergy. *allergy* 68, 966–973 (2013). – **711.**Molina, C. L'allergie à l'aube du troisième millénaire. (John Libbey Eurotext, 1995). – **712.**Archive.org. Full text of 'a study of the cause of sudden death following the injection of horse serum'. <https://www.archive.org/stream/astudycasesudd00andegoog/astudycasesudd00andegoog_djvu.txt> – **713.**Klossek, J.-M., Annesi-Maesano, I., Pribil, C. & Didier, A. Un tiers des adultes ont une rhinite allergique en France (enquête INSTANT). *Presse Médicale* 38, 1220–1229 (2009). – **714.**Black, C. A. P. Delayed type hypersensitivity: Current theories with a historic perspective. *Dermatol. Online J.* 5, (1999). – **715.**Gell, P. G. H. & Benacerraf, B. II. studies on hypersensitivity delayed hypersensitivity to denatured proteins in guinea pigs. *immunology* 2, 64–70 (1959). – **716.**Benacerraf, B. & Gell, P. G. H. Studies on hypersensitivity I. delayed and arthus-type skin reactivity to protein conjugates in guinea pigs. *immunology* 2, 53–63 (1959). – **717.**Ganeshan, K. et al. Impairing oral tolerance promotes allergy and anaphylaxis: A new murine food allergy model. *J. Allergy Clin. Immunol.* 123, 231–238.e4 (2009). – **718.**Rupa, P., Hamilton, K., Cirinna, M. & Wilkie, B. N. A neonatal swine model of allergy induced by the major food allergen chicken ovomucoid (gal d 1). *Int. Arch. Allergy Immunol.* 146, 11–18 (2008). – **719.**Inserm. Anaphylaxie. (2010). <<http://www.inserm.fr/thematiques/immunologie-inflammation-infectiologie-et-microbiologie/dossiers-d-information/anaphylaxie>> – **720.**Sicherer, S. H. Epidemiology of food allergy. *J. Allergy Clin. Immunol.* 127, 594–602 (2011). – **721.**Bublin, M. & Breiteneder, H. Cross-reactivity of peanut allergens. *Curr Allergy Asthma Rep* 14, (2014). – **722.**Allergen.org. IUIS allergen nomenclature home page. <<http://www.allergen.org/>> – **723.**Bublin, M. et al. IgE cross-reactivity between the major peanut allergen ara h 2 and the nonhomologous allergens ara h 1 and ara h 3. *J. Al-*

- lergy Clin. Immunol. 132, 118–124 (2013). – **724**.UCFA. Utrecht center for food allergy - DBPCFC. <<http://ucfa.nl/in-depth-information/dbpcfc/>> – **725**.Maloney, J. M., Rudengren, M., Ahlstedt, S., Bock, S. A. & Sampson, H. A. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J. Allergy Clin. Immunol. 122, 145–151 (2008). – **726**.Barre, A., Jacquet, G., Sordet, C., Culerrier, R. & Rougé, P. Homology modelling and conformational analysis of IgE-binding epitopes of ara h 3 and other legumin allergens with a cupin fold from tree nuts. Mol. Immunol. 44, 3243–3255 (2007). – **727**.Barre, A. et al. Vicilin allergens of peanut and tree nuts (walnut, hazelnut and cashew nut) share structurally related IgE-binding epitopes. Mol. Immunol. 45, 1231–1240 (2008). – **728**.Mittag, D. et al. Ara h 8, a bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. J. Allergy Clin. Immunol. 114, 1410–1417 (2004). – **729**.Choi, J. H. et al. An IgE-mediated allergic reaction caused by mulberry fruit. Allergy Asthma Immunol Res 7, 195–198 (2015). – **730**.Bolhaar, S. T. H. P. et al. Severe allergy to sharon fruit caused by birch pollen. Int. Arch. Allergy Immunol. 136, 45–52 (2005). – **731**.Mittag, D. et al. Soybean allergy in patients allergic to birch pollen: Clinical investigation and molecular characterization of allergens. J. Allergy Clin. Immunol. 113, 148–154 (2004). – **732**.Vieths, S., Scheurer, S. & Ballmer-Weber, B. Current understanding of cross-reactivity of food allergens and pollen. Ann. N. Y. Acad. Sci. 964, 47–68 (2002). – **733**.Bublil, N. Kiwifruit allergies. Adv. Food Nutr. Res. 68, 321–340 (2013). – **734**.Ministry of Health, N. Z. Immunisation handbook 2014. <<http://immunisation.book.health.govt.nz/Appendices/Appendix+1+The+history+of+immunisation+in+New+Zealand>> – **735**.Centers for Disease Control and Prevention. Recommended schedule for active immunization of normal infants and children. (1983). <<http://www.cdc.gov/vaccines/schedules/images/schedule1983s.jpg>> – **736**.Centers for Disease Control and Prevention. Notice to readers: Recommended childhood immunization schedule – united states, 2000. (2000). <<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4902a4.htm>> – **737**.Centers for Disease Control and Prevention. Advisory committee on immunization practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years united states, 2013. (2013). <<http://www.cdc.gov/mmwr/preview/mmwrhtml/su6201a2.htm>> – **738**.Ministère de la Santé Publique. Le nouveau calendrier vaccinal. (1990). <http://www.invs.sante.fr/beh/1990/9005/beh_05_1990.pdf> – **739**.Inpes. Calendrier des vaccinations 2015. (2015). <<http://www.inpes.sante.fr/10000/themes/vaccination/calendrier/calendrier-vaccination.asp>> – **740**.EurekaSanté. IMMUGRIP (2015). <<http://www.eureka.sante.fr/medicaments/vidal-famille/medicament-ommug01-IMMUGRIP.html>> – **741**.Comprendrequechoisir. INFANRIX HEXA : La fiche complète. ComprendreChoisir.com. <<http://medicament.comprendrechoisir.com/medicament/voir/5072/infanrix-hexa>> – **742**.OMS. Immunological adjuvants. (1976). <http://whqlibdoc.who.int/trs/WHO_TRS_595.pdf> – **743**.Woodhour, A. F., Metzgar, D. P., Stim, T. B., Tytell, A. A. & Hilleman, M. R. New metabolizable immunologic adjuvant for human use. i. development and animal immune response. Exp Biol Med (Maywood) 116, 516–523 (1964). – **744**.Weibel, R. E., McLean, A., Woodhour, A. F., Friedman, A. & Hilleman, M. R. Ten-year follow-up study for safety of adjuvant 65 influenza vaccine in man. Exp Biol Med (Maywood) 143, 1053–1056 (1973). – **745**.Smith, J. W., Fletcher, W. B., Peters, M., Westwood, M. & Perkins, F. J. Response to influenza vaccine in adjuvant 65-4. J Hyg (Lond) 74, 251–259 (1975). – **746**.Merck. Merck says emulsion of peanut oil extends longevity of flu shot. (1964). <<http://pqasb.pqarchiver.com/djreprints/doc/132896455.html>?FMT=ABS&FMTS=ABS:AI&type=historical&date=Nov%2019, %201964&author=Wall%20Street%20Journal&edition=&startpage=&desc=Merck%20Says%20Emulsion%20Of%20Peanut%20Oil%20Extends%20Longevity%20of%20Flu%20Shot> – **747**.Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a. (1994). <<http://www.google.com/patents/WO1994019013A1>> – **748**. Vaccine compositions comprising inactivated immunogens and live chicken anaemia virus (CAV). (2004). <<http://www.freepatentsonline.com/EP0838222.html>> – **749**. NOVEL PEANUT SKIN EXTRACT AS A VACCINE ADJUVANT. (2006). <<http://www.freepatentsonline.com/WO2005089262A3.html>> – **750**. Influenza vaccine. (2007). <<http://www.freepatentsonline.com/y2007/0141078.html>> – **751**. Sustained release vaccine composition. (2008). <<http://www.freepatentsonline.com/y2008/0199491.html>> – **752**. Vaccine adjuvants: Preparation methods and research protocols. (Humana Press, 2000). <https://books.google.fr/books?id=y3et5Aw5KbC&pg=PA5&lpg=PA5&dq=Vaccine+Adjuvants+o+hagan+vegetable+oil+peanut&source=bl&ots=Eguky_ozJr&sig=Y4qj0bnLbMSOpI6I0bwZWGB9WsI&hl=fr&sa=X&ei=H0cRVOTIBInSaPa8vgvO#v=onepage&q=Vaccine%20Adjuvants%20%20o%20hagan%20vegetable%20oil%20peanut&f=false> – **753**. Nutrition, C. for F. S. & Applied. GRAS substances (SCOGS) database: Peanut oil (packaging). <<http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260946.htm>> – **754**. ADJUVANT COMPOSITIONS AND METHODS OF USE. (2011). <<http://www.freepatentsonline.com/EP2384120A1.html>> – **755**. VACCINES AND VECTORS WITH LIQUID ACTIVE PRINCIPLES CONTAINING AN OIL WHICH CAN BE METABOLISED. (1991). <<http://www.freepatentsonline.com/WO1991000107A1.html>> – **756**. VACCINE COMPRISING AN OIL IN WATER EMULSION ADJUVANT. (2008). <<http://www.freepatentsonline.com/WO2008043774A1.html>> – **757**. OMS. Adjuvants à base de squalène dans les vaccins. WHO. (2006). <http://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/> – **758**. Bloom. Le prix hideux de la beauté. (2012). <http://www.bloomassociation.org/download/FR_Squalene_LONG.pdf> – **759**. Merck. Renseignements pour le consommateur - pneumovax. <http://www.merck.ca/assets/fr/pdf/products/ci/PNEUMOVAX_23-CL_E.pdf> – **760**. GlaxoSmithKline Inc. Renseignements pour le consommateur - twinrix. <http://www.twinrix.ca/media/pdf/ConsumerLeaflet_French.pdf> – **761**. Justice, M. de la. Lois codifiées règlements codifiés. (2015). <<http://laws-lois.justice.gc.ca/fra/lois/P-21/page-1.html>> –

- 762.** Justice, M. de la. Lois codifiées règlements codifiés. (2015). <<http://laws-lois.justice.gc.ca/fr/lois/a-1/page-11.html>> – **763.** Commissioner, O. of the. Legislation - fair packaging and labeling act. <<http://www.fda.gov/RegulatoryInformation/Legislation/ucm148722.htm>> – **764.** Schneider, E. Allergies aux poissons et aux viandes. <http://www.congress-allergologie.com/images/client/163/files/presentations_chairman/1064/V-AT4_4_SCHNEIDER_E.pdf> – **765.** Halsey, N. A. et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (h1N1) vaccines: Reports to VAERS. *vaccine* 31, 6107–6112 (2013). – **766.** Rouleau, I. et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (h1N1pdm09) vaccine. *vaccine* 31, 5989–5996 (2013). – **767.** Maitra, A., Sherriff, A., Griffiths, M. & Henderson, J. Pertussis vaccination in infancy and asthma or allergy in later childhood: Birth cohort study. *bmj* 328, 925–926 (2004). – **768.** Kemp, T. et al. Is infant immunization a risk factor for childhood asthma or allergy? *Epidemiology* 8, 678–680 (1997). – **769.** Hurwitz, E. L. & Morgenstern, H. Effects of diphtheria-tetanus-pertussis or tetanus vaccination on allergies and allergy-related respiratory symptoms among children and adolescents in the united states. *J Manipulative Physiol Ther* 23, 81–90 (2000). – **770.** Anderson, H. R. et al. Immunization and symptoms of atopic disease in children: Results from the international study of asthma and allergies in childhood. *Am J Public Health* 91, 1126–1129 (2001). – **771.** Gong, H. in *Clinical methods: The history, physical, and laboratory examinations* (eds. Walker, H. K., Hall, W. D. & Hurst, J. W.) (Butterworths, 1990). <<http://www.ncbi.nlm.nih.gov/books/NBK358/>> – **772.** Umass-Med. Top 25 public health journals: Evidence-based practice for public health. <<http://library.umassmed.edu/ebpph/top25.cfm>> – **773.** Sampson, H. A. Anaphylaxis and emergency treatment. *pediatrics* 111, 1601–1608 (2003). – **774.** Allergies planétaires, à qui la faute ? (2014). <<https://www.youtube.com/watch?v=OUuwPG7xjk8#t=11>> – **775.** Asthme, allergies et accouchement à l'hôpital. 7/13. (2013). <https://www.youtube.com/watch?v=mq-ewjT7_Q> – **776.** Holbreich, M. et al. Amish children living in northern indiana have a very low prevalence of allergic sensitization. *J. Allergy Clin. Immunol.* 129, 1671–1673 (2012). – **777.** Riedler, J., Eder, W., Oberfeld, G. & Schreuer, M. Austrian children living on a farm have less hay fever, asthma and allergic sensitization. *Clin. Exp. Allergy* 30, 194–200 (2000). – **778.** Rutkowski, K., Sowa, P., Rutkowska-Talipska, J., Sulkowski, S. & Rutkowski, R. Allergic diseases: The price of civilisational progress. *Postepy Dermatol Alergol* 31, 77–83 (2014). – **779.** Hill, D. A. et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. *Nat Med* 18, 538–546 (2012). – **780.** Centre des Mardi. Intolérance congénitale au glucose et au galactose. <<http://www.centredesmardi.org/article1.php?im=37&clg=FR&cia=96>> – **781.** OMS. Liste des membres et du conseiller du comité d'urgence du règlement sanitaire international (2005) concernant la pandémie de grippe (h1N1) 2009. (2010). <http://www.who.int/ihr/emerg_comm_members_2009/fr/> – **782.** CSL. Panvax h1N1 approval for registration for use in australia by therapeutic goods administration. (2009). <<http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1249870443804/prdetail.htm>> – **783.** Les Echos. Pfizer effectue une incursion sur le marché des vaccins. *Lesechos.fr.* (2006). <http://www.lesechos.fr/10/10/2006/LesEchos/19769-120-ECH_pfizer-effectue-une-incursion-sur-le-marche-des-vaccins.htm> – **784.** Pfizer. New pH1N1 vaccine available for swine. (2009). <<http://press.pfizer.com/press-release/new-ph1n1-vaccine-available-swine>> – **785.** Ferguson, N. M., Galvani, A. P. & Bush, R. M. Ecological and immunological determinants of influenza evolution. *nature* 422, 428–433 (2003). – **786.** Ferguson, N. M. et al. Strategies for containing an emerging influenza pandemic in southeast asia. *nature* 437, 209–214 (2005). – **787.** Ferguson, N. M. et al. Strategies for mitigating an influenza pandemic. *nature* 442, 448–452 (2006). – **788.** Cauchemez, S., Valleron, A.-J., Boëlle, P.-Y., Flahault, A. & Ferguson, N. M. Estimating the impact of school closure on influenza transmission from sentinel data. *nature* 452, 750–754 (2008). – **789.** UK Parliament. House of commons - scientific advice and evidence in emergencies - science and technology committee. <<http://www.publications.parliament.uk/pa/cm201011/cmselect/cmsctech/498/49809.htm>> – **790.** UK Parliament. House of commons hansard written answers. (2009). <<http://www.publications.parliament.uk/pa/cm200809/cm-hansrd/cm090716/text/90716w0029.htm>> – **791.** Imperial College. Home - professor sir. john beddington. <<http://www.imperial.ac.uk/people/j.beddington>> – **792.** Tazi-Ahni, R. et al. Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): Evidence of association with alopecia areata in the down syndrome region. *Hum. Genet.* 106, 639–645 (2000). – **793.** CASMI. Sir gordon duff. <<http://casmi.org.uk/sir-gordon-duff/>> – **794.** Cabinet Office. The lead government department and its role guidance and best practice. <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/61355/lead-government-departments-role.pdf> – **795.** Chatham House. Professor david r harper CBE CBIol FSB FFPH hon FRSPH. Chatham house. <<http://www.chathamhouse.org/node/12710>> – **796.** Harper Public Health Consulting. Harper public health consulting limited. (2015). <<http://harperpublichealth.com/>> – **797.** GOV.UK. Professor dame sally davies. <<https://www.gov.uk/government/people/sally-davies>> – **798.** Imperial College. Professor dame sally davies. <<http://www1.imperial.ac.uk/publichealth/about/womeninscience/athenaswanevents/womeninpublichealthlecture/>> – **799.** Daily Mail. Stop your children being flu 'super spreaders', parents told. *Mail online.* (2014). <<http://www.dailymail.co.uk/news/article-2852466/Stop-children-flu-super-spreaders-health-chiefs-tell-parents-Dame-Sally-Owens-says-crucial-two-four-year-olds-vaccinated.html>> – **800.** GlaxoSmithKline Inc. Board of directors | GSK. (2015). <<http://www.gsk.com/en-gb/about-us/board-of-directors/>> – **801.** Daily Mail. Government virus expert paid 116k by swine flu vaccine manufacturers. *Mail online.* (2009). <<http://www.dailymail.co.uk/news/article-1202389/Government-virus-expert-paid-116k-swine-flu-vaccine-manufacturers.html>> – **802.** Russell, B. J. 1.5bn swine flu vaccine boost for GSK and astra. (2009). <<http://www.telegraph.co.uk/finance/6432931/1.5bn-swine-flu-vaccine-boost-for-GSK-and-Astra.html>> – **803.** Drug Development Technology. Pandemrix - adjuvanted h1N1 influenza vaccine. <<http://www.drugdevelopment-technology.com/projects/pandemrix/>> – **804.** Cardiff University. Dr meirion evans - research. <

- cine.cf.ac.uk/person/dr-meirion-rhys-evans/research/ – **805**. Five Nations Health Protection. Conference booklet 2006 cardiff. (2006). <<http://5nations.org.uk/Downloads/ConferenceBooklet-2006-Cardiff.pdf>> – **806**. Evans, M. R. & Watson, P. A. Why do older people not get immunised against influenza?: A community survey. *vaccine* 21, 2421–2427 (2003). – **807**. Merck Serono. Merck serono resumes stimuvax clinical program in lung cancer. (2010). – **808**. AstraZeneca. Live attenuated influenza vaccine, LAIV. (2014). <<http://www.astrazeneca.co.uk/medicines/infection/Product/live-attenuated-influenza-vaccine-laiiv>> – **809**. St George's University of London. Professor george griffin. <<http://www.sgul.ac.uk/research-profiles/a-z/professor-george-griffin>> – **810**. Department of Health UK. SPI members biographies : Scientific pandemic influenza advisory committee (SPI). (2011). <http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/SPI/DH_095670?PageOperation=email#_12> – **811**. Hall, A. J. The united kingdom joint committee on vaccination and immunisation. *vaccine* 28, Supplement 1, A54–A57 (2010). – **812**. Whittle, H. et al. Observational study of vaccine efficacy 14 years after trial of hepatitis b vaccination in gambian children. *bmj* 325, 569 (2002). – **813**. Sara L Thomas, J. G. W. Contacts with varicella or with children and protection against herpes zoster in adults: A case-control study. *lancet* 360, 678–82 (2002). – **814**. OMS. Strategic advisory group of experts on immunization (SAGE) decade of vaccines working group (established march 2013). WHO. (2014). <http://www.who.int/immunization/sage/sage_wg_decade_vaccines/en/> – **815**. Wikipedia. National institute for biological standards and control. Wikipedia, the free encyclopedia (2014). <http://en.wikipedia.org/w/index.php?title=National_Institute_for_Biological_Standards_and_Control&oldid=607264547> – **816**. NBSB. Annual report & accounts. (2009). <<http://www.nibsc.org/PDF/NBSB%20Annual%20Report%202009.pdf?q=reportaccounts>> – **817**. Sanofi Pasteur. Sanofi pasteur renforce la préparation a la pandémie avec le premier essai clinique d'un nouveau vaccin h7N1 sur culture cellulaire. (2006). <<http://www.sanofipasteur.com/fr/Documents/PDF/PR/20060919-Sanofi-pasteur-renforce-la-preparation-%C3%A0-la-pandemie-avec-le-premier-essai-clinique-d-un-nouveau-vaccin-H7N1-sur-la-culture-cellulaire.pdf>> – **818**. Commission Européenne. Un vaccin contre l'influenza aviaire se révèle prometteur lors d'essais cliniques. (2007). <http://europa.eu/rapid/press-release_IP-07-1298_fr.htm?locale=en> – **819**. Medicines Act 1968. Medicines act 1968 advisory bodies, annual reports 2007. – **820**. Information, N. C. for B., Pike, U. S. N. L. of M. 8. R., MD, B. & Usa, 2. No items found - PubMed - NCBI. – **821**. University College of London. Susan michie. <<http://www.ucl.ac.uk/health-psychology/people/michie>> – **822**. Gardner, B., McAteer, J., Davies, A. & Michie, S. How can MMR uptake be increased? A literature review and intervention feasibility study. report to the national social marketing centre. (2008). <<http://discovery.ucl.ac.uk/103057/>> – **823**. Gardner, B., McAteer, J., Davies, A. & Michie, S. Views towards compulsory MMR vaccination in the UK. *Arch Dis Child* 95, 658–659 (2010). – **824**. Loren-catto, F., Michie, S. & West, R. Method for identifying behaviour change techniques (BCTs) for stop smoking behavioural support delivered in practice. <http://www.uknsc.org/uknsc2011_poster_128.php> – **825**. NICE. Behaviour change: Individual approaches | guidance and guidelines. (2012). <<http://www.nice.org.uk/guidance/ph49/documents/behaviour-change-minutes-pdg-1>> – **826**. Brown, J., Michie, S. & West, R. The case of stop smoking services in england. *Br. J. Psychiatry* 202, 74–74 (2013). – **827**. ISIRV. Angus nicoll, head, programme for influenza and other respiratory viruses, ECDC, sweden. <<http://www.isirv.org/site/index.php/board-members/10-board/180-angus-nicoll>> – **828**. Nicoll, A., Ciancio, B., Tsolova, S., Blank, P. & Yilmaz, C. The scientific basis for offering seasonal influenza immunisation to risk groups in europe. *Euro Surveill.* 13, (2008). – **829**. University of Leicester. University of leicester professor karl nicholson leads human clinical trial with avian influenza vaccine. <<http://www.le.ac.uk/ebulletin-archive/ebulletin/news/press-releases/2000-2009/2006/06/nparticle.2006-06-07.html>> – **830**. Times Higher Education. Flu vaccine misses its target. Times higher education. (1994). <<http://www.timeshighereducation.co.uk/news/flu-vaccine-misses-its-target/154342.article>> – **831**. Cooper, N. J. et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza a and b: Systematic review and meta-analyses of randomised controlled trials. *bmj* 326, 1235 (2003). – **832**. Nicholson, K. G. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. *neuraminidase inhibitor flu treatment investigator group. lancet* 355, 1845–1850 (2000). – **833**. DBIO. Top 100 journals in biology and medicine. (2009). <<http://dbiosla.org/publications/resources/dbio100.html>> – **834**. Cohen, D. Complications: Tracking down the data on oseltamivir. *bmj* 339, b5387 (2009). – **835**. Kaiser L et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. *Arch Intern Med* 163, 1667–1672 (2003). – **836**. The Bureau of Investigative Journalism. WHO swine flu advisors had links to drug companies. (2010). <<https://www.thebureauinvestigates.com/2010/06/07/who-swine-flu-advisors-had-links-to-drug-companies/>> – **837**. Cohen, D. & Carter, P. WHO and the pandemic flu 'conspiracies'. *bmj* 340, c2912 (2010). – **838**. OMS. Biographie succincte du dr margaret chan. WHO. <<http://www.who.int/dg/chan/fr/>> – **839**. Sénat. La grippe a (h1N1) : Retours sur la première pandémie du XXIe siècle (rapport). (2010). <<http://www.senat.fr/rap/r09-685-1/r09-685-112.html>> – **840**. Flu Summit. Prof peter openshaw. <<http://www.flusummit.org/engine/speakers/openshaw>> – **841**. Imperial College. Honours and memberships - peter openshaw - professor of experimental medicine. (2015). <<http://www.imperial.ac.uk/people/p.openshaw/honours-and-memberships.html>> – **842**. Bavarian Nordic. Bavarian nordic. (2015). <<http://www.bavarian-nordic.com/>> – **843**. Nguyen-Van-Tam, J. S., Openshaw, P. J. M. & Nicholson, K. G. Antivirals for influenza: Where now for clinical practice and pandemic preparedness? *The Lancet* 384, 386–387 (2014). – **844**. Bewick, T. et al. Clinical and laboratory features distinguishing pandemic h1N1 influenza-related pneumonia from inter-pandemic community-acquired pneumonia in adults. *thorax* 2010.151522 (2011). doi:10.1136/thx.2010.151522 – **845**. University College of London. Prof deenan pillay. <<http://www.ucl.ac.uk/slms/people/show.php?UPI=DPILL78>> – **846**. GOV.UK. Expert advisory group on AIDS - groups. <<https://www.gov.uk/government/groups/expert-advisory-group-on-aids>> – **847**. GOV.UK. EXPERT ADVISORY GROUP ON AIDS, providing expert scientific advice on HIV. (2010).

- <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/274473/EAGA-Annual-Report-2009.pdf> – **848**. International Vaccine Institute. International workshop to discuss vaccines against influenza at IVI. (2007). <http://www.ivi.int/web/www/07_01;jsessionid=F70D1563D5408D89C1FBE5730D918812?_p_p_id=EXT_BBS1&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-1&p_p_col_pos=1&p_p_col_count=2&_EXT_BBS_struts_action=%2Fext%2Fbbs%2Fview_message&_EXT_BBS_sCategory=&_EXT_BBS_sSubCategory=&_EXT_BBS_sTitle=&_EXT_BBS_sWriter=&_EXT_BBS_sTag=&_EXT_BBS_sContent=&_EXT_BBS_sCategory2=&_EXT_BBS_sSubCategory2=&_EXT_BBS_sKeyType=&_EXT_BBS_sKeyword=&_EXT_BBS_curPage=9&_EXT_BBS_messageId=88> – **849**. INFLUENZA VIRUS NEURAMINIDASE CRYSTAL STRUCTURE AND THEIR USE THEREOF. (2007).
- <<http://www.freepatentsonline.com/WO2007141516A2.html>> – **850**. Air, G. M. Influenza neuraminidase. *Influenza Other Respi Viruses* 6, 245–256 (2012). – **851**. Sanofi Pasteur MDS. Sanofi pasteur MSD dédié au vaccin et à la prévention des maladies infectieuses. <<http://www.spmsd.fr/>> – **852**. LinkedIn. Jonathan van-tam. (2014). <<https://uk.linkedin.com/pub/jonathan-van-tam/14/8b3/a8b>> – **853**. OMS. Grippe a(H1N1): Le niveau d'alerte pandémique passe en phase 6. WHO. (2009).
- <http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/fr/> – **854**. OMS. Qu'est-ce que la phase 6? (2009). <http://www.who.int/csr/disease/swineflu/frequently_asked_questions/levels_pandemic_alert/fr/> – **855**. Les économistes des plateaux télé. (2012). <<https://www.youtube.com/watch?v=SDU742g-QoZw>> – **856**. NEJM. About NEJM - past and present. New england journal of medicine. <<http://www.nejm.org/page/about-nejm/history-and-mission>> – **857**. Altman, L. K. New england journal of medicine names third editor in a year. *The New York Times*: U.S. (2000). <<http://www.nytimes.com/2000/05/12/us/new-england-journal-of-medicine-names-third-editor-in-a-year.html>> – **858**. NEJM. Media center - the NEJM editor-in-chief. New england journal of medicine. (2015). <<http://www.nejm.org/page/media-center/editor-in-chief>> – **859**. Mitka M. NEJM editor jerome p. kassirer, md, loses post over 'administrative issues'. *jama* 282, 622–623 (1999). – **860**. Kassirer, J. P. On the take: How america's complicity with big business can endanger your health. (Oxford University Press, 2005). – **861**. DeAngelis, C. D. Book review. *N. Engl. J. Med.* 351, 2459–2459 (2004). – **862**. NIH. Changing the face of medicine | dr. marcia angell. <http://www.nlm.nih.gov/changingthefaceofmedicine/physicians/biography_10.html> – **863**. Angell, M. The truth about the drug companies. *The New York Review of Books* (2004). <<http://www.nybooks.com/articles/archives/2004/jul/15/the-truth-about-the-drug-companies/>> – **864**. Angell, M. Drug companies & doctors: A story of corruption. *The New York Review of Books* (2009). <<http://www.nybooks.com/articles/archives/2009/jan/15/drug-companies-doctors-a-story-of-corruption/>> – **865**. Government Publishing Office. Congressional record, volume 154 issue 91. (2008). <<http://origin.www.gpo.gov/fdsys/pkg/CREC-2008-06-04/html/CREC-2008-06-04-pt1-PgS5029-2.htm>> – **866**. Cooney, E. Psychiatrists under fire supported by mass. general. (2008). <<http://lcmmedia.typepad.com/pharmola/2008/06/psychiatrists-under-fire-supported-by-mass-general-by-eli-zabath-cooneyjune-11-2008-three-harvard-psychiatrists-facing-a-us.html#more>> – **867**. The Wall Street Journal. I was doing the right thing. *Wall Street Journal: Opinion* (2008). <<http://www.wsj.com/articles/SB122965241735720719>> – **868**. Nature News Blog. Harvard scientists disciplined for not declaring ties to drug companies. (2011). <http://blogs.nature.com/news/2011/07/harvard_scientists_disciplined.html> – **869**. The Harvard Crimson. Document: The doctors' apology letter. (2011). <<http://www.thecrimson.com/flash-graphic/2011/7/2/medical-school-colleagues-letter/>> – **870**. InCites. Second bimonthly period of 2007 - top 10 researchers in psychiatry/psychology. <<http://in-cites.com/top/2007/second07-psy.html>> – **871**. ESI Topics. Attention deficit hyperactivity disorder (ADHD/ADD) - interview with dr. joseph biederman. (2005). <<http://www.esi-topics.com/add/interviews/JosephBiederman.html>> – **872**. United States District Court for the Eastern district of Pennsylvania. United states of america v. janssen pharmaceuticals, inc. (2013). <<http://www.justice.gov/sites/default/files/opa/legacy/2013/11/04/janssen-info.pdf>> – **873**. Fisk, J. F. C. %J pushed risperdal with golf, popcorn, witness says. *Bloomberg.com*. <<http://www.bloomberg.com/news/articles/2012-09-25/j-j-pushed-risperdal-with-golf-popcorn-witness-says>> – **874**. Statista.com. Top antipsychotic drug sales in the united states 2011-2012 | statistic. *Statista*. <<http://www.statista.com/statistics/242480/sales-of-antipsychotic-drugs-in-the-us/>> – **875**. Jansen. Risperdal. <<http://www.janssenpharmaceuticalsinc.com/assets/risperdal.pdf>> – **876**. NIH. Risperidone: MedlinePlus drug information. (2012). <<http://www.nlm.nih.gov/medlineplus/druginfo/meds/a694015.html#side-effects>> – **877**. AFSSAPS. Rapport public d'évaluation, risperdal. (2005). <http://ansm.sante.fr/var/ansm_site/storage/original/application/74364a3a13ca6a7a543da09bf576ea30.pdf> – **878**. Rosenheck, R. A. et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. *N. Engl. J. Med.* 364, 842–851 (2011). – **879**. Samson, K. NerveCenter: Senate probe seeks industry payment data on individual academic researchers. *Ann Neurol.* 64, A7–A9 (2008). – **880**. United States District Court for the district of Massachusetts. United states v. GlaxoSmithKline. <<http://www.justice.gov/sites/default/files/opa/legacy/2012/07/02/us-complaint.pdf>> – **881**. Keller, M. B. et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry* 40, 762–772 (2001). – **882**. Harris, G. Top psychiatrist didn't report drug makers' pay. *The New York Times: Health / Health Care Policy* (2008). <<http://www.nytimes.com/2008/10/04/health/policy/04drug.html>> – **883**. Gottlieb, S. FDA censures NEJM editor. *BMJ* 320, 1562 (2000). – **884**. Sibbald, B. NEJM's new editor cut ties with 20 drug companies before taking helm. *CMAJ* 163, 1182–1182 (2000). – **885**. Drazen, J. M. & Curfman, G. D. Financial associations of authors. *N. Engl. J. Med.* 346, 1901–1902 (2002). – **886**. Lexchin, J. & Light, D. W. Commercial influence and the content of medical journals. *bmj* 332, 1444–1447 (2006). – **887**. Wilkes, M. S., Doblin, B. H. & Shapiro, M. F. Pharmaceutical advertisements in leading medical

- journals: Experts' assessments. *Ann. Intern. Med.* 116, 912–919 (1992). – **888.** Godlee, F, Smith, J. & Marcovitch, H. Wakefield's article linking MMR vaccine and autism was fraudulent. *bmj* 342, (2011). – **889.** Deer, B. How the case against the MMR vaccine was fixed. *bmj* 342, (2011). – **890.** hwdadmin. Wakefield's article linking MMR vaccine and autism was fraudulent. *bmj* 342, (2011). – **891.** Godlee, F. Institutional and editorial misconduct in the MMR scare. *bmj* 342, (2011). – **892.** Godlee, F. The fraud behind the MMR scare. *bmj* 342, (2011). – **893.** Whoriskey, P. As drug industry's influence over research grows, so does the potential for bias. *The Washington Post* (2012). <http://www.washingtonpost.com/business/economy/as-drug-industries-influence-over-research-grows-so-does-the-potential-for-bias/2012/11/24/bb64d596-1264-11e2-be82-c3411b7680a9_story.html> – **894.** Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *N. Engl. J. Med.* 343, 1520–1528 (2000). – **895.** Topol, E. J. Failing the public health rofecoxib, merck, and the FDA. *N. Engl. J. Med.* 351, 1707–1709 (2004). – **896.** Government Publishing Office. RISK AND RESPONSIBILITY: THE ROLES OF FDA AND PHARMACEUTICAL COMPANIES IN ENSURING THE SAFETY OF APPROVED DRUGS, LIKE VIOXX. (2005). <<http://www.gpo.gov/fdsys/pkg/CHRG-109hhr21483/html/CHRG-109hhr21483.htm>> – **897.** Bekelman JE, Li Y & Gross CP. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. *jama* 289, 454–465 (2003). – **898.** Bhandari, M. et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. *CMAJ* 170, 477–480 (2004). – **899.** Ridker P & Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. *jama* 295, 2270–2274 (2006). – **900.** Borzak S. Funding of clinical trials. *jama* 296, 1969–1969 (2006). – **901.** The Washington Post. Scientists and drug company connections. *The Washington Post* (2012). <http://www.washingtonpost.com/business/economy/scientists-and-drug-company-connections/2012/11/24/f4711d8e-36a1-11e2-9cfa-e41bac906cc9_graphic.html> – **902.** Danger vaccin col de l'utérus (gardasil). (2011). <<https://www.youtube.com/watch?v=xAvG-1TFtdM>> – **903.** Wikipédia. Liste des ministres français de la Santé. Wikipédia (2014). <https://fr.wikipedia.org/w/index.php?title=Liste_des_ministres_fran%C3%A7ais_de_la_Sant%C3%A9&oldid=106953341> – **904.** Haut Conseil de la Santé Publique. Les déclarations publiques d'intérêts des membres du collège, des commissions et des comités techniques. – **905.** Rue89. Cancer : Une pub interdite plombe le vaccin gardasil. (2010). <<http://rue89.nouvelobs.com/2010/12/07/cancer-linterdiction-dune-pub-plombe-le-vaccin-gardasil-178864s>> – **906.** Haute Autorité de Santé. Haute autorité de santé - login. (2015). <http://www.has-sante.fr/portail/plugins/ModuleHAS/custom/privateLoginHAS.jsp?redirect=http%3A%2F%2Fwww.has-sante.fr%2Fportail%2Fupload%2Fdocs%2Fapplication%2Fpdf%2F2009-07%2Fbaldauf_jean-jacques_-_declaration_publique_dinterets_du_29-05-09.pdf> – **907.** Ouverture.net. Le figaro oublie d'indiquer les liens d'intérêts d'un médecin auteur d'un article. (2012). <<http://www.ouvertures.net/le-figaro-oublie-d%C2%B4indiquer-les-liens-d%C2%B4interets-d%C2%B4un-medecin-auteur-d%C2%B4un-article/>> – **908.** Haute Autorité de Santé. En tant que professionnel de terrain, qu'est ce qui permet d'expliquer la recommandation de la HAS d'organiser le dépistage du cancer du col de l'utérus ? (2010). <http://www.has-sante.fr/portail/jcms/c_1000378/fr/en-tant-que-professionnel-de-terrain-quest-ce-qui-permet-dexpliquer-la-recommandation-de-la-has-dorganiser-le-depistage-du-cancer-du-col-de-luterus?xtmc=&xtcr=1> – **909.** Ouverture.net. Conseil de l'ordre des médecins : tout article doit indiquer les liens d'intérêts du praticien. (2012). <<http://www.ouvertures.net/conseil-de-l%C2%B4ordre-des-medecins-tout-article-doit-indiquer-les-liens-dinteret-du-praticien/>> – **910.** Le Figaro. Peut-on mieux prévenir le cancer du col de l'utérus ? Le Figaro. (2012). <<http://www.lefigaro.fr/sciences/2012/02/09/01008-20120209ARTFIG00799-peut-on-mieux-prevenir-le-cancer-du-col-de-l-uterus.php>> – **911.** Haute Autorité de Santé. État des lieux et recommandations pour le dépistage du cancer du col de l'utérus en France. (2010). <http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/argumentaire_recommandations_depistage_cancer_du_col_de_luterus.pdf> – **912.** Krémer, P. Pilule : enquête sur ces médecins liés aux laboratoires. *Le Monde.fr: Société* (2013). <http://www.lemonde.fr/societe/article/2013/01/10/pilule-enquete-sur-ces-medecins-lies-aux-laboratoires_1814864_3224.html> – **913.** Assemblée Nationale. Mme roselyne bachelot-narquin. <http://www.assemblee-nationale.fr/13/tribun/fiches_id/332.asp> – **914.** Parlement Européen. Roselyne BACHELOT-NARQUIN. <http://www.europarl.europa.eu/meps/fr/28179/ROSELYNE_BACHELOT-NARQUIN_home.html> – **915.** Fakir. Le vrai CV de roselyne bachelot. (2009). <<http://www.fakirpresse.info/Le-vrai-CV-de-Roselyne-Bachelot.html>> – **916.** Là-bas si j'y suis. L'alibi des lobbies. (2009). <http://la-bas.org/spip.php?page=article&id_article=1796> – **917.** L'alibi des lobbies. <<http://media.la-bas.org/mp3/091124/091124.mp3>> – **918.** Wikipédia. Jean Narquin. Wikipédia (2015). <http://fr.wikipedia.org/w/index.php?title=Jean_Narquin&oldid=114757988> – **919.** AstraZeneca. Merger partners in brief. <<http://archive.wikiwix.com/cache?url=http://www.astrazeneca.com/about-us/history/merger-partners-in-brief?itemId=3888482%26nav=yes&title=Historique%20de%20ZenecaGroup%20PLC>> – **920.** Haute Autorité de Santé. Avis de la commission pour le fluenz. (2012). <http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-08/fluenz_18072012_ct12345.pdf> – **921.** Haut Conseil de la Santé Publique. Vaccination contre la grippe saisonnière par le vaccin fluenz. (2011). <<http://www.hcsp.fr/explore.cgi/avis-rapportsdomaine?clefr=235>> – **922.** Rosenwald, M. S. Sales of MedImmune's flu vaccine drop sharply. *The Washington Post* (2006). <<http://www.washingtonpost.com/wp-dyn/content/article/2006/02/02/AR2006020202320.html>> – **923.** Joyeux. Pétition à l'attention de madame la ministre de la santé marisol tourraine. (2015). <http://petition.ipsn.eu/pe-nurie-vaccin-dt-polio/index.php?utm_source=TRANSCRIPT&utm_medium=Newsletter-gratuite&utm_campaign=201505-26-DTP_VdT> – **924.** Le Parisien. Polémique sur la vaccination : le Pr Joyeux invite Touraine à débattre. *leparisien.fr*. (2015). <<http://www.leparisien.fr/societe/polemique-sur-la-vaccination-le-pr-joyeux-invite-touraine-a-debattre-01-06-2015-4823043.php>> – **925.** NPA Quimper. La ministre soigne la santé d'un labo (le canard enchaîné). *Le blog du NPA* 29. (2012). <<http://npa29quimper.over-blog.fr/article-la-ministre-soigne>>

la-sante-d-un-labo-le-canard-enchaîne-109247837.html) – **926**. ANSM. Commission d'autorisation de mise sur le marché des médicaments. (2012). <http://www.sante.gouv.fr/IMG/pdf/Commission_AMM_Missions-Composition_Juin2012.pdf> – **927**. Assises du médicament. Déclaration publique d'intérêts. – **928**. Public Sénat. Audition médiateur. (2011). <http://replay.publicsenat.fr/vod/audition/auditions-médiateur-daniel-vittecoq-et-jean-francois-bergmann/68657> – **929**. Sénat. Mission commune d'information sur le médiateur : Compte rendu de la semaine du 28 mars 2011. (2011). <http://www.senat.fr/compte-rendu-commissions/20110328/médiateur.html#toc6> – **930**. ANSM. Décision DG n2012-238 portant nominations à l'ANSM. (2012). <http://www.france-biotech.org/wp-content/uploads/2012/09/nomination_ansm.pdf> – **931**. ANSM. Médicaments en cardiologie, endocrinologie, gynécologie, urologie. (2014). <http://ansm.sante.fr/L-ANSM2/Directions-produits/Médicaments-en-cardiologie-endocrinologie-gynecologie-urologie/\%28offset\%29/1> – **932**. European Medicines Agency. Emmerich 2015-01-13 DOI form version-number: 2 public declaration of interests and confidentiality undertaking of european medicines agency. (2015). <http://www.ema.europa.eu/docs/en_GB/document_library/contacts/emmerichj_DI.pdf> – **933**. Corporama. Société EUTHERAPIE à SURESNES, 921 50 (SIREN 402230197). <https://corporama.com/fr/societe/eutherapie/402230197> – **934**. ANSM. Point sur l'utilisation des nouveaux anticoagulants oraux pradaxa (dabigatran), xarelto (rivaroxaban) et éliquis (apixaban). (2013). <http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux-Pradaxa-dabigatran-Xarelto-rivaroxaban-et-Eliquis-apixaban-Communiqués> – **935**. Pradaxa: L'ANSM appelle à ne pas arrêter le traitement. (2013). <https://www.youtube.com/watch?v=sWgYP1qKMlo> – **936**. Le Parisien. Anticoagulant Pradaxa : premières plaintes en France après quatre décès. leparisien.fr. (2013). <http://www.leparisien.fr/leparisienne/sante/anticoagulant-pradaxa-premieres-plaintes-en-france-apres-quatre-deces-09-10-2013-3209453.php> – **937**. Ministère de la Santé Publique. Marisol touraine lance www.transparence.sante.gouv.fr, un site internet unique sur les liens d'intérêts entre entreprises et professionnels de santé. (2014). <http://www.sante.gouv.fr/marisol-touraine-lance-www-transparence-sante-gouv-fr-un-site-internet-unique-sur-les-liens-d-interets-entre-entreprises-et-professionnels-de-sante.html> – **938**. Ministère de la Santé Publique. Base de données publique transparence santé. (2015). <https://www.transparence.sante.gouv.fr/flow/rechercheBeneficiaires;jsessionid=7A10DF9C2E76AF435A5D8DA1C4067B89.sunshine-public?execution=e1s1> – **939**. Marianne. Au delà du médiateur, le conflit d'intérêt est dans tout le secteur. Marianne. (2011). <http://www.marianne.net/Au-dela-du-Mediateur-le-conflit-d-interet-est-dans-tout-le-secteur_a202419.html> – **940**. Le Figaro. Médiateur : Les parlementaires mis en cause. (2011). <http://sante.lefigaro.fr/actualite/2011/02/25/10758-médiateur-parlementaires-mis-cause> – **941**. David Thomas. Affaire médiateur : Le député gérard bapt lave blanc ! Mais pas encore plus blanc !. Le post. (2011). <http://archives-lepost.huffingtonpost.fr/article/2011/02/24/2416458_affaire-médiateur-le-depute-gerard-bapt-lave-blanc-mais-pas-encore-plus-blanc.html> – **942**. Rachel Bertrand. Enquête sur médiateur : Les parlementaires effacent discrètement leurs conflits d'intérêt d'un site internet compromettant. AgoraVox. (2011). <http://www.agoravox.fr/tribune-libre/article/enquete-sur-médiateur-les-90823> – **943**. Haute Autorité pour la transparence de la vie publique. Déclaration d'intérêts et d'activités au titre d'un mandat parlementaire. (2014). <http://www.hatvp.fr/livraison/dossiers/bapt-gerard-dia-depute-31.pdf> – **944**. S. R. Affaire médiateur : Le sénat censure wikipedia. Le post. (2011). <http://archives-lepost.huffingtonpost.fr/article/2011/04/07/2458559_affaire-médiateur-le-senat-censure-wikipedia.html> – **945**. Wikipédia. Gérard Bapt : Historique des versions. Wikipédia <https://fr.wikipedia.org/w/index.php?title=G%C3%A9rard_Bapt&action=history> – **946**. Geo IP Tool. Regardez mon information d'IP: 217.156.140.234. <https://geoiptool.com/fr/?IP=217.156.140.234> – **947**. Attkisson, S., 2008 & Pm, 6. How independent are vaccine defenders? (2008). <http://www.cbsnews.com/news/how-independent-are-vaccine-defenders/> – **948**. Offit, P. A. Deadly choices: How the anti-vaccine movement threatens us all. (Basic Books, 2011). <https://books.google.fr/books?id=t_poH5CezDUC&pg=PA201&dq=aap+342,000+wyeth&source=bl&ots=VJalqkwJGrI&sig=o_CeIro19nWygPR2tzRrxhdq64&hl=fr&sa=X&ei=aRb-U4jRFpLbajmSggbO#v=onepage&q&f=false> – **949**. American Academy of Pediatrics. HPV vaccine recommendations. (2012). <http://pediatrics.aappublications.org/content/early/2012/02/22/peds.2011-3865.full.pdf> – **950**. American Academy of Pediatrics. Human papillomavirus (HPV). (2009). <http://www2.aap.org/immunization/illnesses/hpv/hpv.html> – **951**. Every Child By Two. Vaccine benefits. <http://www.ecbt.org/index.php/facts_and_issues/article/vaccine_benefits> – **952**. Every Child By Two. Vaccinate your baby. <http://www.ecbt.org/index.php/about/article/vaccinate_your_baby> – **953**. SourceWatch. Every child by two. <http://www.sourcewatch.org/index.php/Every_Child_By_Two> – **954**. LinkedIn. Craig engesser | LinkedIn. <https://www.linkedin.com/pub/craig-engesser/7/356/244> – **955**. Every Child By Two. Policy on acceptance of funding from external partners. (2009). <http://www.ecbt.org/images/articles/PolicyOnAcceptanceOffundingFromExternalPartners.pdf> – **956**. Google. Recherche google. (2015). <https://www.google.fr/search?q=wyeth+grant+site:www.ecbt.org%2F&ei=TOleVcnRFImP7Ab4qYHQBA> – **957**. Left Brain Right Brain. Paul of fit explains the money side of the rotavirus vaccine he worked on. Left brain right brain. (2009). <http://leftbrainrightbrain.co.uk/2009/09/14/paul-of-fit-explains-the-money-side-of-the-rotavirus-vaccine-he-worked-on/> – **958**. Wikipédia. Gardasil. Wikipédia (2015). <https://fr.wikipedia.org/w/index.php?title=Gardasil&oldid=115173152> – **959**. RealClearPolitics. Rick perry: Gardasil 'was about saving people's lives'. (2011). <http://www.realclearpolitics.com/video/2011/09/13/rick_perry_gardasil_was_about_saving_peoples_lives.html> – **960**. The Texas Tribune. On the records: In debate, perry understated his merck support. The texas tribune. (2011). <http://www.texastribune.org/2011/09/13/records-fact-checking-perrys-merck-contributions/> – **961**. CNN. Did bachmann's drug lobbyist claims ring true? (2011). <http://www.cnn.com/2011/POLITICS/09/13/truth.squad.lobbyist.claim/index.html> – **962**. CBS News. Super PAC backing rick perry to spend \$55 million to beat rivals, docu-

- ments reveal. Msnbc.com. (2011). <http://www.nbcnews.com/id/44402386/ns/politics-decision_2012/t/super-pac-banking-rick-perry-spend-million-beat-rivals-documents-reveal/> – **963**. Cooper, K. Republican governors association raises \$22 million, lists donors (updated). Roll call blog: Political MoneyLine blog. (2014). <<http://blogs.rollcall.com/moneyline/republican-governors-association-raises-22-million-lists-donors/?dcz=>>> – **964**. Public Integrity. Big oil fuels pro-perry super PAC, contributions total \$5.5 million. Center for public integrity. (2012). <<http://www.publicintegrity.org/2012/01/31/8063/big-oil-fuels-pro-perry-super-pac-contributions-total-55-million>> – **965**. Fitzgerald, A. Perry's merck donations more than acknowledged during debate. Bloomberg.com. (2011). <<http://www.bloomberg.com/news/articles/2011-09-13/perry-s-merck-donations-greater-than-said>> – **966**. IRS. Basic search. <<http://forms.irs.gov/app/pod/basicSearch/search?execution=e1s1&max=10&offset=10>> – **967**. Bristol-Myers Squibb. Bristol-myers squibb and pfizer announce charitable donations of more than \$1 million to support cardiovascular education for patients and caregivers. (2014). <<http://news.bms.com/press-release/bristol-myers-squibb-and-pfizer-announce-charitable-donations-more-1-million-support>> – **968**. American Heart Association. Clinical practice guidelines for prevention. (2014). <http://my.americanheart.org/professional/ScienceNews/Clinical-Practice-Guidelines-for-Prevention_UCM_457211_Article.jsp> – **969**. American Heart Association. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. (2013). <<https://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.full.pdf>> – **970**. Bristol-Myers Squibb. HIGH-LIGHTS OF PRESCRIBING INFORMATION, pravachol. (2013). <http://packageinserts.bms.com/pi/pi_pravachol.pdf> – **971**. Pfizer. TRUMENBA (meningococcal group b vaccine) is now available. (2014). <http://www.pfizer.com/news/press-release/press-release-detail/trumenba_meningococcal_group_b_vaccine_is_now_available> – **972**. Bright, M. & McVeigh, T. Meningitis advisers funded by drug firms. The guardian. (2000). <<http://www.theguardian.com/uk/2000/sep/03/tracymcveigh.martinbright>> – **973**. France 24. Santé - GlaxoSmithKline condamné à une amende de 3 milliards de dollars pour fraude. France 24. (2012). <<http://www.france24.com/fr/20120703-glaxosmithkline-fraude-amende-record-pharmacie-industrie-justice-etats-unis-sante/>> – **974**. NY Daily News. British drugmaker to pay \$3 billion in fines. NY daily news. (2012). <<http://www.nydailynews.com/life-style/health/glaxosmithkline-pay-3-billion-fines-largest-health-care-fraud-settlement-u-s-history-article-1.1106795>> – **975**. AFSSAPS. Suspension de l'autorisation de mise sur le marché des médicaments contenant de la rosiglitazone (avandia, avandamet, avaglim). (2010). <<http://archive.wikiwix.com/cache?url=http://www.afssaps.fr/Infos-de-securite/Communiqués-Points-presse/Suspension-de-l-autorisation-de-mise-sur-le-marche-des-médicaments-contenant-de-la-rosiglitazone-Avandia-R-Avandamet-R-Avaglim-R-Communiqué&title=%5B1%5D>> – **976**. Daily Mail. GlaxoSmithKline to pay \$3 billion fine after pleading guilty to healthcare fraud - the biggest in U.S. history. Mail online. (2012). <<http://www.dailymail.co.uk/news/article-2167742/GlaxoSmithKline-pay-3b-fine-pleading-guilty-healthcare-fraud.html>> – **977**. Reuters. Forte amende en chine pour GSK et prison pour un ex-dirigeant. (2014). <<http://fr.reuters.com/article/idFRKBN0-HEOX20140919>> – **978**. Pharmaceutical Manufacturing. Mark reilly sex tape adds to GSK bribery scandal woes. (2014). <<http://www.pharmamanufacturing.com/industrynews/2014/mark-reilly-sex-tape-gsk-bribery/>> – **979**. GlaxoSmithKline Inc. Sir andrew witty | GSK. <<http://www.gsk.com/en-gb/about-us/board-of-directors/sir-andrew-witty>> – **980**. Treanor, J. GlaxoSmithKline chief's pay package more than doubles to 6.7m. The guardian. (2012). <<http://www.theguardian.com/business/2012/mar/12/glaxosmithkline-chief-pay-andrew-witty>> – **981**. Department of Justice. GlaxoSmithKline to plead guilty and pay \$3 billion to resolve fraud allegations and failure to report safety data. (2012). <<http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report>> – **982**. Thomas, K. & Schmidt, M. S. GlaxoSmithKline agrees to pay \$3 billion in fraud settlement. The New York Times (2012). <<http://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html>> – **983**. Bilan. Marc faber prédit une nouvelle crise. Bilan. (2014). <<http://www.bilan.ch/node/1014314>> – **984**. Perceval. Délits et crimes financiers : Pourquoi les banquiers ne vont jamais en prison. Fortune. (2014). <<http://fortune.fdesouche.com/332371-delits-et-crimes-financiers-pourquoi-les-banquiers-ne-vont-jamais-en-prison>> – **985**. Bilan. Les bonus des mastodontes de la city font encore des vagues. Bilan. (2014). <<http://www.bilan.ch/node/1014260>> – **986**. Department of Justice. Abbott labs to pay \$1.5 billion to resolve criminal & civil investigations of off-label promotion of depakote. (2012). <<http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote>> – **987**. Department of Justice. #07-782: 09-28-07 bristol-myers squibb to pay more than \$515 million to resolve allegations of illegal drug marketing and pricing. (2007). <http://www.justice.gov/archive/opa/pr/2007/September/07_civ_782.html> – **988**. Department of Justice. #09-038: Eli lilly and company agrees to pay \$1.415 billion to resolve allegations of off-label promotion of zyprexa (2009-01-15). (2009). <<http://www.justice.gov/archive/opa/pr/2009/January/09-civ-038.html>> – **989**. Statista.com. Top antipsychotic drug sales in the united states 2011-2012. Statista. (2015). <<http://www.statista.com/statistics/242480/sales-of-antipsychotic-drugs-in-the-us/>> – **990**. Wikipedia.en. Medicines and healthcare products regulatory agency. Wikipedia, the free encyclopedia (2015). <https://en.wikipedia.org/w/index.php?title=Medicines_and_Healthcare_Products_Regulatory_Agency&oldid=659452438> – **991**. Department of Justice. Justice department announces largest health care fraud settlement in its history. (2009). <<http://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history>> – **992**. Vtirapen, J. & Even, P. Médicaments effets secondaires la mort. (Le Cherche midi, 2014). – **993**. Rutube. Morts sur ordonnance. (2015). <<http://rutube.ru/video/bbef05f1f3be51841ab5344fd51afe8c/>> – **994**. Prozac, FDA advisory committee hearing september 20th 1991. (1991). <<http://www.youtube.com/watch?v=Om2J9g-ssKo>> – **995**. Finances.net. Bruxelles sanctionne le laboratoire lundbeck pour une entente concernant les médicaments génériques. Finances.net. (2013). <<http://www.finances.net/infos/actions/Bruxelles-sanctionne-le-laboratoire-Lundbeck-pour-une-entente-concernant-les-m%C3%A9dicaments-g%C3%A9n%C3%A9riques-462716>> – **996**. Le MOCI. UE/Concurrence : Les labora-

toires servier écopot d'une amende de 331 millions d'euros. Le moci. (2014). <<http://www.lemoci.com/ueconcurrance-les-laboratoires-servier-ecopot-dune-amende-de-331-millions-deuros/>> – **997**. Francetvinfo. La commission européenne veut sanctionner neuf groupes pharmaceutiques pour des accords anticoncurrentiels. Francetv info. (2013). <http://www.francetvinfo.fr/economie/entreprises/la-commission-europeenne-veut-sanctionner-neuf-groupes-pharmaceutiques_339012.html> – **998**. Autorité de la Concurrence. Ouvrir de nouvelles voies de croissance. (2014). <<http://www.autoritedelaconcurrence.fr/doc/synthese2013web.pdf>> – **999**. Department of Justice. #07-1000: 12-13-07 merck settles clean water act violations at its montgomery county, pennsylvania pharmaceutical plant. (2007). <http://www.justice.gov/archive/opa/pr/2007/December/07_endr_1000.html> – **1000**. EasyBourse. Merck verse 688 m \$ pour avoir menti sur l'efficacité de son médicament anti-cholestéro. (2013). <<https://www.easybourse.com/bourse/sante/article/25144/merck-verse-688-m-pour-avoir-menti-sur-lefficacite-de-son-medicament-anti-cholesterol.html>> – **1001**. United States District Court for the Eastern district of Pennsylvania. Merck mumps vaccine antitrust litigation. (2012). <<http://freepdfhosting.com/24cea13c07.pdf>> – **1002**. The Wall Street Journal. Did merck unfairly monopolize the market for a mumps vaccine? WSJ blogs - pharmlot. (2014). <<http://blogs.wsj.com/pharmlot/2014/09/10/did-merck-unfairly-monopolize-the-market-for-a-mumps-vaccine/>> – **1003**. European Medicines Agency. European medicines agency acts on deficiencies in roche medicines-safety reporting. (2012). <http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/06/news_detail_001539.jsp&mid=WC0b01ac058004d5c1> – **1004**. OMS. Variole. WHO. (2015). <<http://www.who.int/topics/smallpox/fr/>> – **1005**. Direction générale de la santé. Bulletin officiel n2002-50. (2002). <<http://www.sante.gouv.fr/fichiers/bo/2002/02-50/a0503932.htm>> – **1006**. EuroSurveillance. RECOMMANDATIONS BICHAT* SUR LA PRISE EN CHARGE CLINIQUE DES PATIENTS ATTEINTS DE VARIOLE LIÉE OU NON À UN ACTE DE BIOTERRORISME. (2004). <http://ec.europa.eu/health/ph_threats/Bioterrorisme/clin_gui_smallpox_fr.pdf> – **1007**. Sanofi Pasteur. Couverture vaccinale. (2014). <http://sanofipasteur.com/fr/la_valeur_des_vaccins/couverture_vaccinale/> – **1008**. Unicef. Sept maladies maîtrisées par le vaccin. (1996). <<http://www.unicef.org/french/pon96/hevaccin.htm>> – **1009**. AFSSAPS. Fiche n7 'variole'. (2008). <http://ansm.sante.fr/var/ansm_site/storage/original/application/bb3-da7fdb5614350cc875ec6b7403f48.pdf> – **1010**. INED. Le vaccin contre la variole. Ined - institut national d'études démographiques. <<http://www.ined.fr/fr/tout-savoir-population/memos-demo/fiches-pedagogiques/le-vaccin-contre-la-variole/>> – **1011**. OMS. L'éradication de la variole. (1979). <http://whqlibdoc.who.int/publications/a41464_fre.pdf> – **1012**. Maxisciences. Variole : Des échantillons du virus découverts dans des fioles aux états-unis. GenSIDE découverte. (2014). <http://www.maxisciences.com/variole/variole-des-echantillons-du-virus-decouverts-dans-des-fioles-aux-etats-unis_art33015.html> – **1013**. Roush SW, Murphy TV & Vaccine-Preventable Disease Table Working Group a. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the united states. *jama* 298, 2155–2163 (2007). – **1014**. McKinlay, J. B. & McKinlay, S. M. The questionable contribution of medical measures to the decline of mortality in the united states in the twentieth century. *Milbank Mem Fund Q Health Soc* 55, 405–428 (1977). – **1015**. Milot, J. La mortalité infantile au tournant du XXe siècle au canada français. *Paediatr Child Health* 15, e6–e8 (2010). – **1016**. Medicalorama. La scarlatine. <http://www.medicalorama.com/html/sante_enfants/scarlatine> – **1017**. Duncan, C. J., Duncan, S. R. & Scott, S. The dynamics of scarlet fever epidemics in england and wales in the 19th century. *Epidemiol Infect* 117, 493–499 (1996). – **1018**. Comprendre les lumières. (2013). <<https://www.youtube.com/watch?v=mQ7m-gtv3DY>> – **1019**. Maclure, A. & Stewart, G. T. Admission of children to hospitals in glasgow: Relation to unemployment and other deprivation variables. *lancet* 2, 682–685 (1984). – **1020**. Prix Galien. Lauréats : Lauréats par spécialités médicales. (2015). <<http://www.prixgalien.com/fr/05/02/laureats-par-specialites-medicales.htm>> – **1021**. Skyrock. Vaccination contre le cancer du col de l'utérus, pour ou contre ? Skyrock. (2009). <<http://gardasil-njs.skyrock.com/>> – **1022**. Ross JS et al. Pooled analysis of rofecoxib placebo-controlled clinical trial data: Lessons for postmarket pharmaceutical safety surveillance. *Arch Intern Med* 169, 1976–1985 (2009). – **1023**. Food and Drug Administration. Sequence of events with VIOXX, since opening of IND. (2005). <http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_04_E-FDA-TAB-C.htm> – **1024**. Wadman, M. Merck settles viiox lawsuits for \$4.85 billion. *Nat. News* (2007). doi:10.1038/450324b – **1025**. Zinka, B., Rauch, E., Buettner, A., Rueff, F. & Penning, R. Unexplained cases of sudden infant death shortly after hexavalent vaccination. *vaccine* 24, 5779–5780 (2006). – **1026**. Kries, R. von et al. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, haemophilus influenzae type b): Is there a signal? *Eur. J. Pediatr.* 164, 61–69 (2005). – **1027**. Traversa, G. et al. Sudden unexpected deaths and vaccinations during the first two years of life in italy: A case series study. *PLoS ONE* 6, e16363 (2011). – **1028**. Flanagan, K. L. et al. Heterologous (nonspecific) and sex-differential effects of vaccines: Epidemiology, clinical trials, and emerging immunologic mechanisms. *Clin. Infect. Dis.* 57, 283–289 (2013). – **1029**. Gervassi, A. L. & Horton, H. Is infant immunity actively suppressed or immature? *Virology* (Auckl) 5, 1–9 (2014). – **1030**. Wikipedia.en. List of largest pharmaceutical settlements. Wikipedia, the free encyclopedia (2015). <https://en.wikipedia.org/w/index.php?title=List_of_largest_pharmaceutical_settlements&oldid=652098644> – **1031**. Roth, A. et al. Low birth weight infants and calmette-guérin bacillus vaccination at birth: Community study from guinea-bissau. *Pediatr. Infect. Dis. J.* 23, 544–550 (2004). – **1032**. Kristensen, I., Fine, P., Aaby, P. & Jensen, H. Routine vaccinations and child survival: Follow up study in guinea-bissau, west Africa Commentary: An unexpected finding that needs confirmation or rejection. *bmj* 321, 1435 (2000). – **1033**. Aaby, P. et al. Testing the hypothesis that diphtheriatetanuspertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. *BMJ Open* 2, (2012). – **1034**. Aaby, P., Jensen, H., Gomes, J., Fernandes, M. & Lisse, I. M. The introduction of diphtheria-tetanus-pertussis vaccine and child mortality in rural guinea-bissau: An observational study. *Int J Epidemiol* 33, 374–380 (2004). – **1035**. San-

- koh, O. et al. The non-specific effects of vaccines and other childhood interventions: The contribution of INDEPTH health and demographic surveillance systems. *Int J Epidemiol* 43, 645–653 (2014). – **1036**. Bawah, A. A. et al. The impact of immunization on the association between poverty and child survival: Evidence from kassena-nankana district of northern ghana. *Scand J Public Health* 38, 95–103 (2010). – **1037**. Elguero, E., Simondon, K. B., Vaugelade, J., Marra, A. & Simondon, F. Non-specific effects of vaccination on child survival? A prospective study in senegal. *Trop. Med. Int. Health* 10, 956–960 (2005). – **1038**. Breiman, R. F. et al. Effect of infant immunisation on childhood mortality in rural bangladesh: Analysis of health and demographic surveillance data. *The Lancet* 364, 2204–2211 (2004). – **1039**. Fine, P. E. M. & Smith, P. G. Editorial: ‘Non-specific effects of vaccines’ an important analytical insight, and call for a workshop. *Trop. Med. Int. Health* 12, 1–4 (2007). – **1040**. London School of Hygiene and Tropical Medicine. Peter smith. <<http://www.lshmt.ac.uk/aboutus/people/smith.peter>> – **1041**. OMS. Relevé épidémiologique hebdomadaire. 83, 285–292 (2008). – **1042**. Ministère de la Santé Publique. Calendrier vaccinal et recommandations vaccinales 2013. (2013). <http://www.social-sante.gouv.fr/IMG/pdf/Calendrier_vaccinal_ministere_sante_2014.pdf> – **1043**. Garly, M.-L. et al. Hepatitis b vaccination associated with higher female than male mortality in guinea-bissau: An observational study. *Pediatr. Infect. Dis. J.* 23, 1086–1092 (2004). – **1044**. Krishnan, A. et al. Non-specific sex-differential effect of DTP vaccination may partially explain the excess girl child mortality in ballabgarh, india. *Trop. Med. Int. Health* 18, 1329–1337 (2013). – **1045**. Gil, A. et al. Vaccination and heterologous immunity: Educating the immune system. *Trans. R. Soc. Trop. Med. Hyg.* 109, 62–69 (2015). – **1046**. Knudsen, K. M. et al. Child mortality following standard, medium or high titre measles immunization in west africa. *Int J Epidemiol* 25, 665–673 (1996). – **1047**. Smedman, L. et al. Immunosuppression after measles vaccination. *Acta Paediatr.* 83, 164–168 (1994). – **1048**. Aaby, P. et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: Reanalysis of west african studies. *lancet* 361, 2183–2188 (2003). – **1049**. Aaby, P. et al. Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: An observational study within a randomised trial. *Arch Dis Child archdischild-2011-300646* (2012). doi:10.1136/archdischild-2011-300646 – **1050**. Benn, C. S. et al. Interaction between neonatal vitamin a supplementation and timing of measles vaccination: A retrospective analysis of three randomized trials from guinea-bissau. *vaccine* 32, 5468–5474 (2014). – **1051**. Pourcyrus, M., Korones, S. B., Arheart, K. L. & Bada, H. S. Primary immunization of premature infants with gestational age \hat{c} 35 weeks: Cardiorespiratory complications and c-reactive protein responses associated with administration of single and multiple separate vaccines simultaneously. *J. Pediatr.* 151, 167–172 (2007). – **1052**. Stensballe, L. G. et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in guinea-bissau: A beneficial effect of BCG vaccination for girls community based case-control study. *vaccine* 23, 1251–1257 (2005). – **1053**. Miller, N. Z. & Goldman, G. S. Infant mortality rates regressed against number of vaccine doses routinely given: Is there a biochemical or synergistic toxicity? *Hum Exp Toxicol* 0960327111407644 (2011). doi:10.1177/0960327111407644 – **1054**. Sage journals. Human & experimental toxicology. (2015). <<http://het.sagepub.com/>> – **1055**. Central Intelligence Agency. The world factbook, infant mortality rate. (2015). <<https://www.cia.gov/library/publications/the-world-factbook/rankorder/2091rank.html>> – **1056**. Child Mortality Estimates. Neonatal mortality estimates. <http://www.childmortality.org/files_v19/download/NMR.xlsx> – **1057**. Central Intelligence Agency. The world factbook, death rate. (2015). <<https://www.cia.gov/library/publications/the-world-factbook/rankorder/2066rank.html>> – **1058**. GlaxoSmithKline Inc. HIGHLIGHTS OF PRESCRIBING INFORMATION, rotarix. (2014). <https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rotarix/pdf/ROTARIX-PI-PIL.PDF> – **1059**. Food and Drug Administration. Approved products - summary basis for regulatory action - rotarix. (2008). <<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133543.htm>> – **1060**. Institut Pierre Delbet. Professeur pierre delbet. (2014). <<http://www.institutpierdelbet.org/professeur.pierre.delbet.html>> – **1061**. Insecula.com. Douleur. <<http://www.insecula.com/oeuvre/O0015628.html>> – **1062**. Delbet, P. Politique préventive du cancer. (Sciences libres, 2009). – **1063**. Delbet, P. La carence en magnésium. ses causes actuelles. 70, 228–230 (1929). – **1064**. Hercberg, S. Statut minéral et vitaminique de la population française. <<http://www.ipubli.inserm.fr/bitstream/handle/10608/190?sequence=24>> – **1065**. Le Quotidien du Médecin. Le pain a sa place dans une alimentation équilibrée. Le quotidien du médecin. (2001). <<http://www.lequotidiendumedecin.fr/>> – **1066**. Neveu, A., Billi, M. & Farma, J. I. Le chlorure de magnésium dans les maladies infectieuses. (Sciences libres, 2010). – **1067**. Nice Matin. L'ex-élu nicoïse faxe aux antilles son remède miracle contre la dengue. (2010). <<http://www.nicematin.com/article/derniere-minute/faxe-elue-nicoise-faxe-aux-antilles-son-remede-miracle-contre-la-dengue.283775.html>> – **1068**. Portail de la Guadeloupe. Chlorure de magnésium, remède contre le chikungunya et ebola. <<http://www.portail-guadeloupe.com/chlorure-magnesium-soigner-chikungunya.html>> – **1069**. Portail de la Guadeloupe. Comment soigner et guérir du chikungunya - témoignages et étude scientifique. <<http://www.portail-guadeloupe.com/soigner-guerir-chikungunya.html>> – **1070**. Souccar, T. Du chlorure de magnésium contre ebola. sérieusement ? <<http://www.thierrysouccar.com/blog/du-chlorure-de-magnesium-contre-ebola-serieusement/>> – **1071**. De Lamballerie, X. et al. On chikungunya acute infection and chloroquine treatment. *Vector Borne Zoonotic Dis.* 8, 837–839 (2008). – **1072**. dimitri. Chikungunya | chlorure de magnésium. (2013). <<http://www.chlorure-de-magnesium.fr/chikungunya/>> – **1073**. AMESSI. Les bienfaits du chlorure de magnésium. (2014). <<http://www.ameSSI.org/les-bienfaits-du-chlorure-de-magnesium/>> – **1074**. Alternative Santé. Imposture du tétanos. (2014). <<http://www.alternativesante.fr/vaccins/le-roman-du-tetanos/>> – **1075**. Légifrance. Décret n 2007-1111 du 17 juillet 2007 relatif à l'obligation vaccinale par le vaccin antituberculeux BCG. (2007). <<http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT00000464863&dateTexte=&categorieLien=id>> – **1076**. Légifrance. Code de la santé publique - article l3111-2. <

GITEXT000006072665\&cidArticle=LEGIARTI000006687781> – **1077**. Légifrance. Code de la santé publique - article r3111-2. <<http://www.legifrance.gouv.fr/affichCodeArticle.do?idArticle=LEGIARTI000006911702\&cidTexte=LEGITEXT000006072665>> – **1078**. Légifrance. Code de la santé publique - article l3111-1. <http://www.legifrance.gouv.fr/affichCodeArticle.do;jsessionid=E67F2E97EEA8FCA30-DE980807202A051.tpdjo07v_3?cidTexte=LEGITEXT000006072665\&cidArticle=LEGIARTI000006687777\&dateTexte=\&categorieLien=cid> – **1079**. Ligue Nationale Pour la Liberté des Vaccinations. Législation vaccinale en france. (2015). <http://www.infovacinn.fr/legislation_vaccinale.html> – **1080**. Légifrance. Code de la santé publique - article l3131-1. <http://www.legifrance.gouv.fr/affichCodeArticle.do;jsessionid=01D-FEDC827C587653E38F62126C04A1D.tpdjo02v_2?idArticle=LEGIARTI000006687867\&cidTexte=LEGITEXT000006072665\&dateTexte=20091004> – **1081**. Haut Conseil de la Santé Publique. Avis relatif aux ruptures de stocks et aux tensions d'approvisionnement des vaccins combinés contenant la valence coqueluche. (2015). <http://ansm.sante.fr/content/download/74407/946347/version/1/file/rs-1503092vacc_coqueluche_reco_HCS.pdf> – **1082**. Votre Santé. Des crèches exigent toujours le BCG : C'est illégal ! (2015). <<http://www.votre-sante.com/news.php?dateedit=1240683522>> – **1083**. Service Public. Faut-il faire vacciner son enfant pour l'inscrire en collectivité ? (2014). <<http://vosdroits.service-public.fr/particuliers/F767.xhtml>> – **1084**. ALIS. ALIS - association liberté information santé. (2015). <<http://www.alis-france.com/lois.php>> – **1085**. ALIS. Précisions au sujet des contre-indications aux vaccinations. <http://www.alis-france.com/download/precision_contre_indications.pdf> – **1086**. Légifrance. Code de la santé publique - article l3116-4. <<http://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=LEGITEXT000006072665\&cidArticle=LEGIARTI000006687829>> – **1087**. France 3 Bourgogne. Yonne : Que risquent les parents auxerrois qui refusent de faire vacciner leur enfant ? . France 3 bourgogne. (2015). <<http://france3-regions.francetvinfo.fr/bourgogne/2015/03/09/yonne-que-risquent-les-parents-auxerrois-qui-refusent-de-faire-vacciner-leur-enfant-671055.html>> – **1088**. Conseil Constitutionnel. Décision n 2015-458 QPC du 20 mars 2015. (2015). <<http://www.conseil-constitutionnel.fr/conseil-constitutionnel/francais/les-decisions/acces-par-date/decisions-depuis-1959/2015/2015-458-qpc/decision-n-2015-458-qpc-du-20-mars-2015.143458.html>> – **1089**. Légifrance. Code de la santé publique - article l1111-4. <<http://www.legifrance.gouv.fr/affichCodeArticle.do?idArticle=LEGIARTI000006685767\&cidTexte=LEGITEXT000006072665>> – **1090**. Wikipédia. Vaccination. Wikipédia (2015). <<https://fr.wikipedia.org/w/index.php?title=Vaccination\&oldid=115051536>> – **1091**. Sanofi Pasteur. Chiffres clés, sanofi pasteur, conception et fabrication de vaccins, information vaccination. (2015). <http://www.sanofi-pasteur.com/fr/sanofi_pasteur/chiffres_cles/> – **1092**. Loin du troupeau. Éloge de l'immobilité. (2012). <<http://loindutroupeau.blogspot.fr/2012/09/eloge-de-limmobilite.html>> – **1093**. Loin du troupeau. Vers l'épuisement des ressources. (2013). <<http://loindutroupeau.blogspot.fr/2013/02/vers-lepuisement-des-ressources.html>> – **1094**. Holland, M. Monitoring system to globally track false social media claims on dangers of vaccines. Daily Telegraph. (2013). <<http://www.dailytelegraph.com.au/technology/monitoring-system-to-globally-track-false-social-media-claims-on-dangers-of-vaccines/story-fni0byb5-1226640823800>> – **1095**. Ordre des Médecins. Ordre des médecins, twitter. (2015). <https://twitter.com/ordre_medecins> – **1096**. Académie de Médecine. La vaccination demeure un des fondements de la médecine préventive. (2015). <<http://www.academie-medicine.fr/wp-content/uploads/2015/06/15.6.16-BEGUE-v-15.6.18-EC.pdf>> – **1097**. Le Monde. CESE : 'La pétition contre le mariage pour tous est irrecevable'. Le Monde.fr: Société (2013). <http://www.lemonde.fr/societe/article/2013/02/22/cese-la-petition-contre-le-mariage-pour-tous-est-irrecevable_1836889_3224.html> – **1098**. LCI. Pourquoi une pétition anti-vaccin fait polémique. (2015). <<http://lci.tf1.fr/science/sante/pourquoi-une-petition-anti-vaccin-fait-polemique-8615492.html>> – **1099**. Dailymotion. Alain juppé démontre à david pujadas qu'il était de droite et qu'il ne l'est plus. Dailymotion. <http://www.dailymotion.com/video/x276cww_alain-juppe-demontre-a-david-pujadas-qu-il-etait-de-droite-et-qu-il-ne-l-est-plus_webcam> – **1100**. Dailymotion. Georges marchais sur l'immigration. Dailymotion. (2012). <http://www.dailymotion.com/video/xq70wb_georges-marchais-sur-l-immigration_news> – **1101**. Histoire revisitée. Dossier : Petite histoire de la 'préférence nationale'. Site de réinformation historique. <<http://historierevisitee.over-blog.com/dossier-petite-histoire-de-la-preference-nationale.html>>